BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3507] [Article Influence: 404.7] [Reference Citation Analysis]
Number Citing Articles
1 Li MX, Zhao H, Bi XY, Li ZY, Huang Z, Han Y, Zhou JG, Zhao JJ, Zhang YF, Cai JQ. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma: Validation in a Chinese cohort. Hepatol Res. 2017;47:731-741. [PMID: 27558521 DOI: 10.1111/hepr.12796] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
2 Yeh MM, Yeung RS, Apisarnthanarax S, Bhattacharya R, Cuevas C, Harris WP, Hon TLK, Padia SA, Park JO, Riggle KM, Daoud SS. Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. World J Hepatol 2015; 7(11): 1460-1483 [PMID: 26085907 DOI: 10.4254/wjh.v7.i11.1460] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
3 Caserta MP, Sakala M, Shen P, Gorden L, Wile G. Presurgical planning for hepatobiliary malignancies: clinical and imaging considerations. Magn Reson Imaging Clin N Am 2014;22:447-65. [PMID: 25086939 DOI: 10.1016/j.mric.2014.04.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
4 Li H, Wang L, Chen L, Zhao H, Cai J, Yao J, Zheng J, Yang Y, Wang G. Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio in Hepatocellular Carcinoma Patients Treated with Liver Transplantation. J Cancer 2020;11:2171-80. [PMID: 32127944 DOI: 10.7150/jca.39615] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
5 Faletti R, Cassinis MC, Fonio P, Bergamasco L, Pavan LJ, Rapellino A, David E, Gandini G. Multiparametric Gd-EOB-DTPA magnetic resonance in diagnosis of HCC: dynamic study, hepatobiliary phase, and diffusion-weighted imaging compared to histology after orthotopic liver transplantation. Abdom Imaging. 2015;40:46-55. [PMID: 24965896 DOI: 10.1007/s00261-014-0180-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
6 Berliner L, Lemke HU, vanSonnenberg E, Ashamalla H, Mattes MD, Dosik D, Hazin H, Shah S, Mohanty S, Verma S, Esposito G, Bargellini I, Battaglia V, Caramella D, Bartolozzi C, Morrison P. Model-guided therapy for hepatocellular carcinoma: a role for information technology in predictive, preventive and personalized medicine. EPMA J 2014;5:16. [PMID: 25538797 DOI: 10.1186/1878-5085-5-16] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
7 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol 2015; 7(5): 738-752 [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
8 江林宫, 孟鸿宇, 张火俊. 放射性肝损伤的研究进展. 世界华人消化杂志 2017; 25(20): 1811-1818 [DOI: 10.11569/wcjd.v25.i20.1811] [Reference Citation Analysis]
9 Papatheodoridis GV, Manolakopoulos S, Touloumi G, Nikolopoulou G, Raptopoulou-Gigi M, Gogos C, Vafiadis-Zouboulis I, Karamanolis D, Chouta A, Ilias A, Drakoulis C, Mimidis K, Ketikoglou I, Manesis E, Mela M, Hatzis G, Dalekos GN;  HepNet. Greece Study Group. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort. J Viral Hepat. 2015;22:120-127. [PMID: 25040685 DOI: 10.1111/jvh.12283] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
10 Hazin H, Dosik D. Personalized Chemotherapy for Hepatocellular Carcinoma. In: Berliner L, Lemke HU, editors. An Information Technology Framework for Predictive, Preventive and Personalised Medicine. Cham: Springer International Publishing; 2015. pp. 53-60. [DOI: 10.1007/978-3-319-12166-6_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Tak KY, Jang B, Lee SK, Nam HC, Sung PS, Bae SH, Choi JY, Yoon SK, Jang JW. Use of M2BPGi in HCC patients with TACE. J Gastroenterol Hepatol 2021. [PMID: 34031909 DOI: 10.1111/jgh.15553] [Reference Citation Analysis]
12 Ganne-carrié N, Chaffaut C, Bourcier V, Archambeaud I, Perarnau J, Oberti F, Roulot D, Moreno C, Louvet A, Dao T, Moirand R, Goria O, Nguyen-khac E, Carbonell N, Antonini T, Pol S, de Ledinghen V, Ozenne V, Henrion J, Péron J, Tran A, Perlemuter G, Amiot X, Zarski J, Beaugrand M, Chevret S. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. Journal of Hepatology 2018;69:1274-83. [DOI: 10.1016/j.jhep.2018.07.022] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 11.7] [Reference Citation Analysis]
13 González R, Rodríguez-Hernández MA, Negrete M, Ranguelova K, Rossin A, Choya-Foces C, Cruz-Ojeda P, Miranda-Vizuete A, Martínez-Ruiz A, Rius-Pérez S, Sastre J, Bárcena JA, Hueber AO, Padilla CA, Muntané J. Downregulation of thioredoxin-1-dependent CD95 S-nitrosation by Sorafenib reduces liver cancer. Redox Biol 2020;34:101528. [PMID: 32388267 DOI: 10.1016/j.redox.2020.101528] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
14 Yasui K, Takashima H, Miyagawa M, Miyazawa K, Ochiai T, Mukaisho K, Amaike H, Ueda K, Morikawa J, Otsuji E, Yoshikawa T. Selective accumulation of platinum and formation of platinum-DNA adducts in hepatocellular carcinoma after transarterial chemoembolization with miriplatin. Hepatol Res 2013;43:1093-9. [PMID: 23347452 DOI: 10.1111/hepr.12059] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Yu R, Tan Z, Xiang X, Dan Y, Deng G. Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data. BMC Cancer. 2017;17:608. [PMID: 28863782 DOI: 10.1186/s12885-017-3609-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
16 Pompili M, Saviano A, de Matthaeis N, Cucchetti A, Ardito F, Federico B, Brunello F, Pinna AD, Giorgio A, Giulini SM, De Sio I, Torzilli G, Fornari F, Capussotti L, Guglielmi A, Piscaglia F, Aldrighetti L, Caturelli E, Calise F, Nuzzo G, Rapaccini GL, Giuliante F. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ⩽3cm. Results of a multicenter Italian survey. Journal of Hepatology 2013;59:89-97. [DOI: 10.1016/j.jhep.2013.03.009] [Cited by in Crossref: 160] [Cited by in F6Publishing: 158] [Article Influence: 20.0] [Reference Citation Analysis]
17 Xu Y, Chen J, Wang H, Zheng H, Feng D, Zhang A, Leng J, Duan W, Yang Z, Chen M, Shi X, Cai S, Ji W, Jiang K, Zhang W, Chen Y, Gu W, Dong J, Lu S. Perioperative and long-term outcomes of liver resection for hepatitis B virus-related hepatocellular carcinoma without versus with hepatic inflow occlusion: study protocol for a prospective randomized controlled trial. Trials 2016;17:492. [PMID: 27724929 DOI: 10.1186/s13063-016-1621-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
18 Yin T, Li W, Zhao P, Wang Y, Zheng J. Treatment efficacy of CT-guided percutaneous microwave ablation for primary hepatocellular carcinoma. Clin Radiol 2017;72:136-40. [PMID: 27890422 DOI: 10.1016/j.crad.2016.10.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
19 Long J, Lin J, Wang A, Wu L, Zheng Y, Yang X, Wan X, Xu H, Chen S, Zhao H. PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. J Hematol Oncol. 2017;10:146. [PMID: 28774337 DOI: 10.1186/s13045-017-0511-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 10.0] [Reference Citation Analysis]
20 Ho CH, Chuang HC, Wu IC, Tsai HW, Lin YJ, Sun HY, Young KC, Chiu YC, Cheng PN, Liu WC, Tan TH, Chang TT. Prediction of early hepatocellular carcinoma recurrence using germinal center kinase-like kinase. Oncotarget 2016;7:49765-76. [PMID: 27343552 DOI: 10.18632/oncotarget.10176] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
21 Zhang Y, Jiang X, Li X, Găman MA, Kord-Varkaneh H, Rahmani J, Salehi-Sahlabadi A, Day AS, Xu Y. Serum Vitamin D Levels and Risk of Liver Cancer: A Systematic Review and Dose-Response Meta-Analysis of Cohort Studies. Nutr Cancer 2021;73:1-9. [PMID: 32705896 DOI: 10.1080/01635581.2020.1797127] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
22 Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol 2015; 7(12): 1632-1651 [PMID: 26140083 DOI: 10.4254/wjh.v7.i12.1632] [Cited by in Crossref: 120] [Cited by in F6Publishing: 107] [Article Influence: 20.0] [Reference Citation Analysis]
23 Kong JY, Li SM, Fan HY, Zhang L, Zhao HJ, Li SM. Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma. Medicine (Baltimore) 2018;97:e11872. [PMID: 30113483 DOI: 10.1097/MD.0000000000011872] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
24 Espelund U, Grønbæk H, Villadsen GE, Simonsen K, Vestergaard PF, Jørgensen JO, Flyvbjerg A, Vilstrup H, Frystyk J. The Circulating IGF System in Hepatocellular Carcinoma: The Impact of Liver Status and Treatment. Growth Horm IGF Res 2015;25:174-81. [PMID: 26068014 DOI: 10.1016/j.ghir.2015.05.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
25 Scheiner B, Kirstein M, Popp S, Hucke F, Bota S, Rohr-Udilova N, Reiberger T, Müller C, Trauner M, Peck-Radosavljevic M, Vogel A, Sieghart W, Pinter M. Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma. Liver Cancer 2019;8:203-17. [PMID: 31192156 DOI: 10.1159/000489833] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
26 Yao S, Wei Y, Ye Z, Chen J, Duan T, Zhang Z, Song B. Hepatic Steatosis Has No Effect in Diagnosis Accuracy of LI-RADS v2018 Categorization of Hepatocellular Carcinoma in MR Imaging. J Magn Reson Imaging 2021. [PMID: 34121266 DOI: 10.1002/jmri.27783] [Reference Citation Analysis]
27 Nakachi K, Tamai H, Mori Y, Shingaki N, Moribata K, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M. Prediction of poorly differentiated hepatocellular carcinoma using contrast computed tomography. Cancer Imaging. 2014;14:7. [PMID: 25608454 DOI: 10.1186/1470-7330-14-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
28 Chen J, Fang A, Chen M, Tuoheti Y, Zhou Z, Xu L, Chen J, Pan Y, Wang J, Zhu H, Zhang Y. A novel inflammation-based nomogram system to predict survival of patients with hepatocellular carcinoma. Cancer Med 2018;7:5027-35. [PMID: 30259688 DOI: 10.1002/cam4.1787] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
29 Scatton O, Goumard C, Cauchy F, Fartoux L, Perdigao F, Conti F, Calmus Y, Boelle PY, Belghiti J, Rosmorduc O. Early and resectable HCC: Definition and validation of a subgroup of patients who could avoid liver transplantation. J Surg Oncol. 2015;118:1007-1015. [PMID: 25918872 DOI: 10.1002/jso.23916] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
30 Nierhoff J, Chávez Ortiz AA, Herrmann E, Zeuzem S, Friedrich-rust M. The efficiency of acoustic radiation force impulse imaging for the staging of liver fibrosis: a meta-analysis. Eur Radiol 2013;23:3040-53. [DOI: 10.1007/s00330-013-2927-6] [Cited by in Crossref: 120] [Cited by in F6Publishing: 103] [Article Influence: 15.0] [Reference Citation Analysis]
31 Shi L, Yan P, Liang Y, Sun Y, Shen J, Zhou S, Lin H, Liang X, Cai X. Circular RNA expression is suppressed by androgen receptor (AR)-regulated adenosine deaminase that acts on RNA (ADAR1) in human hepatocellular carcinoma. Cell Death Dis 2017;8:e3171. [PMID: 29144509 DOI: 10.1038/cddis.2017.556] [Cited by in Crossref: 63] [Cited by in F6Publishing: 71] [Article Influence: 15.8] [Reference Citation Analysis]
32 Moon AM, Weiss NS, Beste LA, Su F, Ho SB, Jin GY, Lowy E, Berry K, Ioannou GN. No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis. Gastroenterology. 2018;155:1128-1139.e6. [PMID: 29981779 DOI: 10.1053/j.gastro.2018.06.079] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 16.7] [Reference Citation Analysis]
33 Francica G. Needle track seeding after radiofrequency ablation for hepatocellular carcinoma: prevalence, impact, and management challenge. J Hepatocell Carcinoma 2017;4:23-7. [PMID: 28176952 DOI: 10.2147/JHC.S106558] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
34 Sinn DH, Kang D, Kang M, Paik SW, Guallar E, Cho J, Gwak GY. Late presentation of hepatitis B among patients with newly diagnosed hepatocellular carcinoma: a national cohort study. BMC Cancer 2019;19:286. [PMID: 30922251 DOI: 10.1186/s12885-019-5508-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Takada H, Tsuchiya K, Yasui Y, Nakakuki N, Tamaki N, Suzuki S, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Asahina Y, Enomoto N, Izumi N. Irregular vascular pattern by contrast-enhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. Cancer Med 2016;5:3111-20. [PMID: 27748052 DOI: 10.1002/cam4.932] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
36 Kim MN, Kim BK, Kim SU, Park JY, Ahn SH, Han KH, Kim DY. Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. Scand J Gastroenterol 2019;54:1283-90. [PMID: 31593481 DOI: 10.1080/00365521.2019.1673478] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
37 Chiba T, Suzuki E, Saito T, Ogasawara S, Ooka Y, Tawada A, Iwama A, Yokosuka O. Biological features and biomarkers in hepatocellular carcinoma. World J Hepatol 2015; 7(16): 2020-2028 [PMID: 26261691 DOI: 10.4254/wjh.v7.i16.2020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
38 Degroote H, Piñero F, Costentin C, Notarpaolo A, Boin IF, Boudjema K, Baccaro C, Chagas AL, Bachellier P, Ettorre GM, Poniachik J, Muscari F, Di Benedetto F, Duque SH, Salame E, Cillo U, Gadano A, Vanlemmens C, Fagiuoli S, Rubinstein F, Burra P, Cherqui D, Silva M, Van Vlierberghe H, Duvoux C; French-Italian-Belgium and Latin American collaborative group for HCC and liver transplantation. International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria. JHEP Rep 2021;3:100331. [PMID: 34485882 DOI: 10.1016/j.jhepr.2021.100331] [Reference Citation Analysis]
39 Wan P, Zhang JJ, Li QG, Xu N, Zhang M, Chen XS, Han LZ, Xia Q. Living-donor or deceased-donor liver transplantation for hepatic carcinoma: A case-matched comparison. World J Gastroenterol 2014; 20(15): 4393-4400 [PMID: 24764678 DOI: 10.3748/wjg.v20.i15.4393] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
40 Rodríguez de Lope C, Reig M, Matilla A, Ferrer MT, Dueñas E, Mínguez B, F Castroagudín J, Ortiz I, Pascual S, Lledó JL, Gallego A, Arenas JI, Aracil C, Forne M, Muñoz C, Pons F, Sala M, Iñarrairaegui M, Martin-Llahi M, Andreu V, Garre C, Rendón P, Fuentes J, Crespo J, Rodríguez M, Bruix J, Varela M; en representación del Grupo de Estudio de Cáncer Hepático (GECH). Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. Med Clin (Barc) 2017;149:61-71. [PMID: 28279536 DOI: 10.1016/j.medcli.2016.12.048] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
41 Ippolito D, Querques G, Okolicsanyi S, Talei Franzesi C, Pecorelli A, Lombardi S, Orsini E, Strazzabosco M, Sironi S. Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions. Eur J Radiol 2018;106:62-8. [PMID: 30150052 DOI: 10.1016/j.ejrad.2018.07.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
42 Kirstein MM, Voigtländer T, Schweitzer N, Hinrichs JB, Marquardt J, Wörns MA, Kloeckner R, Fründt TW, Ittrich H, Wacker F, Rodt T, Manns MP, Wege H, Weinmann A, Vogel A. Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease. United European Gastroenterol J 2018;6:238-46. [PMID: 29511553 DOI: 10.1177/2050640617716597] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
43 Baboci L, Capolla S, Di Cintio F, Colombo F, Mauro P, Dal Bo M, Argenziano M, Cavalli R, Toffoli G, Macor P. The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target. J Oncol 2020;2020:4638192. [PMID: 32184825 DOI: 10.1155/2020/4638192] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
44 Lee S, Jeong WK, Rhim H. Repeated percutaneous radiofrequency ablation for hepatocellular carcinoma in patients with cirrhosis: assessment of safety based on liver function and portal hypertension parameters. J Vasc Interv Radiol. 2014;25:1573-1579. [PMID: 25108816 DOI: 10.1016/j.jvir.2014.06.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
45 Delacourt AT, Mehta AS. Liver Cancer (Current Therapies). Reference Module in Biomedical Sciences. Elsevier; 2021. [DOI: 10.1016/b978-0-12-820472-6.00007-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Kim DY, Kim HJ, Han KH, Han SY, Heo J, Woo HY, Um SH, Kim YH, Kweon YO, Lim HY, Yoon JH, Lee WS, Lee BS, Lee HC, Ryoo BY, Yoon SK. Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data. Cancer Res Treat 2016;48:1243-52. [PMID: 26910470 DOI: 10.4143/crt.2015.278] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
47 Li L, Mo F, Hui EP, Chan SL, Koh J, Tang NLS, Yu SCH, Yeo W. The association of liver function and quality of life of patients with liver cancer. BMC Gastroenterol 2019;19:66. [PMID: 31046687 DOI: 10.1186/s12876-019-0984-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
48 Bogdanovic A, Bulajic P, Masulovic D, Bidzic N, Zivanovic M, Galun D. Liver resection versus transarterial chemoembolization for huge hepatocellular carcinoma: a propensity score matched analysis. Sci Rep 2021;11:4493. [PMID: 33627697 DOI: 10.1038/s41598-021-83868-9] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Kobayashi M, Kudo M, Izumi N, Kaneko S, Azuma M, Copher R, Meier G, Pan J, Ishii M, Ikeda S. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. J Gastroenterol 2019;54:558-70. [PMID: 30788569 DOI: 10.1007/s00535-019-01554-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
50 Costentin CE, Decaens T, Laurent A, Nault J, Paule B, Letoublon C, Luciani A, Calderaro J, Adam R, Bricault I, Amaddeo G, Cherqui D, Mallat A, Samuel D, Duvoux C, Ganne-carrié N, Roudot-thoraval F, Vibert E. Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis. Liver Int 2017;37:1869-76. [DOI: 10.1111/liv.13491] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
51 Levi Sandri GB, Lai Q, Bosco S, Berloco PB. Liver splenosis mimicking hepatocellular carcinoma in cirrhotic liver. Liver Int 2014;34:162. [PMID: 23834329 DOI: 10.1111/liv.12250] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
52 Waidmann O, Trojan J. Novel drugs in clinical development for hepatocellular carcinoma. Expert Opin Investig Drugs. 2015;24:1075-1082. [PMID: 26108356 DOI: 10.1517/13543784.2015.1058776] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
53 Ando Y, Ishigami M, Ito T, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, Fujishiro M. Sarcopenia impairs health-related quality of life in cirrhotic patients. Eur J Gastroenterol Hepatol 2019;31:1550-6. [PMID: 31206408 DOI: 10.1097/MEG.0000000000001472] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
54 Park SH, Bang CS, Kim DJ. Biomarkers in HCV Infection. Adv Clin Chem 2015;70:131-96. [PMID: 26231487 DOI: 10.1016/bs.acc.2015.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
55 Abraham JA, Golubnitschaja O. Time for paradigm change in management of hepatocellular carcinoma: is a personalized approach on the horizon? Per Med 2016;13:455-67. [PMID: 29767598 DOI: 10.2217/pme-2016-0013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
56 Bitterman DS, Sanford NN, Niemierko A, Mahal BA, Qadan M, Ganguli S, Blaszkowsky LS, Zhu AX, Hong TS, Devlin PM, Goyal L, Wo JY. Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma: A Propensity Score-adjusted Analysis. Am J Clin Oncol 2019;42:564-72. [PMID: 31166209 DOI: 10.1097/COC.0000000000000560] [Reference Citation Analysis]
57 Zhang X, Lin X, Qiu H, Peng Z. An investigation of efficacy, safety, and prognostic factors of drug-eluting beads-transarterial chemoembolization operation with CalliSpheres® Microspheres in treating Chinese hepatocellular carcinoma patients. J Clin Lab Anal 2019;33:e22975. [PMID: 31328832 DOI: 10.1002/jcla.22975] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
58 Kim HY, Nam JY, Lee J, Lee HA, Chang Y, Lee HY, Cho H, Lee DH, Cho YY, Cho EJ, Yu SJ, Lee JM, Kim YJ, Yoon J. Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B-endemic area. Aliment Pharmacol Ther 2018;47:1490-501. [DOI: 10.1111/apt.14623] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
59 An J, Na SK, Shim JH, Park YS, Jun MJ, Lee JH, Song GW, Lee HC, Yu E. Histological expression of methionine adenosyl transferase (MAT) 2A as a post-surgical prognostic surrogate in patients with hepatocellular carcinoma. J Surg Oncol. 2018;117:892-901. [PMID: 29448301 DOI: 10.1002/jso.24994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
60 Ferrín G, Aguilar-Melero P, Rodríguez-Perálvarez M, Montero-Álvarez JL, de la Mata M. Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility. Hepat Med 2015;7:1-10. [PMID: 25926760 DOI: 10.2147/HMER.S50161] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
61 Bruguera M. Historia de la hepatología en Cataluña. Gastroenterología y Hepatología 2013;36:484-91. [DOI: 10.1016/j.gastrohep.2013.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Wang Q, Fiel MI, Blank S, Luan W, Kadri H, Kim KW, Manizate F, Rosenblatt AG, Labow DM, Schwartz ME. Impact of liver fibrosis on prognosis following liver resection for hepatitis B-associated hepatocellular carcinoma. Br J Cancer. 2013;109:573-581. [PMID: 23846171 DOI: 10.1038/bjc.2013.352] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
63 Vandewynckel YP, Laukens D, Bogaerts E, Paridaens A, Van den Bussche A, Verhelst X, Van Steenkiste C, Descamps B, Vanhove C, Libbrecht L. Modulation of the unfolded protein response impedes tumor cell adaptation to proteotoxic stress: a PERK for hepatocellular carcinoma therapy. Hepatol Int. 2015;9:93-104. [PMID: 25598862 DOI: 10.1007/s12072-014-9582-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
64 Muszbek N, Evans R, Remak E, Brennan VK, Colaone F, Shergill S, Ross P, Mullan D. Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC). Expert Rev Pharmacoecon Outcomes Res 2021;:1-8. [PMID: 34488517 DOI: 10.1080/14737167.2021.1973892] [Reference Citation Analysis]
65 Qi X, Guo X. Sorafenib for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis: a systematic review of comparative studies. Prz Gastroenterol. 2015;10:142-147. [PMID: 26516379 DOI: 10.5114/pg.2015.52470] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
66 Wang X, Wang W, Ma X, Lu X, Li S, Zeng M, Xu K, Yang C. Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance? Eur Radiol 2020;30:5337-47. [PMID: 32385649 DOI: 10.1007/s00330-020-06861-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
67 Ettorre GM, Levi Sandri GB, Laurenzi A, Colasanti M, Meniconi RL, Lionetti R, Santoro R, Lepiane P, Sciuto R, Pizzi G, Cianni R, Golfieri R, D'Offizi G, Pellicelli AM, Antonini M, Vennarecci G. Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation. World J Surg 2017;41:241-9. [PMID: 27495316 DOI: 10.1007/s00268-016-3682-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
68 Buonaguro L, Tagliamonte M, Petrizzo A, Damiano E, Tornesello ML, Buonaguro FM. Cellular prognostic markers in hepatocellular carcinoma. Future Oncol 2015;11:1591-8. [PMID: 26043213 DOI: 10.2217/fon.15.39] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
69 Perisetti A, Goyal H, Yendala R, Thandassery RB, Giorgakis E. Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements. World J Gastroenterol 2021; 27(24): 3466-3482 [PMID: 34239263 DOI: 10.3748/wjg.v27.i24.3466] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Begini P, Gigante E, Antonelli G, Carbonetti F, Iannicelli E, Anania G, Imperatrice B, Maria Pellicelli A, Delle Fave G, Marignani M. Sarcopenia Predicts Reduced Survival in Patients with Hepatocellular Carcinoma at First Diagnosis. Annals of Hepatology 2017;16:107-14. [DOI: 10.5604/16652681.1226821] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
71 Zhou H, Su L, Liu C, Li B, Li H, Xie Y, Sun D. CTHRC1 May Serve As A Prognostic Biomarker For Hepatocellular Carcinoma. Onco Targets Ther 2019;12:7823-31. [PMID: 31576140 DOI: 10.2147/OTT.S219429] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Tsochatzis EA, Meyer T, O’beirne J, Burroughs AK. Transarterial therapies for hepatocellular carcinoma (HCC): A long way towards standardization. Journal of Hepatology 2013;58:194. [DOI: 10.1016/j.jhep.2012.08.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
73 Palmieri VO, Santovito D, Marano G, Minerva F, Ricci L, D'Alitto F, Angelelli G, Palasciano G. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. Radiol Med 2015;120:627-33. [PMID: 25599661 DOI: 10.1007/s11547-014-0494-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
74 Zhang W, Tan Y, Shen S, Jiang L, Yan L, Yang J, Li B, Wen T, Zeng Y, Wang WT, Xu M. Prognostic nomogram for hepatocellular carcinoma in adolescent and young adult patients after hepatectomy. Oncotarget 2017;8:106393-404. [PMID: 29290957 DOI: 10.18632/oncotarget.18192] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
75 Kim NJ, Jacob DA, Ioannou GN, John BV, Rogal S, Rozenberg-Ben-Dror K. Rates and Predictors of Undergoing Different Hepatocellular Carcinoma Screening Tests in Patients With Cirrhosis. Am J Gastroenterol 2021;116:411-5. [PMID: 33252455 DOI: 10.14309/ajg.0000000000001000] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
76 Fang YS, Wu Q, Zhao HC, Zhou Y, Ye L, Liu SS, Li XX, Du WD. Do combined assays of serum AFP, AFP-L3, DCP, GP73, and DKK-1 efficiently improve the clinical values of biomarkers in decision-making for hepatocellular carcinoma? A meta-analysis. Expert Rev Gastroenterol Hepatol 2021;15:1065-76. [PMID: 33691550 DOI: 10.1080/17474124.2021.1900731] [Reference Citation Analysis]
77 Golfieri R, Bilbao JI, Carpanese L, Cianni R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Cappelli A, Rodriguez M. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. J Hepatol. 2013;59:753-761. [PMID: 23707371 DOI: 10.1016/j.jhep.2013.05.025] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 7.0] [Reference Citation Analysis]
78 Ye SL, Chen X, Yang J, Bie P, Zhang S, Liu F, Liu L, Zhou J, Dou K, Yip CS, Yang X. Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data. Tumour Biol 2017;39:1010428317695030. [PMID: 28349781 DOI: 10.1177/1010428317695030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
79 Yu MH, Kim JH, Yoon J, Kim H, Chung JW, Han JK, Choi B. Small (≤1-cm) Hepatocellular Carcinoma: Diagnostic Performance and Imaging Features at Gadoxetic Acid–enhanced MR Imaging. Radiology 2014;271:748-60. [DOI: 10.1148/radiol.14131996] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 9.0] [Reference Citation Analysis]
80 Hendricks-Wenger A, Saunier S, Simon A, Grider D, Luyimbazi D, Allen IC, Vlaisavljevich E. Histotripsy for the Treatment of Cholangiocarcinoma in a Patient-Derived Xenograft Mouse Model. Ultrasound Med Biol 2021:S0301-5629(21)00423-3. [PMID: 34750030 DOI: 10.1016/j.ultrasmedbio.2021.10.002] [Reference Citation Analysis]
81 Cross TJS, Villanueva A, Shetty S, Wilkes E, Collins P, Adair A, Jones RL, Foxton MR, Meyer T, Stern N, Warshow U, Khan N, Prince M, Khakoo S, Alexander GJ, Khan S, Reeves H, Marshall A, Williams R. A national survey of the provision of ultrasound surveillance for the detection of hepatocellular carcinoma. Frontline Gastroenterol 2016;7:82-9. [PMID: 28840911 DOI: 10.1136/flgastro-2015-100617] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
82 Sauerbruch T, Appenrodt B, Schmitz V, Spengler U. The conservative and interventional treatment of the complications of liver cirrhosis: Part 2 of a series on liver cirrhosis. Dtsch Arztebl Int 2013;110:126-32, I. [PMID: 23505400 DOI: 10.3238/arztebl.2013.0126] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
83 Boas FE, Kamaya A, Do B, Desser TS, Beaulieu CF, Vasanawala SS, Hwang GL, Sze DY. Classification of hypervascular liver lesions based on hepatic artery and portal vein blood supply coefficients calculated from triphasic CT scans. J Digit Imaging 2015;28:213-23. [PMID: 25183580 DOI: 10.1007/s10278-014-9725-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
84 Pinato DJ, Allara E, Chen TY, Trevisani F, Minguez B, Zoli M, Harris M, Dalla Pria A, Merchante N, Platt H, Jain M, Caturelli E, Kikuchi L, Pineda J, Nelson M, Farinati F, Rapaccini GL, Aytaman A, Yin M, Tan CK, Bower M, Giannini EG, Bräu N; Liver Cancer in HIV and ITA.LI.CA Study Groups. Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. J Clin Oncol 2019;37:296-304. [PMID: 30562130 DOI: 10.1200/JCO.18.00885] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
85 Nabih MI, Aref WM, Fathy MM. Significance of plasma osteopontin in diagnosis of hepatitis C virus-related hepatocellular carcinoma. Arab J Gastroenterol. 2014;15:103-107. [PMID: 25249230 DOI: 10.1016/j.ajg.2014.08.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
86 Zeng C, Tang Y, Jiang Y, Zuo Z, Tao H. Long noncoding RNAs as biomarkers for the diagnosis of hepatocellular carcinoma: A meta-analysis. Pathol Res Pract 2021;224:153546. [PMID: 34332221 DOI: 10.1016/j.prp.2021.153546] [Reference Citation Analysis]
87 Kim HY, Kim CW, Choi JY, Park CH, Lee CD, Yim HW. A Decade-old Change in the Screening Rate for Hepatocellular Carcinoma Among a Hepatitis B Virus-infected Population in Korea. Chin Med J (Engl) 2016;129:15-21. [PMID: 26712427 DOI: 10.4103/0366-6999.172551] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
88 Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Misdiagnosis of hepatocellular carcinoma in patients receiving no local-regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form. Clin Transplant 2017;31. [PMID: 28881064 DOI: 10.1111/ctr.13107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
89 Mahnken AH. Current status of transarterial radioembolization. World J Radiol 2016; 8(5): 449-459 [PMID: 27247711 DOI: 10.4329/wjr.v8.i5.449] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
90 Tao J, Zhang W, Yue H, Zhu G, Wu W, Gong W, Fang H, He G, Hu X, Zhao H, Liu A. Prevalence of Hepatitis B Virus Infection in Shenzhen, China, 2015-2018. Sci Rep 2019;9:13948. [PMID: 31558731 DOI: 10.1038/s41598-019-50173-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
91 Hernandez-Gea V, Alsinet C, Llovet JM. Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies? J Hepatol 2013;59:882-4. [PMID: 23673136 DOI: 10.1016/j.jhep.2013.05.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
92 Regenboog M, van Dussen L, Verheij J, Weinreb NJ, Santosa D, Vom Dahl S, Häussinger D, Müller MN, Canbay A, Rigoldi M, Piperno A, Dinur T, Zimran A, Mistry PK, Salah KY, Belmatoug N, Kuter DJ, Hollak CEM. Hepatocellular carcinoma in Gaucher disease: an international case series. J Inherit Metab Dis 2018;41:819-27. [PMID: 29423829 DOI: 10.1007/s10545-018-0142-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
93 Kozlowska J, Mikula T, Suchacz M, Jabnonska J, Stanczak W, Cianciara J, Wiercinska-Drapalo A. Pigment epithelium-derived factor and matrix metalloproteinase-9 in liver cirrhosis. Saudi J Gastroenterol 2016;22:375-9. [PMID: 27748324 DOI: 10.4103/1319-3767.191143] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
94 Shen JD, Fu SZ, Ju LL, Wang YF, Dai F, Liu ZX, Ji HZ, Shao JG, Bian ZL. High expression of ubiquitin-conjugating enzyme E2A predicts poor prognosis in hepatocellular carcinoma. Oncol Lett 2018;15:7362-8. [PMID: 29725449 DOI: 10.3892/ol.2018.8189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
95 Allaire M, Nault J. Advances in management of hepatocellular carcinoma. Current Opinion in Oncology 2017;29:288-95. [DOI: 10.1097/cco.0000000000000378] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
96 Nam HC, Jang B, Song MJ. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma. World J Gastroenterol 2016; 22(40): 8853-8861 [PMID: 27833376 DOI: 10.3748/wjg.v22.i40.8853] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
97 Xiang X, Zhong JH, Wang YY, You XM, Ma L, Xiang BD, Li LQ. Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma. Clin Transl Oncol 2017;19:891-7. [PMID: 28160206 DOI: 10.1007/s12094-017-1621-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
98 Wang Q, Xia D, Bai W, Wang E, Sun J, Huang M, Mu W, Yin G, Li H, Zhao H, Li J, Zhang C, Zhu X, Wu J, Gong W, Li Z, Lin Z, Pan X, Shi H, Shao G, Liu J, Yang S, Zheng Y, Xu J, Song J, Wang W, Wang Z, Zhang Y, Ding R, Zhang H, Yu H, Zheng L, Gu W, You N, Wang G, Zhang S, Feng L, Liu L, Zhang P, Li X, Chen J, Xu T, Zhou W, Zeng H, Huang W, Jiang W, Zhang W, Shao W, Li L, Niu J, Yuan J, Lv Y, Li K, Yin Z, Xia J, Fan D, Han G;  China HCC-TACE Study Group. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. J Hepatol. 2019;70:893-903. [PMID: 30660709 DOI: 10.1016/j.jhep.2019.01.013] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 25.0] [Reference Citation Analysis]
99 Jiang Y, Tie C, Wang Y, Bian D, Liu M, Wang T, Ren Y, Liu S, Bai L, Chen Y, Duan Z, Zheng S, Zhang J. Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From Cirrhosis. Front Oncol 2020;10:1759. [PMID: 33014866 DOI: 10.3389/fonc.2020.01759] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
100 Gbolahan OB, Schacht MA, Beckley EW, LaRoche TP, O'Neil BH, Pyko M. Locoregional and systemic therapy for hepatocellular carcinoma. J Gastrointest Oncol. 2017;8:215-228. [PMID: 28480062 DOI: 10.21037/jgo.2017.03.13] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 9.5] [Reference Citation Analysis]
101 Park B, Choi KS, Suh M, Shin JY, Jun JK. Factors associated with compliance with recommendations for liver cancer screening in Korea: a nationwide survey in Korea. PLoS One 2013;8:e68315. [PMID: 23840846 DOI: 10.1371/journal.pone.0068315] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
102 Yang Z, Qin W, Chen Y, Yuan B, Song X, Wang B, Shen F, Fu J, Wang H. Cholesterol inhibits hepatocellular carcinoma invasion and metastasis by promoting CD44 localization in lipid rafts. Cancer Letters 2018;429:66-77. [DOI: 10.1016/j.canlet.2018.04.038] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
103 Gao X, Chen H, Huang X, Li H, Liu Z, Bo X. ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance. Onco Targets Ther 2019;12:1629-40. [PMID: 30881018 DOI: 10.2147/OTT.S196713] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
104 Soulaidopoulos S, Goulis I, Giannakoulas G, Panagiotidis T, Doumtsis P, Karasmani A, Oikonomou T, Tzoumari T, Karvounis H, Cholongitas Ε. Hepatopulmonary syndrome is associated with the presence of hepatocellular carcinoma in patients with decompensated cirrhosis. Ann Gastroenterol 2017;30:225-31. [PMID: 28243044 DOI: 10.20524/aog.2016.0117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
105 Chan AWH, Zhong J, Berhane S, Toyoda H, Cucchetti A, Shi K, Tada T, Chong CCN, Xiang BD, Li LQ, Lai PBS, Mazzaferro V, García-Fiñana M, Kudo M, Kumada T, Roayaie S, Johnson PJ. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol 2018;69:1284-93. [PMID: 30236834 DOI: 10.1016/j.jhep.2018.08.027] [Cited by in Crossref: 131] [Cited by in F6Publishing: 122] [Article Influence: 43.7] [Reference Citation Analysis]
106 Zhang XY, Li C, Wen TF, Yan LN, Li B, Yang JY, Wang WT, Jiang L. Synchronous splenectomy and hepatectomy for patients with hepatocellular carcinoma and hypersplenism: A case-control study. World J Gastroenterol 2015; 21(8): 2358-2366 [PMID: 25741142 DOI: 10.3748/wjg.v21.i8.2358] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
107 Hirata A, Hirata T, Takahashi Y, Nakayama T. Surveillance rates for hepatocellular carcinoma among patients with cirrhosis, chronic hepatitis B, and chronic hepatitis C based on Japanese claims database. Hepatol Res. 2017;47:283-292. [PMID: 27027417 DOI: 10.1111/hepr.12714] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
108 Scharitzer M, Tamandl D, Ba-ssalamah A. Zufallsbefunde von Leber, Gallensystem, Pankreas und Milz bei asymptomatischen Patienten: Bewertung und Managementempfehlung. Radiologe 2017;57:270-8. [DOI: 10.1007/s00117-017-0235-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
109 Mehdizadeh A, Somi MH, Darabi M, Jabbarpour-bonyadi M. Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma. Mol Biol Rep 2016;43:107-16. [DOI: 10.1007/s11033-016-3943-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
110 Choi SY, Kim KA, Choi W, Kwon Y, Cho SB. Usefulness of Cone-Beam CT-Based Liver Perfusion Mapping for Evaluating the Response of Hepatocellular Carcinoma to Conventional Transarterial Chemoembolization. J Clin Med 2021;10:713. [PMID: 33670213 DOI: 10.3390/jcm10040713] [Reference Citation Analysis]
111 Xie H, Yu H, Tian S, Yang X, Wang X, Wang H, Guo Z. MEIS-1 level in unresectable hepatocellular carcinoma can predict the post-treatment outcomes of radiofrequency ablation. Oncotarget 2018;9:15252-65. [PMID: 29632641 DOI: 10.18632/oncotarget.24165] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
112 Feng D, Wang M, Hu J, Li S, Zhao S, Li H, Liu L. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases. Ann Transl Med 2020;8:553. [PMID: 32411776 DOI: 10.21037/atm.2020.02.116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
113 Fornari F, Ferracin M, Trerè D, Milazzo M, Marinelli S, Galassi M, Venerandi L, Pollutri D, Patrizi C, Borghi A, Foschi FG, Stefanini GF, Negrini M, Bolondi L, Gramantieri L. Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC. PLoS One 2015;10:e0141448. [PMID: 26509672 DOI: 10.1371/journal.pone.0141448] [Cited by in Crossref: 79] [Cited by in F6Publishing: 83] [Article Influence: 13.2] [Reference Citation Analysis]
114 Zhao Y, Wu L, Qin H, Li Q, Shen C, He Y, Yang H. Preoperative combi-elastography for the prediction of early recurrence after curative resection of hepatocellular carcinoma. Clin Imaging 2021;79:173-8. [PMID: 34087717 DOI: 10.1016/j.clinimag.2021.05.020] [Reference Citation Analysis]
115 Huang Y, Ge W, Zhou J, Gao B, Qian X, Wang W. The Role of Tumor Associated Macrophages in Hepatocellular Carcinoma. J Cancer 2021;12:1284-94. [PMID: 33531974 DOI: 10.7150/jca.51346] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
116 Sydor S, Best J, Messerschmidt I, Manka P, Vilchez-Vargas R, Brodesser S, Lucas C, Wegehaupt A, Wenning C, Aßmuth S, Hohenester S, Link A, Faber KN, Moshage H, Cubero FJ, Friedman SL, Gerken G, Trauner M, Canbay A, Bechmann LP. Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC. Clin Transl Gastroenterol 2020;11:e00131. [PMID: 32352707 DOI: 10.14309/ctg.0000000000000131] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
117 Xie DY, Fan HK, Ren ZG, Fan J, Gao Q. Identifying Clonal Origin of Multifocal Hepatocellular Carcinoma and Its Clinical Implications. Clin Transl Gastroenterol 2019;10:e00006. [PMID: 30829920 DOI: 10.14309/ctg.0000000000000006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
118 Díaz-González Á, Forner A. Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2016;30:1001-10. [PMID: 27938779 DOI: 10.1016/j.bpg.2016.10.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
119 Takeda A, Sanuki N, Kunieda E. Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer. World J Gastroenterol 2014; 20(15): 4220-4229 [PMID: 24764660 DOI: 10.3748/wjg.v20.i15.4220] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
120 Rim CH, Kim CY, Yang DS, Yoon WS. The role of external beam radiotherapy for hepatocellular carcinoma patients with lymph node metastasis: a meta-analysis of observational studies. Cancer Manag Res. 2018;10:3305-3315. [PMID: 30233246 DOI: 10.2147/cmar.s175703] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
121 Khalili M, Stewart S. Hepatocellular screening in hepatitis-B infected Asian Americans. J Viral Hepat 2013;20:515-6. [PMID: 23730847 DOI: 10.1111/jvh.12070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
122 Hodgson A, Almansouri Z, Adeyi O, Fischer SE. Gross and microscopic changes of liver neoplasms and background hepatic structures following neoadjuvant therapy. J Clin Pathol 2019;72:112-9. [PMID: 30670563 DOI: 10.1136/jclinpath-2018-205596] [Reference Citation Analysis]
123 Feng GS, Hanley KL, Liang Y, Lin X. Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies. Hepatology 2021;73 Suppl 1:104-14. [PMID: 32715491 DOI: 10.1002/hep.31479] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
124 Shiba S, Shibuya K, Okamoto M, Okazaki S, Komatsu S, Kubota Y, Nakano T, Ohno T. Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma. Radiat Oncol 2020;15:195. [PMID: 32795340 DOI: 10.1186/s13014-020-01634-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
125 Xie ZB, Wang XB, Peng YC, Zhu SL, Ma L, Xiang BD, Gong WF, Chen J, You XM, Jiang JH, Li LQ, Zhong JH. Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. Hepatol Res. 2015;45:190-200. [PMID: 25388603 DOI: 10.1111/hepr.12450] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 6.9] [Reference Citation Analysis]
126 Schoenberg MB, Bucher JN, Vater A, Bazhin AV, Hao J, Guba MO, Angele MK, Werner J, Rentsch M. Resection or Transplant in Early Hepatocellular Carcinoma. Dtsch Arztebl Int 2017;114:519-26. [PMID: 28835324 DOI: 10.3238/arztebl.2017.0519] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
127 Daher S, Massarwa M, Benson AA, Khoury T. Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review. J Clin Transl Hepatol. 2018;6:69-78. [PMID: 29607307 DOI: 10.14218/jcth.2017.00031] [Cited by in Crossref: 97] [Cited by in F6Publishing: 76] [Article Influence: 24.3] [Reference Citation Analysis]
128 Aby ES, Winters AC, Lin J, Bui A, Kawamoto J, Goetz MB, Bhattacharya D, Pisegna JR, May FP, Patel AA, Benhammou JN. A Telephone and Mail Outreach Program Successfully Increases Uptake of Hepatocellular Carcinoma Surveillance. Hepatol Commun 2020;4:825-33. [PMID: 32490319 DOI: 10.1002/hep4.1511] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Lencioni R. Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer. 2012;1:41-50. [PMID: 24159570 DOI: 10.1159/000339019] [Cited by in Crossref: 28] [Cited by in F6Publishing: 45] [Article Influence: 4.0] [Reference Citation Analysis]
130 Sanuki N, Takeda A, Mizuno T, Oku Y, Eriguchi T, Iwabuchi S, Kunieda E. Tumor response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis. AJR Am J Roentgenol. 2013;201:W812-W820. [PMID: 24261388 DOI: 10.2214/ajr.12.10169] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
131 Li R, Cai P, Ma KS, Ding SY, Guo DY, Yan XC. Dynamic enhancement patterns of intrahepatic cholangiocarcinoma in cirrhosis on contrast-enhanced computed tomography: risk of misdiagnosis as hepatocellular carcinoma. Sci Rep. 2016;6:26772. [PMID: 27226026 DOI: 10.1038/srep26772] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
132 Cappelli A, Pettinato C, Golfieri R. Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. J Hepatocell Carcinoma 2014;1:163-82. [PMID: 27508185 DOI: 10.2147/JHC.S50472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
133 Silva MF, Strasser SI, Carrilho FJ. Is hepatic venous pressure gradient assessment required before liver resection in patients with cirrhosis and hepatocellular carcinoma? Clinics (Sao Paulo) 2013;68:437-40. [PMID: 23778344 DOI: 10.6061/clinics/2013(04)01] [Reference Citation Analysis]
134 Forner A, Gilabert M, Bruix J, Raoul JL. Reply: Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. Nat Rev Clin Oncol 2015;12:10. [PMID: 25421282 DOI: 10.1038/nrclinonc.2014.122-c2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
135 Moche M, Busse H, Futterer JJ, Hinestrosa CA, Seider D, Brandmaier P, Kolesnik M, Jenniskens S, Blanco Sequeiros R, Komar G, Pollari M, Eibisberger M, Portugaller HR, Voglreiter P, Flanagan R, Mariappan P, Reinhardt M. Clinical evaluation of in silico planning and real-time simulation of hepatic radiofrequency ablation (ClinicIMPPACT Trial). Eur Radiol 2020;30:934-42. [DOI: 10.1007/s00330-019-06411-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
136 Takeda H, Nishikawa H, Osaki Y, Tsuchiya K, Joko K, Ogawa C, Taniguchi H, Orito E, Uchida Y, Izumi N; Japanese Red Cross Liver Study Group. Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma. Hepatol Res 2015;45:E130-40. [PMID: 25581351 DOI: 10.1111/hepr.12480] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
137 Spano JP, Poizot-Martin I, Costagliola D, Boué F, Rosmorduc O, Lavolé A, Choquet S, Heudel PE, Leblond V, Gabarre J, Valantin MA, Solas C, Guihot A, Carcelain G, Autran B, Katlama C, Quéro L. Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group. Ann Oncol 2016;27:397-408. [PMID: 26681686 DOI: 10.1093/annonc/mdv606] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
138 Sun JJ, Wang K, Zhang CZ, Guo WX, Shi J, Cong WM, Wu MC, Lau WY, Cheng SQ. Postoperative Adjuvant Transcatheter Arterial Chemoembolization After R0 Hepatectomy Improves Outcomes of Patients Who have Hepatocellular Carcinoma with Microvascular Invasion. Ann Surg Oncol. 2016;23:1344-1351. [PMID: 26714945 DOI: 10.1245/s10434-015-5008-z] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 12.0] [Reference Citation Analysis]
139 Golfieri R, Renzulli M, Mosconi C, Forlani L, Giampalma E, Piscaglia F, Trevisani F, Bolondi L. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? J Vasc Interv Radiol. 2013;24:509-517. [PMID: 23428355 DOI: 10.1016/j.jvir.2012.12.013] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 6.9] [Reference Citation Analysis]
140 Li S, Peck-Radosavljevic M, Ubl P, Wadsak W, Mitterhauser M, Rainer E, Pinter M, Wang H, Nanoff C, Kaczirek K, Haug A, Hacker M. The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab. Eur J Nucl Med Mol Imaging 2017;44:1732-41. [PMID: 28555333 DOI: 10.1007/s00259-017-3724-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
141 Somma F, Stoia V, Serra N, D'Angelo R, Gatta G, Fiore F. Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival. PLoS One 2019;14:e0216935. [PMID: 31141552 DOI: 10.1371/journal.pone.0216935] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
142 Bolondi L, Craxi A, Trevisani F, Daniele B, Di Costanzo GG, Fagiuoli S, Cammà C, Bruzzi P, Danesi R, Spandonaro F. Refining sorafenib therapy: lessons from clinical practice. Future Oncol. 2015;11:449-465. [PMID: 25360997 DOI: 10.2217/fon.14.261] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
143 Chon YE, Kim SU, Seo YS, Lee HW, Lee HA, Kim MN, Roh YH, Park JY, Kim DY, Ahn SH, Tak WY, Park SY, Kim BK. Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B. J Gastroenterol Hepatol 2021. [PMID: 34478195 DOI: 10.1111/jgh.15678] [Reference Citation Analysis]
144 Yokoo T, Singal AG, Diaz de Leon A, Ananthakrishnan L, Fetzer DT, Pedrosa I, Khatri G. Prevalence and clinical significance of discordant LI-RADS® observations on multiphase contrast-enhanced MRI in patients with cirrhosis. Abdom Radiol 2020;45:177-87. [DOI: 10.1007/s00261-019-02133-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
145 Gao Z, Du G, Pang Y, Fu Z, Liu C, Liu Y, Zhou B, Kong D, Shi B, Jiang Z, Jin B. Adjuvant transarterial chemoembolization after radical resection contributed to the outcomes of hepatocellular carcinoma patients with high-risk factors. Medicine (Baltimore) 2017;96:e7426. [PMID: 28816936 DOI: 10.1097/MD.0000000000007426] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
146 An J, Chang S, Kim HI, Song GW, Shim JH. The clinical behavior and survival of patients with hepatocellular carcinoma and a family history of the disease. Cancer Med 2019;8:6624-33. [PMID: 31532075 DOI: 10.1002/cam4.2543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
147 von Köckritz L, Dufour JF. Management of chronic hepatitis C in 2017. Hamostaseologie 2017;37:186-95. [PMID: 27896359 DOI: 10.5482/HAMO-16-07-0019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
148 Reis H, Pütter C, Megger DA, Bracht T, Weber F, Hoffmann A, Bertram S, Wohlschläger J, Hagemann S, Eisenacher M, Scherag A, Schlaak JF, Canbay A, Meyer HE, Sitek B, Baba HA. A structured proteomic approach identifies 14-3-3Sigma as a novel and reliable protein biomarker in panel based differential diagnostics of liver tumors. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 2015;1854:641-50. [DOI: 10.1016/j.bbapap.2014.10.024] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
149 Finkelmeier F, Dultz G, Peiffer KH, Kronenberger B, Krauss F, Zeuzem S, Sarrazin C, Vermehren J, Waidmann O. Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals. Liver Cancer 2018;7:190-204. [PMID: 29888208 DOI: 10.1159/000486812] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
150 Hsieh WY, Chen PH, Lin IY, Su CW, Chao Y, Huo TI, Huang YH, Hou MC, Lin HC, Wu JC. The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma. Sci Rep 2017;7:42577. [PMID: 28209963 DOI: 10.1038/srep42577] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
151 Xing H, Zheng YJ, Han J, Zhang H, Li ZL, Lau WY, Shen F, Yang T. Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis. Hepatobiliary Pancreat Dis Int. 2018;17:487-495. [PMID: 30257796 DOI: 10.1016/j.hbpd.2018.09.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
152 Li B, Pu K, Wu X. Identifying novel biomarkers in hepatocellular carcinoma by weighted gene co-expression network analysis. J Cell Biochem 2019. [PMID: 30746803 DOI: 10.1002/jcb.28420] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
153 Chen ZX, Jian ZW, Wu XW, Wang JC, Peng JY, Lao XM. Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization. Cancer Med 2019;8:5097-107. [PMID: 31313476 DOI: 10.1002/cam4.2380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
154 Low HM, Choi JY, Tan CH. Pathological variants of hepatocellular carcinoma on MRI: emphasis on histopathologic correlation. Abdom Radiol (NY) 2019;44:493-508. [PMID: 30145629 DOI: 10.1007/s00261-018-1749-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
155 Cui X, Wu Y, Wang Z, Liu X, Wang S, Qin C. MicroRNA-34a expression is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. Tumour Biol. 2015;36:3887-3893. [PMID: 25596083 DOI: 10.1007/s13277-014-3031-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
156 Yaghmai V, Besa C, Kim E, Gatlin JL, Siddiqui NA, Taouli B. Imaging Assessment of Hepatocellular Carcinoma Response to Locoregional and Systemic Therapy. American Journal of Roentgenology 2013;201:80-96. [DOI: 10.2214/ajr.13.10706] [Cited by in Crossref: 53] [Cited by in F6Publishing: 18] [Article Influence: 6.6] [Reference Citation Analysis]
157 Pascut D, Sukowati CHC, Antoniali G, Mangiapane G, Burra S, Mascaretti LG, Buonocore MR, Crocè LS, Tiribelli C, Tell G. Serum AP-endonuclease 1 (sAPE1) as novel biomarker for hepatocellular carcinoma. Oncotarget 2019;10:383-94. [PMID: 30719231 DOI: 10.18632/oncotarget.26555] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
158 Kim HY, Park JW. Current immunotherapeutic strategies in hepatocellular carcinoma: recent advances and future directions. Therap Adv Gastroenterol 2017;10:805-14. [PMID: 29051790 DOI: 10.1177/1756283X17722061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
159 Zhang Z, Chen P, Xie H, Cao P. Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: A systematic review and meta-analysis. Cancer Med 2020;9:1349-64. [PMID: 31876977 DOI: 10.1002/cam4.2799] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
160 Lin YC, Lee BH, Alagie J, Su CH. Combination treatment of ergosterol followed by amphotericin B induces necrotic cell death in human hepatocellular carcinoma cells. Oncotarget 2017;8:72727-38. [PMID: 29069821 DOI: 10.18632/oncotarget.20285] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
161 Strazzulla A, Matera G, Mammone SV, Vaccaro V, Pisani V, Costa C, Manti F, Doldo P, Cosco L, Quintieri F, Cesario F, Liberto MC, Giancotti A, Torti C, Focà A. Challenging clinical cases in HCV infection. BMC Infect Dis 2014;14 Suppl 5:S7. [PMID: 25236848 DOI: 10.1186/1471-2334-14-S5-S7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
162 Richtig G, Aigelsreiter A, Schwarzenbacher D, Ress AL, Adiprasito JB, Stiegelbauer V, Hoefler G, Schauer S, Kiesslich T, Kornprat P, Winder T, Eisner F, Gerger A, Stoeger H, Stauber R, Lackner C, Pichler M. SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types. PLoS One 2017;12:e0187814. [PMID: 29121666 DOI: 10.1371/journal.pone.0187814] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
163 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67:145-172. [PMID: 28427765 DOI: 10.1016/j.jhep.2017.03.022] [Cited by in Crossref: 409] [Cited by in F6Publishing: 326] [Article Influence: 102.3] [Reference Citation Analysis]
164 Cisneros-garza L, González-huezo M, López-cossio J, Kuljacha-gastelum A. Caracterización del carcinoma hepatocelular en México. Revista de Gastroenterología de México 2018;83:223-7. [DOI: 10.1016/j.rgmx.2017.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
165 Nault JC, De Reyniès A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, Decaens T, Franco D, Imbeaud S, Rousseau F. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology. 2013;145:176-187. [PMID: 23567350 DOI: 10.1053/j.gastro.2013.03.051] [Cited by in Crossref: 226] [Cited by in F6Publishing: 209] [Article Influence: 28.3] [Reference Citation Analysis]
166 Kim TK, Khalili K, Jang HJ. Local ablation therapy with contrast-enhanced ultrasonography for hepatocellular carcinoma: a practical review. Ultrasonography 2015;34:235-45. [PMID: 26169081 DOI: 10.14366/usg.15018] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
167 Ng KKC, Chok KSH, Chan ACY, Cheung TT, Wong TCL, Fung JYY, Yuen J, Poon RTP, Fan ST, Lo CM. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. British Journal of Surgery 2017;104:1775-84. [DOI: 10.1002/bjs.10677] [Cited by in Crossref: 90] [Cited by in F6Publishing: 83] [Article Influence: 22.5] [Reference Citation Analysis]
168 Howard SA, Krajewski KM, Weissman BN, Seltzer SE, Ramaiya NH, Van den Abbeele AD. Cancer Imaging Training in the 21st Century: An Overview of Where We Are, and Where We Need To Be. Journal of the American College of Radiology 2015;12:714-20. [DOI: 10.1016/j.jacr.2015.03.044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
169 Shim JH, Jun MJ, Han S, Lee YJ, Lee SG, Kim KM, Lim YS, Lee HC. Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma. Ann Surg. 2015;261:939-946. [PMID: 24950276 DOI: 10.1097/sla.0000000000000747] [Cited by in Crossref: 128] [Cited by in F6Publishing: 66] [Article Influence: 21.3] [Reference Citation Analysis]
170 Graf D, Vallböhmer D, Knoefel WT, Kröpil P, Antoch G, Sagir A, Häussinger D. Multimodal treatment of hepatocellular carcinoma. Eur J Intern Med. 2014;25:430-437. [PMID: 24666568 DOI: 10.1016/j.ejim.2014.03.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 6.7] [Reference Citation Analysis]
171 Chen T, Wong R, Wong P, Rollet-kurhajec KC, Alshaalan R, Deschenes M, Ghali P, Sebastiani G. Occult cirrhosis diagnosed by transient elastography is a frequent and under-monitored clinical entity. Liver Int 2015;35:2285-93. [DOI: 10.1111/liv.12802] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
172 Wörns MA, Galle PR. HCC therapies--lessons learned. Nat Rev Gastroenterol Hepatol 2014;11:447-52. [PMID: 24492278 DOI: 10.1038/nrgastro.2014.10] [Cited by in Crossref: 98] [Cited by in F6Publishing: 92] [Article Influence: 14.0] [Reference Citation Analysis]
173 Kemp L, Clare KE, Brennan PN, Dillon JF. New horizons in hepatitis B and C in the older adult. Age Ageing 2019;48:32-7. [PMID: 30379991 DOI: 10.1093/ageing/afy170] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Shibuya K, Ohno T, Terashima K, Toyama S, Yasuda S, Tsuji H, Okimoto T, Shioyama Y, Nemoto K, Kamada T, Nakano T; Japan Carbon Ion Radiotherapy Study Group. Short-course carbon-ion radiotherapy for hepatocellular carcinoma: A multi-institutional retrospective study. Liver Int. 2018;38:2239-2247. [PMID: 30240527 DOI: 10.1111/liv.13969] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
175 Wong L, Bozhilov K, Hernandez B, Kwee S, Chan O, Ellis L, LeMarchand L. Underlying liver disease and advanced stage liver cancer are associated with elevated neutrophil-lymphocyte ratio. Clin Mol Hepatol. 2019;25:305-316. [PMID: 31001964 DOI: 10.3350/cmh.2019.0004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
176 Li D, Cheng Z, Chen G, Liu F, Wu W, Yu J, Gu Y, Liu F, Ren C, Liang P. A multimodality imaging-compatible insertion robot with a respiratory motion calibration module designed for ablation of liver tumors: a preclinical study. International Journal of Hyperthermia 2018;34:1194-201. [DOI: 10.1080/02656736.2018.1456680] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
177 Chang W, Lee JM, Lee SM, Han JK. No-Touch Radiofrequency Ablation: A Comparison of Switching Bipolar and Switching Monopolar Ablation in Ex Vivo Bovine Liver. Korean J Radiol 2017;18:279-88. [PMID: 28246508 DOI: 10.3348/kjr.2017.18.2.279] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
178 Pinato DJ, Sharma R, Citti C, Platt H, Ventura-Cots M, Allara E, Chen TY, Dalla Pria A, Jain M, Mínguez B, Kikuchi L, Kaufman West E, Merli M, Kaplan DE, Hasson H, Marks K, Nelson M, Núñez M, Aytaman A, Bower M, Bräu N; Liver Cancer in HIV Study Group. The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma. Aliment Pharmacol Ther 2018;47:95-103. [PMID: 29034998 DOI: 10.1111/apt.14356] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
179 Howell J, Balderson G, Hellard M, Gow P, Strasser S, Stuart K, Wigg A, Jeffrey G, Gane E, Angus PW. The increasing burden of potentially preventable liver disease among adult liver transplant recipients: A comparative analysis of liver transplant indication by era in Australia and New Zealand: Increasing burden of preventable liver disease. Journal of Gastroenterology and Hepatology 2016;31:434-41. [DOI: 10.1111/jgh.13082] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
180 Lee SY, Kingham TP, LaGratta MD, Jessurun J, Cherqui D, Jarnagin WR, Kluger MD. PET-avid hepatocellular adenomas: incidental findings associated with HNF1-α mutated lesions. HPB (Oxford) 2015. [PMID: 26472264 DOI: 10.1111/hpb.12489] [Reference Citation Analysis]
181 Testoni SGG, Healey AJ, Dietrich CF, Arcidiacono PG. Systematic review of endoscopy ultrasound-guided thermal ablation treatment for pancreatic cancer. Endosc Ultrasound 2020;9:83-100. [PMID: 32295966 DOI: 10.4103/eus.eus_74_19] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
182 Sakai H, Shirakami Y, Shimizu M. Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents. World J Gastroenterol 2016; 22(1): 394-406 [PMID: 26755885 DOI: 10.3748/wjg.v22.i1.394] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
183 Yamakado K, Hirota S. Sub-classification of intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinomas. World J Gastroenterol 2015; 21(37): 10604-10608 [PMID: 26457020 DOI: 10.3748/wjg.v21.i37.10604] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
184 Signoretti M, Valente R, Repici A, Delle Fave G, Capurso G, Carrara S. Endoscopy-guided ablation of pancreatic lesions: Technical possibilities and clinical outlook. World J Gastrointest Endosc 2017; 9(2): 41-54 [PMID: 28250896 DOI: 10.4253/wjge.v9.i2.41] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
185 Ricco G, Cavallone D, Cosma C, Caviglia GP, Oliveri F, Biasiolo A, Abate ML, Plebani M, Smedile A, Bonino F, Pontisso P, Brunetto MR. Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers.Cancer Biomark. 2018;21:603-612. [PMID: 29278878 DOI: 10.3233/CBM-170551] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
186 Wang XH, Liao B, Hu WJ, Tu CX, Xiang CL, Hao SH, Mao XH, Qiu XM, Yang XJ, Yue X, Kuang M, Peng BG, Li SQ. Novel Models Predict Postsurgical Recurrence and Overall Survival for Patients with Hepatitis B Virus-Related Solitary Hepatocellular Carcinoma ≤10 cm and Without Portal Venous Tumor Thrombus. Oncologist 2020;25:e1552-61. [PMID: 32663354 DOI: 10.1634/theoncologist.2019-0766] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
187 Motola DL, Caravan P, Chung RT, Fuchs BC. Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions. Curr Pathobiol Rep 2014;2:245-56. [PMID: 25396099 DOI: 10.1007/s40139-014-0061-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
188 Xuan Z, Zhou L, Wang Y, Zheng X. Prognostic value of the combination of serum levels of vascular endothelial growth factor, C-reactive protein and contrast-enhanced ultrasound in patients with primary liver cancer who underwent transcatheter arterial chemoembolization. Expert Review of Anticancer Therapy 2017;17:1169-78. [DOI: 10.1080/14737140.2017.1395284] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
189 Cong M, Ou X, Huang J, Long J, Li T, Liu X, Wang Y, Wu X, Zhou J, Sun Y, Shang Q, Chen G, Ma H, Xie W, Piao H, Yang Y, Gao Z, Xu X, Tan Z, Chen C, Zeng N, Wu S, Kong Y, Liu T, Wang P, You H, Jia J, Zhuang H. A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus. OMICS 2020;24:415-23. [PMID: 32522092 DOI: 10.1089/omi.2020.0055] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
190 López-López V, Robles-Campos R, Brusadin R, López-Conesa A, Navarro Á, Arevalo-Perez J, Gil PJ, Parrilla P. Tourniquet-ALPPS is a promising treatment for very large hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Oncotarget 2018;9:28267-80. [PMID: 29963276 DOI: 10.18632/oncotarget.25538] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
191 Choi SH, Byun JH, Kim SY, Lee SJ, Won HJ, Shin YM, Kim PN. Liver Imaging Reporting and Data System v2014 With Gadoxetate Disodium–Enhanced Magnetic Resonance Imaging: Validation of LI-RADS Category 4 and 5 Criteria. Invest Radiol 2016;51:483-90. [DOI: 10.1097/rli.0000000000000258] [Cited by in Crossref: 60] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
192 Czaja AJ. Review article: the management of autoimmune hepatitis beyond consensus guidelines. Aliment Pharmacol Ther 2013;38:343-64. [DOI: 10.1111/apt.12381] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 5.6] [Reference Citation Analysis]
193 Kanda T, Ogasawara S, Chiba T, Haga Y, Omata M, Yokosuka O. Current management of patients with hepatocellular carcinoma. World J Hepatol 2015; 7(15): 1913-1920 [PMID: 26244066 DOI: 10.4254/wjh.v7.i15.1913] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
194 Lee DH, Lee JM, Kang TW, Rhim H, Kim SY, Shin YM, Seo JW, Choi MH, Lee KB. Clinical Outcomes of Radiofrequency Ablation for Early Hypovascular HCC: A Multicenter Retrospective Study. Radiology 2018;286:338-49. [DOI: 10.1148/radiol.2017162452] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
195 Li JF, Zheng EQ, Xie M. Association between rs738409 polymorphism in patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene and hepatocellular carcinoma susceptibility: Evidence from case-control studies. Gene 2019;685:143-8. [PMID: 30403964 DOI: 10.1016/j.gene.2018.11.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
196 Chang RH, Nyamsuren T, Gyawali S, Fu SC, Huang YW, Hu RT, Yang SS. Long-term Nucleos(t)ides Analogues for Chronic Hepatitis B Improve Liver and Spleen Size: A Noninvasive Sonographic Study. J Med Ultrasound 2017;25:161-6. [PMID: 30065482 DOI: 10.1016/j.jmu.2017.03.013] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
197 Mohr R, Schierwagen R, Schwarze-Zander C, Boesecke C, Wasmuth JC, Trebicka J, Rockstroh JK. Liver Fibrosis in HIV Patients Receiving a Modern cART: Which Factors Play a Role? Medicine (Baltimore). 2015;94:e2127. [PMID: 26683921 DOI: 10.1097/md.0000000000002127] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
198 Donati B, Dongiovanni P, Romeo S, Meroni M, McCain M, Miele L, Petta S, Maier S, Rosso C, De Luca L, Vanni E, Grimaudo S, Romagnoli R, Colli F, Ferri F, Mancina RM, Iruzubieta P, Craxi A, Fracanzani AL, Grieco A, Corradini SG, Aghemo A, Colombo M, Soardo G, Bugianesi E, Reeves H, Anstee QM, Fargion S, Valenti L. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Sci Rep. 2017;7:4492. [PMID: 28674415 DOI: 10.1038/s41598-017-04991-0] [Cited by in Crossref: 102] [Cited by in F6Publishing: 102] [Article Influence: 25.5] [Reference Citation Analysis]
199 Varona MA, Soriano A, Aguirre-Jaime A, Garrido S, Oton E, Diaz D, Portero J, Bravo P, Barrera MA, Perera A. Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience. Transplant Proc. 2015;47:84-89. [PMID: 25645778 DOI: 10.1016/j.transproceed.2014.12.013] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
200 Yu R, Ding S, Tan W, Tan S, Tan Z, Xiang S, Zhou Y, Mao Q, Deng G. Performance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) for Hepatocellular Carcinoma Screening in Chinese Population. Hepat Mon. 2015;15:e28806. [PMID: 26300931 DOI: 10.5812/hepatmon.28806v2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
201 Rim CH, Yoon WS. Leaflet manual of external beam radiation therapy for hepatocellular carcinoma: a review of the indications, evidences, and clinical trials. Onco Targets Ther. 2018;11:2865-2874. [PMID: 29844684 DOI: 10.2147/ott.s164651] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
202 Quaia E. State of the Art: LI-RADS for Contrast-enhanced US. Radiology 2019;293:4-14. [DOI: 10.1148/radiol.2019190005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
203 Sultanik P, Ginguay A, Vandame J, Popovici T, Meritet JF, Cynober L, Pol S, Bories PN. Diagnostic accuracy of des-gamma-carboxy prothrombin for hepatocellular carcinoma in a French cohort using the Lumipulse® G600 analyzer. J Viral Hepat 2017;24:80-5. [PMID: 27699936 DOI: 10.1111/jvh.12622] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
204 Yılmaz Y, Güneş A, Topel H, Atabey N. Signaling Pathways as Potential Therapeutic Targets in Hepatocarcinogenesis. J Gastrointest Cancer 2017;48:225-37. [PMID: 28819741 DOI: 10.1007/s12029-017-9958-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
205 Buivydiene A, Liakina V, Kashuba E, Norkuniene J, Jokubauskiene S, Gineikiene E, Valantinas J. Impact of the Uridine⁻Cytidine Kinase Like-1 Protein and IL28B rs12979860 and rs8099917 SNPs on the Development of Hepatocellular Carcinoma in Cirrhotic Chronic Hepatitis C Patients-A Pilot Study. Medicina (Kaunas) 2018;54:E67. [PMID: 30344298 DOI: 10.3390/medicina54050067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
206 Han G, Yang J, Shao G, Teng G, Wang M, Yang J, Liu Z, Feng G, Yang R, Lu L. Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial. Future Oncol. 2013;9:403-410. [PMID: 23469975 DOI: 10.2217/fon.13.11] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
207 Zhang YF, Guo RP, OuYang HY, Shen JX, Zhao J, Tan GS, Le Y, Wei W, Shi M. Target lesion response predicts survival of patients with hepatocellular carcinoma retreated with transarterial chemoembolization. Liver Int 2016;36:1516-24. [PMID: 27105296 DOI: 10.1111/liv.13149] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
208 Liu Y, Mao Y, Wang J, Wang J, Lao X, Chen M, Li S. Hepatocellular carcinoma with en bloc diaphragmatic resection: A single-center experience over 14 years. International Journal of Surgery 2018;53:93-7. [DOI: 10.1016/j.ijsu.2018.03.033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
209 Xu F, Zhang L, Xu Y, Song D, He W, Ji X, Shao J. Hypermethylation of SCAND3 and Myo1g Gene Are Potential Diagnostic Biomarkers for Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2332. [PMID: 32824823 DOI: 10.3390/cancers12082332] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
210 Demir M, Grünewald F, Lang S, Schramm C, Bowe A, Mück V, Kütting F, Goeser T, Steffen HM. Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients. Medicine (Baltimore) 2016;95:e4602. [PMID: 27661015 DOI: 10.1097/MD.0000000000004602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
211 Rong G, Chen Y, Yu Z, Li Q, Bi J, Tan L, Xiang D, Shang Q, Lei C, Chen L, Hu X, Wang J, Liu H, Lu W, Chen Y, Dong Z, Bai W, Yoshida EM, Mendez-Sanchez N, Hu KQ, Qi X, Yang Y. Synergistic Effect of Biejia-Ruangan on Fibrosis Regression in Patients with Chronic Hepatitis B Treated with Entecavir: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial. J Infect Dis 2020:jiaa266. [PMID: 32437567 DOI: 10.1093/infdis/jiaa266] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
212 Khan AS, Fowler KJ, Chapman WC. Current surgical treatment strategies for hepatocellular carcinoma in North America. World J Gastroenterol 2014; 20(41): 15007-15017 [PMID: 25386049 DOI: 10.3748/wjg.v20.i41.15007] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
213 Pamoukdjian F, Canoui-Poitrine F, Longelin-Lombard C, Aparicio T, Ganne N, Wind P, Martinez-Tapia C, Audureau E, Sebbane G, Zelek L, Paillaud E. Diagnostic performance of gait speed, G8 and G8 modified indices to screen for vulnerability in older cancer patients: the prospective PF-EC cohort study. Oncotarget 2017;8:50393-402. [PMID: 28881570 DOI: 10.18632/oncotarget.17361] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
214 Longo L, Rodrigues de Freitas LB, Santos D, Grivicich I, Álvares-da-Silva MR. BCLC-B Subclassification and the Hong Kong Liver Cancer System in Intermediate Hepatocellular Carcinoma: Identifying Candidates for Curative Therapy. Am J Clin Oncol 2019;42:466-71. [PMID: 30913090 DOI: 10.1097/COC.0000000000000539] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
215 Aggarwal M, Arain A, Jin Z. Systemic treatment for hepatocellular carcinoma. Chronic Dis Transl Med 2018;4:148-55. [PMID: 30276361 DOI: 10.1016/j.cdtm.2018.08.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
216 Jang HY, Choi JI, Lee YJ, Park MY, Yeo DM, Rha SE, Jung ES, You YK, Kim DG, Byun JY. Performance of Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging for Predicting Patient Eligibility for Liver Transplantation Based on the Milan Criteria. J Comput Assist Tomogr 2017;41:25-31. [PMID: 27768617 DOI: 10.1097/RCT.0000000000000476] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
217 Nishikawa H, Enomoto H, Iwata Y, Kishino K, Shimono Y, Hasegawa K, Nakano C, Takata R, Ishii A, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Iijima H, Nishiguchi S. Prognostic significance of nonprotein respiratory quotient in patients with liver cirrhosis. Medicine (Baltimore) 2017;96:e5800. [PMID: 28099336 DOI: 10.1097/MD.0000000000005800] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
218 Lin SH, Eng HL, Liu YW, Lin CC, Yong CC, Wang CC, Chen CL, Kuo FY, Cheng YF, Wang JH, Yen YH, Liu TT, Li WF, Chen CH. Characteristics and prognosis of patients with large well-differentiated hepatocellular carcinoma who have undergone resection. Am J Surg 2021:S0002-9610(21)00226-9. [PMID: 33840448 DOI: 10.1016/j.amjsurg.2021.03.065] [Reference Citation Analysis]
219 Kunnimalaiyaan S, Sokolowski K, Gamblin TC, Kunnimalaiyaan M. Suberoylanilide hydroxamic Acid, a histone deacetylase inhibitor, alters multiple signaling pathways in hepatocellular carcinoma cell lines. Am J Surg 2017;213:645-51. [PMID: 28007318 DOI: 10.1016/j.amjsurg.2016.12.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
220 Dhanasekaran R, Talwalkar JA. Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma. Curr Gastroenterol Rep 2015;17:34. [PMID: 26238927 DOI: 10.1007/s11894-015-0459-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
221 Forner A, Rodríguez-Lopez C, Reig M. Natural history and staging for hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2012;1:183-5. [PMID: 31186883 DOI: 10.1002/cld.129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
222 Jang ES, Jeong SH, Kim JW, Choi YS, Leissner P, Brechot C. Diagnostic Performance of Alpha-Fetoprotein, Protein Induced by Vitamin K Absence, Osteopontin, Dickkopf-1 and Its Combinations for Hepatocellular Carcinoma. PLoS One. 2016;11:e0151069. [PMID: 26986465 DOI: 10.1371/journal.pone.0151069] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]
223 Kang KJ, Ahn KS. Is the Barcelona Clinic Liver Cancer guideline for treating intermediate to advanced staged hepatocellular carcinoma still appropriate? Ann Transl Med 2021;9:1. [PMID: 33553294 DOI: 10.21037/atm-2020-132] [Reference Citation Analysis]
224 Bota S, Piscaglia F, Marinelli S, Pecorelli A, Terzi E, Bolondi L. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma. Liver Cancer. 2012;1:190-200. [PMID: 24159584 DOI: 10.1159/000343833] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 8.0] [Reference Citation Analysis]
225 Chang TS, Wu YC, Tung SY, Wei KL, Hsieh YY, Huang HC, Chen WM, Shen CH, Lu CH, Wu CS. Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. Am J Gastroenterol. 2015;110:836-844; quiz 845. [PMID: 25869392 DOI: 10.1038/ajg.2015.100] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 10.3] [Reference Citation Analysis]
226 Gramenzi A, Golfieri R, Mosconi C, Cappelli A, Granito A, Cucchetti A, Marinelli S, Pettinato C, Erroi V, Fiumana S, Bolondi L, Bernardi M, Trevisani F; BLOG (Bologna Liver Oncology Group). Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int. 2015;35:1036-1047. [PMID: 24750853 DOI: 10.1111/liv.12574] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 9.9] [Reference Citation Analysis]
227 Golse N, Joly F, Combari P, Lewin M, Nicolas Q, Audebert C, Samuel D, Allard MA, Sa Cunha A, Castaing D, Cherqui D, Adam R, Vibert E, Vignon-Clementel IE. Predicting the risk of post-hepatectomy portal hypertension using a digital twin: A clinical proof of concept. J Hepatol 2021;74:661-9. [PMID: 33212089 DOI: 10.1016/j.jhep.2020.10.036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
228 Demir M, Nigemeier J, Kütting F, Bowe A, Schramm C, Hoffmann V, Waldschmidt D, Goeser T, Steffen HM. Clinical management of chronic hepatitis B infection: results from a registry at a German tertiary referral center. Infection 2015;43:153-62. [PMID: 25701223 DOI: 10.1007/s15010-015-0751-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
229 Tsilimigras DI, Bagante F, Sahara K, Moris D, Hyer JM, Wu L, Ratti F, Marques HP, Soubrane O, Paredes AZ, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification. Ann Surg Oncol 2019;26:3693-700. [PMID: 31267302 DOI: 10.1245/s10434-019-07580-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 16.5] [Reference Citation Analysis]
230 Liang H, Cui P, Guo Q, Mao X, Wen F, Sun W, Shan M, Lu Z. Prognostic factors of hepatocellular carcinoma patients with portal vein tumor thrombosis treated with transcatheter arterial chemoembolization. Asia Pac J Clin Oncol 2017;13:e331-41. [PMID: 28078806 DOI: 10.1111/ajco.12606] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
231 von Felden J, Heim D, Schulze K, Krech T, Ewald F, Nashan B, Lohse AW, Wege H. High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection. BMC Cancer 2017;17:60. [PMID: 28100188 DOI: 10.1186/s12885-017-3053-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
232 Jha RC, Mitchell DG, Weinreb JC, Santillan CS, Yeh BM, Francois R, Sirlin CB. LI-RADS Categorization of Benign and Likely Benign Findings in Patients at Risk of Hepatocellular Carcinoma: A Pictorial Atlas. American Journal of Roentgenology 2014;203:W48-69. [DOI: 10.2214/ajr.13.12169] [Cited by in Crossref: 31] [Cited by in F6Publishing: 12] [Article Influence: 4.4] [Reference Citation Analysis]
233 Nischalke HD, Lutz P, Krämer B, Söhne J, Müller T, Rosendahl J, Fischer J, Berg T, Hittatiya K, Fischer H, Soyka M, Semmo N, Nattermann J, Sauerbruch T, Strassburg CP, Stickel F, Spengler U. A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease. Journal of Hepatology 2014;61:1073-9. [DOI: 10.1016/j.jhep.2014.06.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
234 Meniconi RL, Komatsu S, Perdigao F, Boëlle PY, Soubrane O, Scatton O. Recurrent hepatocellular carcinoma: a Western strategy that emphasizes the impact of pathologic profile of the first resection. Surgery. 2015;157:454-462. [PMID: 25633732 DOI: 10.1016/j.surg.2014.10.011] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
235 Galastri FL, Nasser F, Affonso BB, Valle LGM, Odísio BC, Motta-Leal Filho JM, Salvalaggio PR, Garcia RG, de Almeida MD, Baroni RH, Wolosker N. Imaging response predictors following drug eluting beads chemoembolization in the neoadjuvant liver transplant treatment of hepatocellular carcinoma. World J Hepatol 2020; 12(1): 21-33 [PMID: 31984118 DOI: 10.4254/wjh.v12.i1.21] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
236 Chen CL, Chang WC, Yi CH, Hung JS, Liu TT, Lei WY, Hsu CS. Association of coffee consumption and liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B: A 5-year population-based cohort study. J Formos Med Assoc 2019;118:628-35. [PMID: 30122312 DOI: 10.1016/j.jfma.2018.08.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
237 Lee M, Chung GE, Lee JH, Oh S, Nam JY, Chang Y, Cho H, Ahn H, Cho YY, Yoo JJ, Cho Y, Lee DH, Cho EJ, Yu SJ, Lee DH, Lee JM, Kim YJ, Yoon JH. Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. Hepatology 2017;66:1556-69. [PMID: 28617992 DOI: 10.1002/hep.29318] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 11.0] [Reference Citation Analysis]
238 Mittal S, Sada YH, El-Serag HB, Kanwal F, Duan Z, Temple S, May SB, Kramer JR, Richardson PA, Davila JA. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015;13:594-601.e1. [PMID: 25148760 DOI: 10.1016/j.cgh.2014.08.013] [Cited by in Crossref: 143] [Cited by in F6Publishing: 137] [Article Influence: 20.4] [Reference Citation Analysis]
239 Li Y, Ruan DY, Jia CC, Zhao H, Wang GY, Yang Y, Jiang N. Surgical resection versus liver transplantation for hepatocellular carcinoma within the Hangzhou criteria: a preoperative nomogram-guided treatment strategy. Hepatobiliary Pancreat Dis Int 2017;16:480-6. [PMID: 28992879 DOI: 10.1016/S1499-3872(17)60052-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
240 Guo JH, Liu SX, Gao S, Kou FX, Zhang X, Wu D, Li XT, Chen H, Wang XD, Liu P, Zhang PJ, Xu HF, Cao G, Zhu LZ, Yang RJ, Zhu X. Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma. World J Gastroenterol 2020; 26(27): 3975-3988 [PMID: 32774071 DOI: 10.3748/wjg.v26.i27.3975] [Reference Citation Analysis]
241 Carville KS, MacLachlan JH, Thursfield V, Cowie BC. Hepatocellular carcinoma over three decades in Victoria, Australia: epidemiology, diagnosis and trends, 1984-2013. Intern Med J 2018;48:835-44. [PMID: 29604152 DOI: 10.1111/imj.13823] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
242 Nguang SH, Wu CK, Liang CM, Tai WC, Yang SC, Ku MK, Yuan LT, Wang JW, Tseng KL, Hung TH, Hsu PI, Wu DC, Chuah SK, Hsu CN. Treatment and Cost of Hepatocellular Carcinoma: A Population-Based Cohort Study in Taiwan. Int J Environ Res Public Health 2018;15:E2655. [PMID: 30486324 DOI: 10.3390/ijerph15122655] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
243 Ha J, Wong RJ. Nonsurgical options for localized hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2017;10:103-6. [PMID: 31186897 DOI: 10.1002/cld.662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
244 Easom NJW, Marks M, Jobe D, Gillmore R, Meyer T, Maini MK, Njie R. ULBP1 Is Elevated in Human Hepatocellular Carcinoma and Predicts Outcome. Front Oncol 2020;10:971. [PMID: 32656081 DOI: 10.3389/fonc.2020.00971] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
245 van Meer S, de Man RA, van den Berg AP, Houwen RH, Linn FH, van Oijen MG, Siersema PD, van Erpecum KJ. No increased risk of hepatocellular carcinoma in cirrhosis due to Wilson disease during long-term follow-up. J Gastroenterol Hepatol. 2015;30:535-539. [PMID: 25160780 DOI: 10.1111/jgh.12716] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
246 Kim JH, Sinn DH, Lee JH, Hyun D, Cho SK, Shin SW, Chang Y, Kim YJ, Yoon JH, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Choi MS. Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. Dig Dis Sci. 2018;63:1062-1071. [PMID: 29442276 DOI: 10.1007/s10620-018-4934-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
247 Patnana M, Menias CO, Pickhardt PJ, Elshikh M, Javadi S, Gaballah A, Shaaban AM, Korivi BR, Garg N, Elsayes KM. Liver Calcifications and Calcified Liver Masses: Pattern Recognition Approach on CT. American Journal of Roentgenology 2018;211:76-86. [DOI: 10.2214/ajr.18.19704] [Cited by in Crossref: 18] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
248 Abdel-Rahman O, Elsayed Z. External beam radiotherapy for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2017;3:CD011314. [PMID: 28267205 DOI: 10.1002/14651858.CD011314.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
249 Liu L, Zhao Y, Jia J, Chen H, Bai W, Yang M, Yin Z, He C, Zhang L, Guo W, Niu J, Yuan J, Cai H, Xia J, Fan D, Han G. The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization. Sci Rep 2016;6:19851. [PMID: 26831408 DOI: 10.1038/srep19851] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
250 Edeline J, Crouzet L, Le Sourd S, Larible C, Brunot A, Le Roy F, Cattenoz C, Latournerie M, Gédouin D, Guillygomarc'h A, Boucher E. Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. Cancer Chemother Pharmacol 2015;75:215-9. [PMID: 25477009 DOI: 10.1007/s00280-014-2645-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
251 Del Poggio P, Olmi S, Ciccarese F, Mazzoleni M, Jazzetti M, Jamoletti C, Mattiello M, Del Poggio A, Portugali V, Stroffolini T. A training program for primary care physicians improves the effectiveness of ultrasound surveillance of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2015;27:1103-8. [PMID: 26049705 DOI: 10.1097/MEG.0000000000000404] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
252 Liu D, Kang H, Gao M, Jin L, Zhang F, Chen D, Li M, Xiao L. Exosome-transmitted circ_MMP2 promotes hepatocellular carcinoma metastasis by upregulating MMP2. Mol Oncol 2020;14:1365-80. [PMID: 31944556 DOI: 10.1002/1878-0261.12637] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
253 Flisiak R, Halota W, Jaroszewicz J, Juszczyk J, Małkowski P, Pawłowska M, Piekarska A, Simon K, Tomasiewicz K, Wawrzynowicz-Syczewska M; Polish Group of Experts for HBV. Recommendations for the treatment of hepatitis B in 2017. Clin Exp Hepatol 2017;3:35-46. [PMID: 28856289 DOI: 10.5114/ceh.2017.67626] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
254 Widmann G, Wallach D, Toporek G, Schullian P, Weber S, Bale R. Angiographic C-Arm CT– Versus MDCT-Guided Stereotactic Punctures of Liver Lesions: Nonrigid Phantom Study. American Journal of Roentgenology 2013;201:1136-40. [DOI: 10.2214/ajr.12.10405] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
255 Lin SM. Local ablation for hepatocellular carcinoma in taiwan. Liver Cancer 2013;2:73-83. [PMID: 24159599 DOI: 10.1159/000343843] [Cited by in Crossref: 26] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
256 Smirne C, Grossi G, Pinato DJ, Burlone ME, Mauri FA, Januszewski A, Oldani A, Minisini R, Sharma R, Pirisi M. Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma. Dig Liver Dis. 2015;47:488-494. [PMID: 25864774 DOI: 10.1016/j.dld.2015.03.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
257 Yoon JH, Park JW, Lee JM. Noninvasive Diagnosis of Hepatocellular Carcinoma: Elaboration on Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guidelines Compared with Other Guidelines and Remaining Issues. Korean J Radiol 2016;17:7-24. [PMID: 26798212 DOI: 10.3348/kjr.2016.17.1.7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
258 Maas M, Beets-Tan R, Gaubert JY, Gomez Munoz F, Habert P, Klompenhouwer LG, Vilares Morgado P, Schaefer N, Cornelis FH, Solomon SB, van der Reijd D, Bilbao JI. Follow-up after radiological intervention in oncology: ECIO-ESOI evidence and consensus-based recommendations for clinical practice. Insights Imaging 2020;11:83. [PMID: 32676924 DOI: 10.1186/s13244-020-00884-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
259 Terzi E, Ray Kim W, Sanchez W, Charlton MR, Schmeltzer P, Gores GJ, Andrews JC, Smyrk TC, Heimbach JK. Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation: MULTIPLE TACE PROCEDURES. Liver Transpl 2015;21:248-57. [DOI: 10.1002/lt.24041] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
260 Yang J, Xu QC, Wang ZY, Lu X, Pan LK, Wu J, Wang C. Integrated Analysis of an lncRNA-Associated ceRNA Network Reveals Potential Biomarkers for Hepatocellular Carcinoma. J Comput Biol 2021;28:330-44. [PMID: 33185458 DOI: 10.1089/cmb.2019.0250] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
261 Schobert IT, Savic LJ, Chapiro J, Bousabarah K, Chen E, Laage-Gaupp F, Tefera J, Nezami N, Lin M, Pollak J, Schlachter T. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE. Eur Radiol 2020;30:5663-73. [PMID: 32424595 DOI: 10.1007/s00330-020-06931-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
262 Yao FY. Conundrum of treatment for early-stage hepatocellular carcinoma: radiofrequency ablation instead of liver transplantation as the first-line treatment? Liver Transpl. 2014;20:257-260. [PMID: 24493329 DOI: 10.1002/lt.23848] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
263 Greco G, Cascella T, Facciorusso A, Nani R, Lanocita R, Morosi C, Vaiani M, Calareso G, Greco FG, Ragnanese A, Bongini MA, Marchianò AV, Mazzaferro V, Spreafico C. Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma. World J Radiol 2017; 9(5): 245-252 [PMID: 28634515 DOI: 10.4329/wjr.v9.i5.245] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
264 Renzulli M, Tovoli F, Clemente A, Ierardi AM, Pettinari I, Peta G, Marasco G, Festi D, Piscaglia F, Cappabianca S, Carrafiello G, Golfieri R. Ablation for hepatocellular carcinoma: beyond the standard indications. Med Oncol 2020;37:23. [PMID: 32166482 DOI: 10.1007/s12032-020-01348-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
265 Herden U, Schoening W, Pratschke J, Manekeller S, Paul A, Linke R, Lorf T, Lehner F, Braun F, Stippel DL, Sucher R, Schmidt H, Strassburg CP, Guba M, van Rosmalen M, Rogiers X, Samuel U, Schön GM, Nashan B. Accuracy of Pretransplant Imaging Diagnostic for Hepatocellular Carcinoma: A Retrospective German Multicenter Study. Can J Gastroenterol Hepatol 2019;2019:8747438. [PMID: 30949459 DOI: 10.1155/2019/8747438] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
266 Kim DK, Han K, Won JY, Kim GM, Kwon JH, Kim MD. Percutaneous cryoablation in early stage hepatocellular carcinoma: analysis of local tumor progression factors. Diagn Interv Radiol 2020;26:111-7. [PMID: 32071029 DOI: 10.5152/dir.2019.19246] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
267 Petit A, Hocquelet A, N'kontchou G, Varin E, Sellier N, Seror O, Sutter O. No-Touch Multi-bipolar Radiofrequency Ablation for the Treatment of Subcapsular Hepatocellular Carcinoma ≤ 5 cm Not Puncturable via the Non-tumorous Liver Parenchyma. Cardiovasc Intervent Radiol 2020;43:273-83. [PMID: 31673728 DOI: 10.1007/s00270-019-02357-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
268 Ren B, Zou G, Xu F, Huang Y, Xu G, He J, Li Y, Zhu H, Yu P. Serum levels of anti-sperm-associated antigen 9 antibody are elevated in patients with hepatocellular carcinoma. Oncol Lett. 2017;14:7608-7614. [PMID: 29344208 DOI: 10.3892/ol.2017.7152] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
269 Zhang M, Wu R, Jiang J, Minuk GY, Niu J. The presence of hepatitis B core antibody is associated with more advanced liver disease in alcoholic patients with cirrhosis. Alcohol. 2013;47:553-558. [PMID: 24041840 DOI: 10.1016/j.alcohol.2013.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
270 Della Corte C, Triolo M, Iavarone M, Sangiovanni A. Early diagnosis of liver cancer: an appraisal of international recommendations and future perspectives. Liver Int 2016;36:166-76. [PMID: 26386254 DOI: 10.1111/liv.12965] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
271 He CB, Lao XM, Lin XJ. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study. Chin J Cancer 2017;36:59. [PMID: 28728568 DOI: 10.1186/s40880-017-0227-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
272 Gao HJ, Zhao MC, Zhang YJ, Zhou DS, Xu L, Li GB, Chen MS, Liu J. Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration. J Cancer Res Clin Oncol. 2015;141:1151-1162. [PMID: 25446815 DOI: 10.1007/s00432-014-1888-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
273 Francica G, Meloni MF, de Sio I, Smolock AR, Brace CL, Iadevaia MD, Santambrogio R, Sironi S, Scaglione M, Lee Jr. FT. Radiofrequency and microwave ablation of subcapsular hepatocellular carcinoma accessed by direct puncture: Safety and efficacy. European Journal of Radiology 2016;85:739-43. [DOI: 10.1016/j.ejrad.2016.01.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
274 Zhu W, Li H, Yu Y, Chen J, Chen X, Ren F, Ren Z, Cui G. Enolase-1 serves as a biomarker of diagnosis and prognosis in hepatocellular carcinoma patients. Cancer Manag Res 2018;10:5735-45. [PMID: 30532594 DOI: 10.2147/CMAR.S182183] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
275 Choudhary NS, Puri R, Saigal S, Bhangui P, Saraf N, Shah V, Nasa M, Sarin H, Guleria M, Sud R. Impact of endoscopic ultrasound-guided fine-needle aspiration in prospective liver transplant recipients with hepatocellular carcinoma and lymphadenopathy. Indian J Gastroenterol. 2016;35:465-468. [PMID: 27933567 DOI: 10.1007/s12664-016-0718-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
276 Ishikawa K, Chiba T, Ooka Y, Suzuki E, Ogasawara S, Maeda T, Yokoyama M, Inoue M, Wakamatsu T, Kusakabe Y, Saito T, Tawada A, Arai M, Kanda T, Maruyama H, Imazeki F, Kato N. Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma. Oncotarget 2018;9:21560-8. [PMID: 29765560 DOI: 10.18632/oncotarget.25108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
277 Suwa K, Seki T, Tsuda R, Yamashina M, Murata M, Yamaguchi T, Nishio A, Okazaki K. Short term treatment results of local ablation with water-cooled microwave antenna for liver cancer: Comparison with radiofrequency ablation. Mol Clin Oncol 2020;12:230-6. [PMID: 32064099 DOI: 10.3892/mco.2020.1983] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
278 Abu-Zeinah GF, Weisman P, Ganesh K, Katz SS, Dogan A, Abou-Alfa GK, Stein EM, Jarnagin W, Mauro MJ, Harding JJ. Acute myeloid leukemia masquerading as hepatocellular carcinoma. J Gastrointest Oncol 2016;7:E31-5. [PMID: 27284485 DOI: 10.21037/jgo.2015.12.01] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
279 Yoon JH, Lee JM, Lee DH, Joo I, Jeon JH, Ahn SJ, Kim ST, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH. A Comparison of Biannual Two-Phase Low-Dose Liver CT and US for HCC Surveillance in a Group at High Risk of HCC Development. Liver Cancer 2020;9:503-17. [PMID: 33083277 DOI: 10.1159/000506834] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
280 Quetglas IM, Moeini A, Pinyol R, Llovet JM. Integration of genomic information in the clinical management of HCC. Best Pract Res Clin Gastroenterol 2014;28:831-42. [PMID: 25260311 DOI: 10.1016/j.bpg.2014.08.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
281 Li J, Liu Y, Yan Z, Wan X, Xia Y, Wang K, Liu J, Lau WY, Wu M, Shen F. A nomogram predicting pulmonary metastasis of hepatocellular carcinoma following partial hepatectomy. Br J Cancer 2014;110:1110-7. [PMID: 24481404 DOI: 10.1038/bjc.2014.19] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
282 Khare T, Khare S, Angdisen JJ, Zhang Q, Stuckel A, Mooney BP, Ridenhour SE, Gitan RS, Hammoud GM, Ibdah JA. Defects in long-chain 3-hydroxy acyl-CoA dehydrogenase lead to hepatocellular carcinoma: A novel etiology of hepatocellular carcinoma. Int J Cancer 2020;147:1461-73. [PMID: 32115688 DOI: 10.1002/ijc.32943] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
283 Stroehl YW, Letzen BS, van Breugel JM, Geschwind JF, Chapiro J. Intra-arterial therapies for liver cancer: assessing tumor response. Expert Rev Anticancer Ther 2017;17:119-27. [PMID: 27983883 DOI: 10.1080/14737140.2017.1273775] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
284 Yin JW, Ping Huang M, Zhong B. Intrahepatic Toll-Like Receptor 3 in Chronic HBV Infection Subjects: Asymptomatic Carriers, Active Chronic Hepatitis, Cirrhosis, and Hepatocellular Carcinoma. Hepat Mon 2016;16:e34432. [PMID: 27630720 DOI: 10.5812/hepatmon.34432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
285 Li L, Liu C, Yang J, Wu H, Wen T, Wang W, Li B, Yan L. Early postoperative controlling nutritional status (CONUT) score is associated with complication III-V after hepatectomy in hepatocellular carcinoma: A retrospective cohort study of 1,334 patients. Sci Rep 2018;8:13406. [PMID: 30194336 DOI: 10.1038/s41598-018-31714-w] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
286 Ikeda S, Tsigelny IF, Skjevik ÅA, Kono Y, Mendler M, Kuo A, Sicklick JK, Heestand G, Banks KC, Talasaz A, Lanman RB, Lippman S, Kurzrock R. Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Oncologist 2018;23:586-93. [PMID: 29487225 DOI: 10.1634/theoncologist.2017-0479] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
287 Howell J, Pinato DJ, Ramaswami R, Arizumi T, Ferrari C, Gibbin A, Burlone ME, Guaschino G, Toniutto P, Black J. Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib. Oncotarget. 2017;8:36161-36170. [PMID: 28212535 DOI: 10.18632/oncotarget.15322] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
288 Cai M, Li B, Lin L, Huang J, An Y, Huang W, Zhou Z, Wang Y, Shuai X, Zhu K. A reduction and pH dual-sensitive nanodrug for targeted theranostics in hepatocellular carcinoma. Biomater Sci 2020;8:3485-99. [PMID: 32432234 DOI: 10.1039/d0bm00295j] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
289 Majerović M, Jelaković M, Premužić M, Štromar IK, Radić D, Mance M, Pleština S, Ostojić R, Rustemović N, Krznarić Z. Hepatocellular Carcinoma Surveillance-Experience from Croatian Referral Centre for Chronic Liver Diseases. J Gastrointest Cancer 2019;50:48-53. [PMID: 29127665 DOI: 10.1007/s12029-017-0011-1] [Reference Citation Analysis]
290 Mishima K, Itano O, Matsuda S, Suzuki S, Onishi A, Tamura M, Inoue M, Abe Y, Yagi H, Hibi T, Kitago M, Shinoda M, Kitagawa Y. Development of human hepatocellular carcinoma in X-linked severe combined immunodeficient pigs: An orthotopic xenograft model. PLoS One 2021;16:e0248352. [PMID: 33750947 DOI: 10.1371/journal.pone.0248352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
291 Yamazoe T, Mori T, Yoshio S, Kanto T. Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics. Glob Health Med 2020;2:273-81. [PMID: 33330821 DOI: 10.35772/ghm.2020.01089] [Reference Citation Analysis]
292 Li Y, Wang H, Li D, Hu J, Zhou D, Li Q, Jiang X, Zhou H, Hu H. Occult hepatitis B virus infection in Chinese cryptogenic intrahepatic cholangiocarcinoma patient population. J Clin Gastroenterol. 2014;48:878-882. [PMID: 24356457 DOI: 10.1097/mcg.0000000000000058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
293 Dhungel B, Jayachandran A, Layton CJ, Steel JC. Seek and destroy: targeted adeno-associated viruses for gene delivery to hepatocellular carcinoma. Drug Deliv 2017;24:289-99. [PMID: 28165834 DOI: 10.1080/10717544.2016.1247926] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
294 Yeh ML, Huang CF, Huang CI, Hsieh MY, Hou NJ, Lin IH, Liang PC, Tsai YS, Hsieh MH, Lin ZY, Chen SC, Dai CY, Huang JF, Yu ML, Chuang WL. The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment. Kaohsiung J Med Sci 2019;35:624-32. [PMID: 31254328 DOI: 10.1002/kjm2.12105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
295 Biederman DM, Titano JJ, Korff RA, Fischman AM, Patel RS, Nowakowski FS, Lookstein RA, Kim E. Radiation Segmentectomy versus Selective Chemoembolization in the Treatment of Early-Stage Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2018;29:30-37.e2. [DOI: 10.1016/j.jvir.2017.08.026] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 9.3] [Reference Citation Analysis]
296 Siddique O, Yoo ER, Perumpail RB, Perumpail BJ, Liu A, Cholankeril G, Ahmed A. The importance of a multidisciplinary approach to hepatocellular carcinoma. J Multidiscip Healthc. 2017;10:95-100. [PMID: 28360525 DOI: 10.2147/jmdh.s128629] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
297 Wang Y, Deng T, Zeng L, Chen W. Efficacy and safety of radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: A meta-analysis. Hepatol Res. 2016;46:58-71. [PMID: 26265000 DOI: 10.1111/hepr.12568] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
298 Rosato V, Ascione A, Nevola R, Fracanzani AL, Piai G, Messina V, Claar E, Coppola C, Fontanella L, Lombardi R, Staiano L, Valente G, Fascione MC, Giorgione C, Mazzocca A, Galiero R, Perillo P, Marrone A, Sasso FC, Adinolfi LE, Rinaldi L. Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study. J Viral Hepat 2021. [PMID: 34582610 DOI: 10.1111/jvh.13617] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
299 Lo CH, Yang JF, Liu MY, Jen YM, Lin CS, Chao HL, Huang WY. Survival and prognostic factors for patients with advanced hepatocellular carcinoma after stereotactic ablative radiotherapy. PLoS One 2017;12:e0177793. [PMID: 28545098 DOI: 10.1371/journal.pone.0177793] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
300 Lucà MG, Nani R, Schranz M, De Giorgio M, Iegri C, Agazzi R, Sala F, Virotta G, Sarti D, Conte G, Pinelli D, Nicora C, Colledan M, Sironi S, Fagiuoli S. Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib. Future Oncology 2018;14:727-35. [DOI: 10.2217/fon-2017-0566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
301 Carling U, Barkhatov L, Reims HM, Storås T, Courivaud F, Kazaryan AM, Halvorsen PS, Dorenberg E, Edwin B, Hol PK. Can we ablate liver lesions close to large portal and hepatic veins with MR-guided HIFU? An experimental study in a porcine model. Eur Radiol 2019;29:5013-21. [PMID: 30737565 DOI: 10.1007/s00330-018-5996-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
302 Iezzi R, Pompili M, Annicchiarico EB, Garcovich M, Siciliano M, Gasbarrini A, Manfredi R. 'Hug sign': a new radiological sign of intraprocedural success after combined treatment for hepatocellular carcinoma. Hepat Oncol 2017;4:69-73. [PMID: 30191055 DOI: 10.2217/hep-2017-0017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
303 Besa C, Lewis S, Pandharipande PV, Chhatwal J, Kamath A, Cooper N, Knight-Greenfield A, Babb JS, Boffetta P, Padron N. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdom Radiol (NY). 2017;42:179-190. [PMID: 27448609 DOI: 10.1007/s00261-016-0841-5] [Cited by in Crossref: 68] [Cited by in F6Publishing: 58] [Article Influence: 22.7] [Reference Citation Analysis]
304 El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492-2502. [PMID: 28434648 DOI: 10.1016/s0140-6736(17)31046-2] [Cited by in Crossref: 1593] [Cited by in F6Publishing: 1029] [Article Influence: 398.3] [Reference Citation Analysis]
305 Yao X, Yan D, Jiang X, Li X, Zeng H, Liu D, Li H. Dual-phase Cone-beam CT-based Navigation Imaging Significantly Enhances Tumor Detectability and Aids Superselective Transarterial Chemoembolization of Liver Cancer. Acad Radiol. 2018;25:1031-1037. [PMID: 29398432 DOI: 10.1016/j.acra.2017.12.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
306 Sacco R, Tapete G, Simonetti N, Sellitri R, Natali V, Melissari S, Cabibbo G, Biscaglia L, Bresci G, Giacomelli L. Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review. J Hepatocell Carcinoma 2017;4:105-10. [PMID: 28795053 DOI: 10.2147/JHC.S103661] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
307 Sacco R, Antonucci M, Bargellini I, Marceglia S, Mismas V, Cabibbo G. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice? Future Oncology 2015;11:2371-3. [DOI: 10.2217/fon.15.173] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
308 An C, Rakhmonova G, Choi JY, Kim MJ. Liver imaging reporting and data system (LI-RADS) version 2014: understanding and application of the diagnostic algorithm. Clin Mol Hepatol 2016;22:296-307. [PMID: 27304548 DOI: 10.3350/cmh.2016.0028] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 9.8] [Reference Citation Analysis]
309 Du F, Jiang R, Gu M, He C, Guan J. The clinical application of 320-detector row CT in transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma. Radiol med 2015;120:690-4. [DOI: 10.1007/s11547-015-0523-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
310 Lee H, Yoon JH, Kim H, Yi NJ, Hong SK, Yoon KC, Kim HS, Ahn SW, Choi JY, Choi Y, Lee HW, Yi JY, Lee KB, Lee KW, Suh KS. False Positive Diagnosis of Hepatocellular Carcinoma in Liver Resection Patients. J Korean Med Sci. 2017;32:315-320. [PMID: 28049244 DOI: 10.3346/jkms.2017.32.2.315] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
311 Yamashita H, Onishi H, Murakami N, Matsumoto Y, Matsuo Y, Nomiya T, Nakagawa K. Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma. J Radiat Res. 2015;56:561-567. [PMID: 25691453 DOI: 10.1093/jrr/rru130] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
312 Costentin CE, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Letouzé E, Imbeaud S, Zucman-Rossi J, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir Group. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. Gastroenterology 2018;155:431-442.e10. [PMID: 29729258 DOI: 10.1053/j.gastro.2018.04.027] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 14.0] [Reference Citation Analysis]
313 Wen X, Jiang X, Li R, Zhang J, Yang P, Shen B. Novel X-Ray Imaging Technology Allows Substantial Patient Radiation Reduction without Image Quality Impairment in Repetitive Transarterial Chemoembolization for Hepatocellular Carcinoma. Academic Radiology 2015;22:1361-7. [DOI: 10.1016/j.acra.2015.07.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
314 Poggi G, Tosoratti N, Montagna B, Picchi C. Microwave ablation of hepatocellular carcinoma. World J Hepatol 2015; 7(25): 2578-2589 [PMID: 26557950 DOI: 10.4254/wjh.v7.i25.2578] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 9.7] [Reference Citation Analysis]
315 Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62:1187-1195. [PMID: 25681552 DOI: 10.1016/j.jhep.2015.02.010] [Cited by in Crossref: 118] [Cited by in F6Publishing: 111] [Article Influence: 19.7] [Reference Citation Analysis]
316 Oh J, Lee JM, Park J, Joo I, Yoon JH, Lee DH, Ganeshan B, Han JK. Hepatocellular Carcinoma: Texture Analysis of Preoperative Computed Tomography Images Can Provide Markers of Tumor Grade and Disease-Free Survival. Korean J Radiol 2019;20:569-79. [PMID: 30887739 DOI: 10.3348/kjr.2018.0501] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]
317 Gabr A, Ali R, Al Asadi A, Mora R, Mouli S, Riaz A, Salem R, Lewandowski RJ. Technical Aspects and Practical Approach Toward Same-Day Y90 Radioembolization in the Management of Hepatocellular Carcinoma. Tech Vasc Interv Radiol. 2019;22:93-99. [PMID: 31079717 DOI: 10.1053/j.tvir.2019.02.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
318 Yeh H, Chiang CC, Yen TH. Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. World J Gastroenterol 2021; 27(26): 4104-4142 [PMID: 34326614 DOI: 10.3748/wjg.v27.i26.4104] [Reference Citation Analysis]
319 de Oliveira RM, Ornelas Ricart CA, Araujo Martins AM. Use of Mass Spectrometry to Screen Glycan Early Markers in Hepatocellular Carcinoma. Front Oncol. 2017;7:328. [PMID: 29379771 DOI: 10.3389/fonc.2017.00328] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
320 Mazzola A, Costantino A, Petta S, Bartolotta TV, Raineri M, Sacco R, Brancatelli G, Cammà C, Cabibbo G. Recurrence of hepatocellular carcinoma after liver transplantation: an update. Future Oncol 2015;11:2923-36. [PMID: 26414336 DOI: 10.2217/fon.15.239] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
321 Tsilimigras DI, Moris D, Hyer JM, Bagante F, Sahara K, Moro A, Paredes AZ, Mehta R, Ratti F, Marques HP, Silva S, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Sasaki K, Rodarte AI, Aucejo FN, Pawlik TM. Hepatocellular carcinoma tumour burden score to stratify prognosis after resection. Br J Surg 2020;107:854-64. [PMID: 32057105 DOI: 10.1002/bjs.11464] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 18.0] [Reference Citation Analysis]
322 Keating GM. Sorafenib: A Review in Hepatocellular Carcinoma. Target Oncol. 2017;12:243-253. [PMID: 28299600 DOI: 10.1007/s11523-017-0484-7] [Cited by in Crossref: 95] [Cited by in F6Publishing: 105] [Article Influence: 23.8] [Reference Citation Analysis]
323 Ogasawara S, Chiba T, Ooka Y, Suzuki E, Maeda T, Yokoyama M, Wakamatsu T, Inoue M, Saito T, Kobayashi K, Kiyono S, Nakamura M, Nakamoto S, Yasui S, Tawada A, Arai M, Kanda T, Maruyama H, Yokosuka O, Kato N. Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. Invest New Drugs 2018;36:332-9. [PMID: 28891038 DOI: 10.1007/s10637-017-0507-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
324 Yamashita YI, Imai K, Kaida T, Yamao T, Tsukamoto M, Nakagawa S, Okabe H, Chikamoto A, Ishiko T, Yoshizumi T, Ikeda T, Maehara Y, Baba H. Multimodal radiofrequency ablation versus laparoscopic hepatic resection for the treatment of primary hepatocellular carcinoma within Milan criteria in severely cirrhotic patients: long-term favorable outcomes over 10 years. Surg Endosc 2019;33:46-51. [PMID: 29872945 DOI: 10.1007/s00464-018-6264-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
325 Personeni N, Pressiani T, Santoro A, Rimassa L. Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications. Drugs Context. 2018;7:212533. [PMID: 30002715 DOI: 10.7573/dic.212533] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
326 Tamai T, Taniyama O, Oda K, Kasai A, Ijyuin S, Sakae H, Onishi H, Tabu K, Kumagai K, Mawatari S, Moriuchi A, Uto H, Ido A. Reduction effect of the quantity of radiation exposure and contrast media by image support system in transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 2018;33:1115-22. [PMID: 28994147 DOI: 10.1111/jgh.14012] [Reference Citation Analysis]
327 Golse N, El Bouyousfi A, Marques F, Bancel B, Mohkam K, Ducerf C, Merle P, Sebagh M, Castaing D, Sa Cunha A, Adam R, Cherqui D, Vibert E, Mabrut J. Large hepatocellular carcinoma: Does fibrosis really impact prognosis after resection? Journal of Visceral Surgery 2018;155:265-73. [DOI: 10.1016/j.jviscsurg.2017.10.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
328 Cucchetti A, Piscaglia F, Pinna AD, Djulbegovic B, Mazzotti F, Bolondi L. Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials. Liver Cancer. 2017;6:337-348. [PMID: 29234637 DOI: 10.1159/000481314] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
329 Bayard Q, Meunier L, Peneau C, Renault V, Shinde J, Nault JC, Mami I, Couchy G, Amaddeo G, Tubacher E, Bacq D, Meyer V, La Bella T, Debaillon-Vesque A, Bioulac-Sage P, Seror O, Blanc JF, Calderaro J, Deleuze JF, Imbeaud S, Zucman-Rossi J, Letouzé E. Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. Nat Commun 2018;9:5235. [PMID: 30531861 DOI: 10.1038/s41467-018-07552-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 14.7] [Reference Citation Analysis]
330 Yan W, Zhu Z, Pan F, Huang A, Dai GH. Overexpression of c-kit(CD117), relevant with microvessel density, is an independent survival prognostic factor for patients with HBV-related hepatocellular carcinoma. Onco Targets Ther 2018;11:1285-92. [PMID: 29563807 DOI: 10.2147/OTT.S157545] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
331 Kapitanov T, Neumann UP, Schmeding M. Hepatocellular Carcinoma in Liver Cirrhosis: Surgical Resection versus Transarterial Chemoembolization-A Meta-Analysis. Gastroenterol Res Pract 2015;2015:696120. [PMID: 25642245 DOI: 10.1155/2015/696120] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
332 Uchikawa S, Kawaoka T, Aikata H, Kodama K, Nishida Y, Inagaki Y, Hatooka M, Morio K, Nakahara T, Murakami E, Hiramatsu A, Tsuge M, Imamura M, Kawakami Y, Chayama K. Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. Hepatol Res 2018;48:814-20. [PMID: 29682855 DOI: 10.1111/hepr.13180] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
333 He W, Li B, Zheng Y, Zou R, Shen J, Cheng D, Tao Q, Liu W, Li Q, Chen G, Yuan Y. Resection vs. ablation for alpha-fetoprotein positive hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver Int 2016;36:1677-87. [DOI: 10.1111/liv.13166] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
334 Mekky MA, Salama RH, Abdel-Aal MF, Ghaliony MA, Zaky S. Studying the frequency of aberrant DNA methylation of APC, P14, and E-cadherin genes in HCV-related hepatocarcinogenesis. Cancer Biomark 2018;22:503-9. [PMID: 29865038 DOI: 10.3233/CBM-171156] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
335 Hintzen KFH, Grote J, Wintjens AGWE, Lubbers T, Eussen MMM, van Schooten FJ, Bouvy ND, Peeters A. Breath analysis for the detection of digestive tract malignancies: systematic review. BJS Open 2021;5:zrab013. [PMID: 33855362 DOI: 10.1093/bjsopen/zrab013] [Reference Citation Analysis]
336 Ohki T, Sato K, Yamagami M, Ito D, Yamada T, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K. Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis. Clin Drug Investig 2015;35:751-9. [PMID: 26446004 DOI: 10.1007/s40261-015-0333-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
337 Hodavance MS, Vikingstad EM, Griffin AS, Pabon-ramos WM, Berg CL, Suhocki PV, Kim CY. Effectiveness of Transarterial Embolization of Hepatocellular Carcinoma as a Bridge to Transplantation. Journal of Vascular and Interventional Radiology 2016;27:39-45. [DOI: 10.1016/j.jvir.2015.08.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
338 Li X, Zhang D, Guan S, Ye W, Liu L, Lou L. Efficacy of anti-VEGF agents in the treatment of elderly hepatocellular carcinoma: a systematic review. Oncotarget 2017;8:93179-85. [PMID: 29190987 DOI: 10.18632/oncotarget.21452] [Reference Citation Analysis]
339 Nishikawa H, Yuri Y, Enomoto H, Ishii A, Iwata Y, Miyamoto Y, Ishii N, Hasegawa K, Nakano C, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Takata R, Iijima H, Nishiguchi S. Effect of psoas muscle mass after endoscopic therapy for patients with esophageal varices. Medicine (Baltimore) 2017;96:e6868. [PMID: 28489785 DOI: 10.1097/MD.0000000000006868] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
340 Hyun MH, Lee YS, Kim JH, Lee CU, Jung YK, Seo YS, Yim HJ, Yeon JE, Byun KS. Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: A meta-analysis of high-quality studies. Hepatology. 2018;68:977-993. [PMID: 29543988 DOI: 10.1002/hep.29883] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 22.0] [Reference Citation Analysis]
341 Rong G, Bai W, Dong Z, Wang C, Lu Y, Zeng Z, Qu J, Lou M, Wang H, Gao X, Chang X, An L, Li H, Chen Y, Hu KQ, Yang Y. Long-term outcomes of percutaneous cryoablation for patients with hepatocellular carcinoma within Milan criteria. PLoS One. 2015;10:e0123065. [PMID: 25849963 DOI: 10.1371/journal.pone.0123065] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 5.5] [Reference Citation Analysis]
342 Gomez-Moreno AZ, Pineda-Tenor D, Jimenez-Sousa MA, Sánchez-Ruano JJ, Artaza-Varasa T, Saura-Montalban J, Ryan P, Resino S. Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study. PLoS One 2017;12:e0184404. [PMID: 28880930 DOI: 10.1371/journal.pone.0184404] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
343 Taylor EJ, Jones RL, Guthrie JA, Rowe IA. Modeling the benefits and harms of surveillance for hepatocellular carcinoma: Information to support informed choices. Hepatology 2017;66:1546-55. [DOI: 10.1002/hep.29315] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
344 Yu WC, Zhang KZ, Chen SG, Liu WF. Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: A prospective observation study. Medicine (Baltimore). 2018;97:e9704. [PMID: 29505026 DOI: 10.1097/md.0000000000009704] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
345 Eltabbakh M, Zaghla H, Abdel-Razek W, Elshinnawy H, Ezzat S, Gomaa A, Waked I. Utility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited setting. Med Oncol 2015;32:432. [PMID: 25502085 DOI: 10.1007/s12032-014-0432-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
346 Poté N, Cauchy F, Albuquerque M, Voitot H, Belghiti J, Castera L, Puy H, Bedossa P, Paradis V. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol. 2015;62:848-854. [PMID: 25450201 DOI: 10.1016/j.jhep.2014.11.005] [Cited by in Crossref: 117] [Cited by in F6Publishing: 126] [Article Influence: 16.7] [Reference Citation Analysis]
347 Forner A, Vilana R, Solé M, Bruix J. Reply to: ''Poor contrast enhanced ultrasonography! There is no limit to its decline in the diagnosis of hepatocellular carcinoma on cirrhosis!''. J Hepatol 2015;62:1453-4. [PMID: 25703082 DOI: 10.1016/j.jhep.2015.02.016] [Reference Citation Analysis]
348 Rudnick SR, Russo MW. Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2018;12:265-75. [PMID: 29231769 DOI: 10.1080/17474124.2018.1417035] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
349 Wang H, Meng F, Zhang B, Jiang P, Hu M, Yu X, Cao H. Long non-coding RNA TTN-AS1 aggravates carcinogenesis through Wnt/β-catenin signaling pathway by sponging miR-1271 in hepatocellular carcinoma. Minerva Med 2020;111:617-9. [PMID: 31295985 DOI: 10.23736/S0026-4806.19.06168-8] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
350 Furukawa K, Shiba H, Horiuchi T, Shirai Y, Haruki K, Fujiwara Y, Sakamoto T, Gocho T, Yanaga K. Survival benefit of hepatic resection for hepatocellular carcinoma beyond the Barcelona Clinic Liver Cancer classification. J Hepatobiliary Pancreat Sci. 2017;24:199-205. [PMID: 28160422 DOI: 10.1002/jhbp.436] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
351 Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, Shin YM, Kim KM, Lim YS, Lee HC. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology. 2013;269:603-611. [PMID: 23864102 DOI: 10.1148/radiol.13130150] [Cited by in Crossref: 75] [Cited by in F6Publishing: 87] [Article Influence: 9.4] [Reference Citation Analysis]
352 Salvatore V, Bolondi L. Clinical impact of ultrasound-related techniques on the diagnosis of focal liver lesions. Liver Cancer. 2012;1:238-246. [PMID: 24159588 DOI: 10.1159/000343838] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
353 Wong GL, Chan HL, Tse YK, Chan HY, Tse CH, Lo AO, Wong VW. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology. 2014;59:986-995. [PMID: 24123097 DOI: 10.1002/hep.26739] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 11.9] [Reference Citation Analysis]
354 Yao X, Yan D, Zeng H, Liu D, Li H. Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma. J Surg Oncol 2016;113:672-7. [PMID: 26989044 DOI: 10.1002/jso.24215] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
355 Wang Z, Peng Y, Hu J, Wang X, Sun H, Sun J, Shi Y, Xiao Y, Ding Z, Yang X, Tang M, Tang Z, Wang J, Lau WY, Fan J, Zhou J. Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Unresectable Hepatitis B Virus-related Hepatocellular Carcinoma: A Single Center Study of 45 Patients. Ann Surg. 2018;. [PMID: 29995681 DOI: 10.1097/sla.0000000000002942] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 22.0] [Reference Citation Analysis]
356 Li M, He J, Pan M, Yu Y, Pan Z, Xu B, Zhu J. Iodine-125 implantation plus transarterial chemoembolization for the treatment of hepatocellular carcinoma of 3-5cm: A propensity score matching study. Dig Liver Dis. 2016;48:1082-1087. [PMID: 27365224 DOI: 10.1016/j.dld.2016.06.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
357 Fanni D, Manchia M, Lai F, Gerosa C, Ambu R, Faa G. Immunohistochemical markers of CYP3A4 and CYP3A7: a new tool towards personalized pharmacotherapy of hepatocellular carcinoma. Eur J Histochem 2016;60:2614. [PMID: 27349315 DOI: 10.4081/ejh.2016.2614] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
358 Lamerz R. Are Biomarkers Still Helpful in Hepatocellular Carcinoma? Digestion 2013;87:118-20. [DOI: 10.1159/000346282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
359 Horowitz JM, Kamel IR, Arif-tiwari H, Asrani SK, Hindman NM, Kaur H, Mcnamara MM, Noto RB, Qayyum A, Lalani T. ACR Appropriateness Criteria ® Chronic Liver Disease. Journal of the American College of Radiology 2017;14:S391-405. [DOI: 10.1016/j.jacr.2017.08.045] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
360 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 89] [Article Influence: 90.0] [Reference Citation Analysis]
361 Crocetti L. Radiofrequency Ablation versus Resection for Small Hepatocellular Carcinoma: Are Randomized Controlled Trials Still Needed? Radiology 2018;287:473-5. [DOI: 10.1148/radiol.2018172822] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
362 You DD, Kim DG, Seo CH, Choi HJ, Yoo YK, Park YG. Prognostic factors after curative resection hepatocellular carcinoma and the surgeon's role. Ann Surg Treat Res 2017;93:252-9. [PMID: 29184878 DOI: 10.4174/astr.2017.93.5.252] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
363 Liu PH, Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Chiou YY, Lin HC, Huo TI. When to Perform Surgical Resection or Radiofrequency Ablation for Early Hepatocellular Carcinoma?: A Nomogram-guided Treatment Strategy. Medicine (Baltimore). 2015;94:e1808. [PMID: 26512576 DOI: 10.1097/md.0000000000001808] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
364 Girotra M, Soota K, Dhaliwal AS, Abraham RR, Garcia-Saenz-de-Sicilia M, Tharian B. Utility of endoscopic ultrasound and endoscopy in diagnosis and management of hepatocellular carcinoma and its complications: What does endoscopic ultrasonography offer above and beyond conventional cross-sectional imaging? World J Gastrointest Endosc 2018; 10(2): 56-68 [PMID: 29467916 DOI: 10.4253/wjge.v10.i2.56] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
365 Di Sandro S, Centonze L, Pinotti E, Lauterio A, De Carlis R, Romano F, Gianotti L, De Carlis L; The NTF Research Group. Surgical and oncological outcomes of hepatic resection for BCLC-B hepatocellular carcinoma: a retrospective multicenter analysis among 474 consecutive cases. Updates Surg 2019;71:285-93. [DOI: 10.1007/s13304-019-00649-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
366 Pitton MB, Kloeckner R, Ruckes C, Wirth GM, Eichhorn W, Wörns MA, Weinmann A, Schreckenberger M, Galle PR, Otto G, Dueber C. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 2015;38:352-60. [PMID: 25373796 DOI: 10.1007/s00270-014-1012-0] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 7.4] [Reference Citation Analysis]
367 Tsai MC, Lin CC, Chen DW, Liu YW, Wu YJ, Yen YH, Huang PY, Yao CC, Chuang CH, Hsiao CC. The Role of Protease-Activated Receptor 2 in Hepatocellular Carcinoma after Hepatectomy. Medicina (Kaunas) 2021;57:574. [PMID: 34199695 DOI: 10.3390/medicina57060574] [Reference Citation Analysis]
368 Wu L, Fu Z, Zhou S, Gong J, Liu CA, Qiao Z, Li S. HIF-1α and HIF-2α: siblings in promoting angiogenesis of residual hepatocellular carcinoma after high-intensity focused ultrasound ablation. PLoS One 2014;9:e88913. [PMID: 24551189 DOI: 10.1371/journal.pone.0088913] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
369 Jang JH, Lee JW, Hong JT, Jin YJ. Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy. J Hepatocell Carcinoma 2015;2:123-9. [PMID: 27508201 DOI: 10.2147/JHC.S44380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
370 Kumar G, Goldberg SN, Gourevitch S, Levchenko T, Torchilin V, Galun E, Ahmed M. Targeting STAT3 to Suppress Systemic Pro-Oncogenic Effects from Hepatic Radiofrequency Ablation. Radiology 2018;286:524-36. [PMID: 28880787 DOI: 10.1148/radiol.2017162943] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
371 Pazgan-Simon M, Serafinska S, Janocha-Litwin J, Simon K, Zuwala-Jagiello J. Diagnostic challenges in primary hepatocellular carcinoma: case reports and review of the literature. Case Rep Oncol Med 2015;2015:878763. [PMID: 25922775 DOI: 10.1155/2015/878763] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
372 Kim GA, Lim YS, Han S, Choi J, Shim JH, Kim KM, Lee HC, Lee YS. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 2018;67:945-952. [PMID: 29055908 DOI: 10.1136/gutjnl-2017-314904] [Cited by in Crossref: 77] [Cited by in F6Publishing: 76] [Article Influence: 19.3] [Reference Citation Analysis]
373 Lee SM, Kim HS, Lee S, Lee JW. Emerging role of 18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma. World J Gastroenterol 2019; 25(11): 1289-1306 [PMID: 30918424 DOI: 10.3748/wjg.v25.i11.1289] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
374 Quiles Granado AM, Laguillo Sala G, Gómez Roselló E, Remollo Friedemann S, Pedraza Gutiérrez S. [Spinal cord compression due to metastasis from a hepatocarcinoma in an human immunodeficiency virus-positive patient. A propos of a case]. Gastroenterol Hepatol 2013;36:437-8. [PMID: 23465581 DOI: 10.1016/j.gastrohep.2012.11.008] [Reference Citation Analysis]
375 Karkampouna S, van der Helm D, Gray PC, Chen L, Klima I, Grosjean J, Burgmans MC, Farina-Sarasqueta A, Snaar-Jagalska EB, Stroka DM, Terracciano L, van Hoek B, Schaapherder AF, Osanto S, Thalmann GN, Verspaget HW, Coenraad MJ, Kruithof-de Julio M. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma. J Pathol. 2018;245:297-310. [PMID: 29604056 DOI: 10.1002/path.5083] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
376 Li R, Yuan MX, Ma KS, Li XW, Tang CL, Zhang XH, Guo DY, Yan XC. Detailed analysis of temporal features on contrast enhanced ultrasound may help differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma in cirrhosis. PLoS One. 2014;9:e98612. [PMID: 24874413 DOI: 10.1371/journal.pone.0098612] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
377 Min JH, Kim YK, Sinn DH, Choi SY, Jeong WK, Lee WJ, Ha SY, Ahn S, Kim MJ. Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. Abdom Radiol (NY) 2018;43:2309-20. [PMID: 29470629 DOI: 10.1007/s00261-018-1480-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
378 Bruix J, Gores G, Mazzaferro V. Authors' response to the letter: Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours or portal hypertension by Zhong et al. Gut 2015;64:522. [PMID: 25311033 DOI: 10.1136/gutjnl-2014-308381] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
379 Bruix J, Takayama T, Mazzaferro V, Chau G-Y, Yang J, Kudo M, Cai J, Poon RT, Han K-H, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Le Berre Marie-Aude, Meinhardt G, Llovet JM, investigators S. Articles Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16: :1344-1354. [PMID: 26361969 DOI: 10.1016/s1470-2045(15)00198-9] [Cited by in Crossref: 436] [Cited by in F6Publishing: 222] [Article Influence: 72.7] [Reference Citation Analysis]
380 Biederman DM, Titano JJ, Bishay VL, Durrani RJ, Dayan E, Tabori N, Patel RS, Nowakowski FS, Fischman AM, Kim E. Radiation Segmentectomy versus TACE Combined with Microwave Ablation for Unresectable Solitary Hepatocellular Carcinoma Up to 3 cm: A Propensity Score Matching Study. Radiology 2017;283:895-905. [DOI: 10.1148/radiol.2016160718] [Cited by in Crossref: 45] [Cited by in F6Publishing: 31] [Article Influence: 11.3] [Reference Citation Analysis]
381 Kim CY, Kim BR, Lee SS, Jeon DH, Lee CM, Kim WS, Cho HC, Kim JJ, Lee JM, Kim HJ, Ha CY, Kim HJ, Kim TH, Jung WT, Lee OJ. Clinical features of hepatitis B and C virus infections, with high α-fetoprotein levels but not hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e5844. [PMID: 28079817 DOI: 10.1097/MD.0000000000005844] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
382 An C, Kim DY, Choi JY, Han KH, Roh YH, Kim MJ. Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial. BMC Cancer 2018;18:915. [PMID: 30249190 DOI: 10.1186/s12885-018-4827-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
383 Cha DI, Lee MW, Kim YK, Kim SH, Park HJ, Rhim H, Lim HK. Assessing patients with hepatocellular carcinoma meeting the Milan criteria: Is liver 3 tesla MR with gadoxetic acid necessary in addition to liver CT? J Magn Reson Imaging 2014;39:842-52. [PMID: 24115384 DOI: 10.1002/jmri.24237] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
384 Lai Q, Lerut JP. Hepatocellular cancer: how to expand safely inclusion criteria for liver transplantation. Curr Opin Organ Transplant. 2014;19:229-234. [PMID: 24811435 DOI: 10.1097/mot.0000000000000085] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
385 Lin H, Zeng L, Yang J, Hu W, Zhu Y. A Machine Learning-Based Model to Predict Survival After Transarterial Chemoembolization for BCLC Stage B Hepatocellular Carcinoma. Front Oncol 2021;11:608260. [PMID: 33738252 DOI: 10.3389/fonc.2021.608260] [Reference Citation Analysis]
386 Kumar N, Khakoo SI. Hepatocellular carcinoma: Prospects for natural killer cell immunotherapy. HLA. 2018;. [PMID: 29667374 DOI: 10.1111/tan.13275] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
387 Otto G, Schuchmann M, Hoppe-lotichius M, Heise M, Weinmann A, Hansen T, Pitton MP. How to decide about liver transplantation in patients with hepatocellular carcinoma: Size and number of lesions or response to TACE? Journal of Hepatology 2013;59:279-84. [DOI: 10.1016/j.jhep.2013.04.006] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 9.4] [Reference Citation Analysis]
388 Shaker MK, Montasser IF, Sakr M, Elgharib M, Dabbous HM, Ebada H, Dorry AE, Bahaa M, Meteini ME. Efficacy of loco-regional treatment for hepatocellular carcinoma prior to living donor liver transplantation: a report from a single center in Egypt. J Hepatocell Carcinoma 2018;5:29-36. [PMID: 29520343 DOI: 10.2147/JHC.S147098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
389 Ponnoprat D, Inkeaw P, Chaijaruwanich J, Traisathit P, Sripan P, Inmutto N, Na Chiangmai W, Pongnikorn D, Chitapanarux I. Classification of hepatocellular carcinoma and intrahepatic cholangiocarcinoma based on multi-phase CT scans.Med Biol Eng Comput. 2020;58:2497-2515. [PMID: 32794015 DOI: 10.1007/s11517-020-02229-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
390 Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Chiou YY, Huo TI. A prognostic model for patients with hepatocellular carcinoma within the Milan criteria undergoing non-transplant therapies, based on 1106 patients. Aliment Pharmacol Ther. 2012;36:551-559. [PMID: 22817677 DOI: 10.1111/j.1365-2036.2012.05226.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
391 Kudo M. Heterogeneity and Subclassification of Barcelona Clinic Liver Cancer Stage B. Liver Cancer 2016;5:91-6. [PMID: 27386427 DOI: 10.1159/000367768] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
392 Gui CH, Baey S, D'cruz RT, Shelat VG. Trans-arterial chemoembolization + radiofrequency ablation versus surgical resection in hepatocellular carcinoma - A meta-analysis. Eur J Surg Oncol 2020;46:763-71. [PMID: 31937433 DOI: 10.1016/j.ejso.2020.01.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 16.0] [Reference Citation Analysis]
393 Lee SY, Mooney MA, Inra ML, Juluru K, Fox AN, Olsen SK, Brown RS, Emond JC, Cherqui D, Kluger MD. Exposure to ionizing radiation during liver transplantation evaluation, waitlist time, and in the postoperative period: A cause for concern: Hepatology. Hepatology 2014;59:496-504. [DOI: 10.1002/hep.26633] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
394 Rastogi A. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma. World J Gastroenterol 2018; 24(35): 4000-4013 [PMID: 30254404 DOI: 10.3748/wjg.v24.i35.4000] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
395 Wan YM, Li YH, Xu ZY, Wu HM, Xu Y, Yang M, Wu XN. The Effect of Transarterial Chemoembolization in Combination With Kang'ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study. Integr Cancer Ther 2018;17:477-85. [PMID: 29108428 DOI: 10.1177/1534735417734913] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
396 Liu C, Xing W, Si T, Yu H, Guo Z. Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study. Oncotarget 2017;8:100734-45. [PMID: 29246017 DOI: 10.18632/oncotarget.20140] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
397 Zhang T, Sun J, He W, Li H, Piao J, Xu H, Duan X. Stereotactic body radiation therapy as an effective and safe treatment for small hepatocellular carcinoma. BMC Cancer 2018;18:451. [PMID: 29678159 DOI: 10.1186/s12885-018-4359-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
398 Ingle PV, Samsudin SZ, Chan PQ, Ng MK, Heng LX, Yap SC, Chai AS, Wong AS. Development and novel therapeutics in hepatocellular carcinoma: a review. Ther Clin Risk Manag. 2016;12:445-455. [PMID: 27042086 DOI: 10.2147/tcrm.s92377] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
399 Baker E, Jacobs C, Martinie J, Iannitti DA, Vrochides D, Swan RZ. Mixed Hepatocellular Carcinoma, Neuroendocrine Carcinoma of the Liver. The American Surgeon 2016;82:1121-5. [DOI: 10.1177/000313481608201130] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 3.4] [Reference Citation Analysis]
400 Nusbaum JD, Smirniotopoulos J, Wright HC, Dash C, Parpia T, Shechtel J, Chang Y, Loffredo C, Shetty K. The Effect of Hepatocellular Carcinoma Surveillance in an Urban Population With Liver Cirrhosis. J Clin Gastroenterol. 2015;Epub ahead of print. [PMID: 25751372 DOI: 10.1097/mcg.0000000000000306] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
401 Buckstein M, Kim E, Fischman A, Blacksburg S, Facciuto M, Schwartz M, Rosenzweig K. Stereotactic body radiation therapy following transarterial chemoembolization for unresectable hepatocellular carcinoma. J Gastrointest Oncol 2018;9:734-40. [PMID: 30151270 DOI: 10.21037/jgo.2018.05.01] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
402 Augustin S, Pons M, Santos B, Ventura M, Genescà J. Identifying Compensated Advanced Chronic Liver Disease: When (Not) to Start Screening for Varices and Clinically Significant Portal Hypertension. In: de Franchis R, editor. Portal Hypertension VI. Cham: Springer International Publishing; 2016. pp. 39-49. [DOI: 10.1007/978-3-319-23018-4_5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
403 Nault JC. Pathogenesis of hepatocellular carcinoma according to aetiology. Best Pract Res Clin Gastroenterol. 2014;28:937-947. [PMID: 25260319 DOI: 10.1016/j.bpg.2014.08.006] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 6.6] [Reference Citation Analysis]
404 Ramzan M, Sturm N, Decaens T, Bioulac-Sage P, Bancel B, Merle P, Tran Van Nhieu J, Slama R, Letoublon C, Zarski JP. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma. Liver Int. 2016;36:434-444. [PMID: 26215124 DOI: 10.1111/liv.12927] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
405 Rodríguez S, Balbinotto Neto G, Kiss G, Brandão A; Liver Transplantation Group. Cost-effectiveness of whole-body bone scans in the pre-liver transplant assessment of patients with hepatocellular carcinoma in Southern Brazil. Clin Transplant 2016;30:399-406. [PMID: 26783162 DOI: 10.1111/ctr.12699] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
406 Yang H, Yang Y, Dou J, Cui R, Cheng Z, Han Z, Liu F, Yu X, Zhou X, Yu J, Liang P. Cholecystectomy is associated with higher risk of recurrence after microwave ablation of hepatocellular carcinoma: a propensity score matching analysis. Cancer Biol Med 2020;17:478-91. [PMID: 32587783 DOI: 10.20892/j.issn.2095-3941.2019.0246] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
407 Wang Y, Wang G, Tan X, Ke K, Zhao B, Cheng N, Dang Y, Liao N, Wang F, Zheng X, Li Q, Liu X, Liu J. MT1G serves as a tumor suppressor in hepatocellular carcinoma by interacting with p53. Oncogenesis 2019;8:67. [PMID: 31732712 DOI: 10.1038/s41389-019-0176-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
408 Kim SU, Seo YS, Lee HA, Kim MN, Kim EH, Kim HY, Lee YR, Lee HW, Park JY, Kim DY, Ahn SH, Han KH, Hwang SG, Rim KS, Um SH, Tak WY, Kweon YO, Kim BK, Park SY. Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy. Clin Gastroenterol Hepatol 2020; 18: 693-699. e1. [PMID: 31252188 DOI: 10.1016/j.cgh.2019.06.028] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
409 Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis. Dig Liver Dis. 2016;48:571-577. [PMID: 26965785 DOI: 10.1016/j.dld.2016.02.005] [Cited by in Crossref: 88] [Cited by in F6Publishing: 89] [Article Influence: 17.6] [Reference Citation Analysis]
410 Shen Y, Zhou C, Zhu G, Shi G, Zhu X, Huang C, Zhou J, Fan J, Ding H, Ren N, Sun H. Liver Stiffness Assessed by Shear Wave Elastography Predicts Postoperative Liver Failure in Patients with Hepatocellular Carcinoma. J Gastrointest Surg 2017;21:1471-9. [DOI: 10.1007/s11605-017-3443-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
411 Chen L, Zeng F, Yao L, Fang T, Liao M, Long J, Xiao L, Deng G. Nomogram based on inflammatory indices for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma. Cancer Med 2020;9:1451-61. [PMID: 31903730 DOI: 10.1002/cam4.2823] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
412 Wu C, Chen P, Qian JJ, Jin SJ, Yao J, Wang XD, Bai DS, Jiang GQ. Effect of marital status on the survival of patients with hepatocellular carcinoma treated with surgical resection: an analysis of 13,408 patients in the surveillance, epidemiology, and end results (SEER) database. Oncotarget 2016;7:79442-52. [PMID: 27769053 DOI: 10.18632/oncotarget.12722] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
413 Vilarinho S, Taddei T. Therapeutic strategies for hepatocellular carcinoma: new advances and challenges. Curr Treat Options Gastroenterol 2015;13:219-34. [PMID: 25791207 DOI: 10.1007/s11938-015-0049-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
414 Kabir T, Ye M, Mohd Noor NA, Woon W, Junnarkar SP, Shelat VG. Preoperative Neutrophil-to-Lymphocyte Ratio Plus Platelet-to-Lymphocyte Ratio Predicts the Outcomes after Curative Resection for Hepatocellular Carcinoma. Int J Hepatol 2019;2019:4239463. [PMID: 31065387 DOI: 10.1155/2019/4239463] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
415 Ehman EC, Umetsu SE, Ohliger MA, Fidelman N, Ferrell LD, Yeh BM, Yee J, Hope TA. Imaging prediction of residual hepatocellular carcinoma after locoregional therapy in patients undergoing liver transplantation or partial hepatectomy. Abdom Radiol (NY) 2016;41:2161-8. [PMID: 27484789 DOI: 10.1007/s00261-016-0837-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
416 Lanza E, Donadon M, Poretti D, Pedicini V, Tramarin M, Roncalli M, Rhee H, Park YN, Torzilli G. Transarterial Therapies for Hepatocellular Carcinoma. Liver Cancer 2016;6:27-33. [PMID: 27995085 DOI: 10.1159/000449347] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
417 de la Torre MA, Buades-Mateu J, de la Rosa PA, Lué A, Bustamante FJ, Serrano MT, Testillano M, Lorente S, Arenas JI, Gil C, Iñarrairaegui M, Sangro B. A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib. Liver Int 2016;36:1206-12. [PMID: 26910784 DOI: 10.1111/liv.13098] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
418 Ahmadzadehfar H, Habibi E, Ezziddin S, Wilhelm K, Fimmers R, Spengler U, Palmedo H, Strunk H, Schild HH, Biersack HJ, Risse J. Survival after 131I-labeled lipiodol therapy for hepatocellular carcinoma: A single-center study based on a long-term follow-up. Nuklearmedizin 2018;53:46-53. [DOI: 10.3413/nukmed-0610-13-07] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
419 Matsui Y, Figi A, Horikawa M, Jahangiri Noudeh Y, Tomozawa Y, Hashimoto K, Kaufman J, Farsad K. Arteriopathy after transarterial chemo-lipiodolization for hepatocellular carcinoma. Diagnostic and Interventional Imaging 2017;98:827-35. [DOI: 10.1016/j.diii.2017.10.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
420 Van Hees S, Michielsen P, Vanwolleghem T. Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol 2016; 22(37): 8271-8282 [PMID: 27729734 DOI: 10.3748/wjg.v22.i37.8271] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
421 Rowe IA, Sherman M. Capitalising on improved rates of diagnosis of early hepatocellular carcinoma. Journal of Hepatology 2016;64:260-1. [DOI: 10.1016/j.jhep.2015.10.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
422 Tabu K, Mawatari S, Oda K, Taniyama O, Toyodome A, Ijuin S, Sakae H, Kumagai K, Kanmura S, Ido A. Highly sensitive Lens culinaris agglutinin-reactive fraction of α-fetoprotein is a predictive marker for hepatocarcinogenesis in long-term observation of patients with chronic liver disease. Mol Clin Oncol 2021;15:174. [PMID: 34276993 DOI: 10.3892/mco.2021.2336] [Reference Citation Analysis]
423 Gao X, Zhan M, Wang L, Ding Y, Niu J. Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC. J Hepatocell Carcinoma 2020;7:347-60. [PMID: 33299823 DOI: 10.2147/JHC.S279657] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
424 King J, Palmer DH, Johnson P, Ross P, Hubner RA, Sumpter K, Darby S, Braconi C, Iwuji C, Swinson D, Collins P, Patel K, Nobes J, Muazzam I, Blesing C, Kirkwood A, Nash S, Meyer T. Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit. Clin Oncol (R Coll Radiol). 2017;29:256-262. [PMID: 27964898 DOI: 10.1016/j.clon.2016.11.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
425 Lee IC, Chau GY, Yeh YC, Chao Y, Huo TI, Su CW, Lin HC, Hou MC, Huang YH. Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure. PLoS One 2017;12:e0188552. [PMID: 29176777 DOI: 10.1371/journal.pone.0188552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
426 Liu J, Zhang H, Xia Y, Yang T, Gao Y, Li J, Wu Y, Shen F. Impact of clinically significant portal hypertension on outcomes after partial hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis. HPB (Oxford). 2019;21:1-13. [PMID: 30082213 DOI: 10.1016/j.hpb.2018.07.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
427 Bahgat DM, Shahin RM, Makar NN, Aziz AO, Hunter SS. Reversion-Inducing-Cysteine-Rich Protein With Kazal Motifs (RECK) Gene Single Nucleotide Polymorphism With Hepatocellular Carcinoma: A Case-Control Study. J Clin Lab Anal 2016;30:36-40. [PMID: 25278269 DOI: 10.1002/jcla.21806] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
428 Takahashi H, Mori K, Sekino Y, Okumura T, Hiyama T, Fukuda K, Hasegawa N, Sakai M, Kikuchi S, Takei Y, Iizumi T, Sakurai H, Minami M. Angiographic Findings in Patients with Hepatocellular Carcinoma Previously Treated Using Proton Beam Therapy. J Oncol 2019;2019:3580379. [PMID: 31354819 DOI: 10.1155/2019/3580379] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
429 Bertot LC, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Chin J, Huang Y, Adams LA. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease. Liver Int. 2018;38:1793-1802. [PMID: 29575516 DOI: 10.1111/liv.13739] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 12.3] [Reference Citation Analysis]
430 Boyer A, Jegonday M, Lanot A, Ficheux M, Lobbedez T, Bechade C. Percutaneous Ablation for Hepatocellular Carcinoma and Peritoneal Dialysis. Perit Dial Int 2017;37:656-8. [DOI: 10.3747/pdi.2017.00073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
431 Kobayashi K, Maruyama H, Kiyono S, Sekimoto T, Kondo T, Shimada T, Takahashi M, Okugawa H, Yokosuka O. Portal response related to shunt occlusion by balloon-occluded retrograde transvenous obliteration may determine the prognosis of cirrhosis. Hepatol Res 2016;46:1321-9. [PMID: 26931092 DOI: 10.1111/hepr.12690] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
432 O’connor PJ, Pasik SD, van der Bom IM, Bishay V, Radaelli A, Kim E. Feasibility of Yttrium-90 Radioembolization Dose Calculation Utilizing Intra-procedural Open Trajectory Cone Beam CT. Cardiovasc Intervent Radiol 2020;43:295-301. [DOI: 10.1007/s00270-019-02198-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
433 Colecchia A, Schiumerini R, Cucchetti A, Cescon M, Taddia M, Marasco G, Festi D. Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol 2014; 20(20): 5935-5950 [PMID: 24876717 DOI: 10.3748/wjg.v20.i20.5935] [Cited by in CrossRef: 87] [Cited by in F6Publishing: 90] [Article Influence: 12.4] [Reference Citation Analysis]
434 Sukowati CHC, Patti R, Pascut D, Ladju RB, Tarchi P, Zanotta N, Comar M, Tiribelli C, Crocè LS. Serum Stem Cell Growth Factor Beta for the Prediction of Therapy Response in Hepatocellular Carcinoma. Biomed Res Int 2018;2018:6435482. [PMID: 30246025 DOI: 10.1155/2018/6435482] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
435 Kikuchi L, Chagas AL, Alencar RSSM, Tani C, Diniz MA, D'Albuquerque LAC, Carrilho FJ. Adherence to BCLC recommendations for the treatment of hepatocellular carcinoma: impact on survival according to stage. Clinics (Sao Paulo) 2017;72:454-60. [PMID: 28954003 DOI: 10.6061/clinics/2017(08)01] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
436 Wang XD, Peng JB, Zhou CY, Que Q, Li HY, He Y, Yang H. Potential therapies for residual hepatoblastoma following incomplete ablation treatment in a nude mouse subcutaneous xenograft model based on lncRNA and mRNA expression profiles. Oncol Rep 2020;43:1915-27. [PMID: 32186781 DOI: 10.3892/or.2020.7545] [Reference Citation Analysis]
437 Vande Lune P, Abdel Aal AK, Klimkowski S, Zarzour JG, Gunn AJ. Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization. J Clin Transl Hepatol 2018;6:175-88. [PMID: 29951363 DOI: 10.14218/JCTH.2017.00045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
438 Lee S, Kang TW, Cha DI, Song KD, Lee MW, Rhim H, Lim HK, Sinn DH, Kim JM, Kim K. Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: Propensity score analyses of long-term outcomes. J Hepatol. 2018;69:70-78. [PMID: 29524532 DOI: 10.1016/j.jhep.2018.02.026] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 14.3] [Reference Citation Analysis]
439 Gao HJ, Xu L, Zhang YJ, Chen MS. Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review. Chin J Cancer 2014;33:259-64. [PMID: 24325788 DOI: 10.5732/cjc.013.10133] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
440 Lai Q, Levi Sandri GB, Lerut J. Selection tool alpha-fetoprotein for patients waiting for liver transplantation: How to easily manage a fractal algorithm. World J Hepatol 2015; 7(15): 1899-1904 [PMID: 26244064 DOI: 10.4254/wjh.v7.i15.1899] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
441 Habib A, Desai K, Hickey R, Thornburg B, Lewandowski R, Salem R. Transarterial approaches to primary and secondary hepatic malignancies. Nat Rev Clin Oncol 2015;12:481-9. [PMID: 25985939 DOI: 10.1038/nrclinonc.2015.78] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
442 Kumar N, Biswas S, Mathew AE, Varghese S, Mathew JE, Nandakumar K, Aranjani JM, Lobo R. Pro-apoptotic and cytotoxic effects of enriched fraction of Elytranthe parasitica (L.) Danser against HepG2 Hepatocellular carcinoma. BMC Complement Altern Med 2016;16:420. [PMID: 27782823 DOI: 10.1186/s12906-016-1395-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
443 Agarwal R, Cao Y, Hoffmeier K, Krezdorn N, Jost L, Meisel AR, Jüngling R, Dituri F, Mancarella S, Rotter B, Winter P, Giannelli G. Precision medicine for hepatocelluar carcinoma using molecular pattern diagnostics: results from a preclinical pilot study. Cell Death Dis 2017;8:e2867. [PMID: 28594404 DOI: 10.1038/cddis.2017.229] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
444 Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterol Hepatol 2018;41:328-49. [PMID: 29631866 DOI: 10.1016/j.gastrohep.2017.12.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
445 Shariff MI, Kim JU, Ladep NG, Crossey MM, Koomson LK, Zabron A, Reeves H, Cramp M, Ryder S, Greer S, Cox IJ, Williams R, Holmes E, Nash K, Taylor-Robinson SD. Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy. J Clin Exp Hepatol 2016;6:186-94. [PMID: 27746614 DOI: 10.1016/j.jceh.2016.03.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
446 Osório FMF, Lauar GM, Lima AS, Vidigal PVT, Ferrari TCA, Couto CA. EPIDEMIOLOGICAL ASPECTS OF HEPATOCELLULAR CARCINOMA IN A REFERRAL CENTER OF MINAS GERAIS, BRAZIL. Arq Gastroenterol 2013;50:97-100. [DOI: 10.1590/s0004-28032013000200015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
447 Yu JH, Jin Y, Lee J, Lee D. Remaining hepatocellular carcinoma risk in chronic hepatitis B patients receiving entecavir/tenofovir in South Korea: HCC risk in CHB patients. Hepatol Res 2018;48:862-71. [DOI: 10.1111/hepr.13194] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
448 Cho HJ, Kim B, Lee JD, Kang DR, Kim JK, Lee JH, Shin SJ, Lee KM, Yoo BM, Lee KJ. Development of Risk Prediction Model for Hepatocellular Carcinoma Progression of Indeterminate Nodules in Hepatitis B Virus-Related Cirrhotic Liver. Am J Gastroenterol. 2017;112:460-470. [PMID: 27779194 DOI: 10.1038/ajg.2016.480] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
449 Ha Y, Han S, Shim JH, Ko GY, Yoon HK, Sung KB, Lee D, Kim KM, Lim YS, Chung YH, Lee YS, Lee HC. Nomograms for Predicting Outcomes after Chemoembolization in Patients with Nonmetastatic Hepatocellular Carcinoma. J Vasc Interv Radiol 2015;26:1093-1101.e1. [PMID: 26077020 DOI: 10.1016/j.jvir.2015.04.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
450 O'Sullivan S, Cagney DN. The emerging role of stereotactic radiotherapy in gastrointestinal malignancies: a review of the literature and analysis from the Irish perspective. Ir J Med Sci 2018;187:887-94. [PMID: 29423821 DOI: 10.1007/s11845-018-1755-8] [Reference Citation Analysis]
451 Horikawa M, Miyayama S, Irie T, Kaji T, Arai Y. Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review. American Journal of Roentgenology 2015;205:764-73. [DOI: 10.2214/ajr.15.14825] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
452 Armengol C, Sarrias MR, Sala M. Hepatocellular carcinoma: Present and future. Med Clin (Barc). 2018;150:390-397. [PMID: 29096967 DOI: 10.1016/j.medcli.2017.08.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
453 Solaini L, Cucchetti A, Piccino M, Gardini A, La Barba G, Serenari M, Cescon M, Ercolani G. Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma. Future Oncol 2019;15:439-49. [PMID: 30620230 DOI: 10.2217/fon-2018-0269] [Reference Citation Analysis]
454 Sayyar M, Saidi M, Zapatka S, Deng Y, Ciarleglio M, Garcia-Tsao G. Platelet count increases after viral elimination in chronic HCV, independent of the presence or absence of cirrhosis. Liver Int 2019;39:2061-5. [PMID: 31365178 DOI: 10.1111/liv.14203] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
455 Sanuki N, Takeda A. Are Head-to-Head Comparisons Between Radiofrequency Ablation and Stereotactic Body Radiotherapy Really Necessary for Localized Hepatocellular Carcinoma? JCO 2018;36:2563-4. [DOI: 10.1200/jco.2018.78.2805] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
456 An J, Kim HI, Chang S, Shim JH. Continued value of the serum alpha-fetoprotein test in surveilling at-risk populations for hepatocellular carcinoma. PLoS One 2020;15:e0238078. [PMID: 32845895 DOI: 10.1371/journal.pone.0238078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
457 Cucchetti A, Cescon M, Golfieri R, Piscaglia F, Renzulli M, Neri F, Cappelli A, Mazzotti F, Mosconi C, Colecchia A. Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma. J Hepatol. 2016;64:79-86. [PMID: 26325538 DOI: 10.1016/j.jhep.2015.08.025] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 9.2] [Reference Citation Analysis]
458 Labib HA, Ahmed HS, Shalaby SM, Wahab EA, Hamed EF. Genetic polymorphism of IL-23R influences susceptibility to HCV-related hepatocellular carcinoma. Cell Immunol. 2015;294:21-24. [PMID: 25666505 DOI: 10.1016/j.cellimm.2015.01.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
459 Rhee H, Nahm JH, Kim H, Choi GH, Yoo JE, Lee HS, Koh MJ, Park YN. Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia: Resistance to transarterial chemoembolization. Mod Pathol. 2016;29:1038-1049. [PMID: 27312064 DOI: 10.1038/modpathol.2016.111] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
460 Gordon-walker TT, Bove K, Veldtman G. Fontan-associated liver disease: A review. Journal of Cardiology 2019;74:223-32. [DOI: 10.1016/j.jjcc.2019.02.016] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 24.5] [Reference Citation Analysis]
461 Peng C, Kaščáková S, Chiappini F, Olaya N, Sandt C, Yousef I, Samuel D, Dumas P, Guettier C, Le Naour F. Discrimination of cirrhotic nodules, dysplastic lesions and hepatocellular carcinoma by their vibrational signature. J Transl Med 2016;14:9. [PMID: 26754490 DOI: 10.1186/s12967-016-0763-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
462 Degasperi E, D'Ambrosio R, Iavarone M, Sangiovanni A, Aghemo A, Soffredini R, Borghi M, Lunghi G, Colombo M, Lampertico P. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. Clin Gastroenterol Hepatol. 2019;17:1183-1191.e7. [PMID: 30613002 DOI: 10.1016/j.cgh.2018.10.038] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 12.0] [Reference Citation Analysis]
463 Hung HH, Lei HJ, Chau GY, Su CW, Hsia CY, Kao WY, Lui WY, Wu WC, Lin HC, Wu JC. Milan criteria, multi-nodularity, and microvascular invasion predict the recurrence patterns of hepatocellular carcinoma after resection. J Gastrointest Surg. 2013;17:702-711. [PMID: 23225107 DOI: 10.1007/s11605-012-2087-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
464 Yonemura Y, Yoshizumi T, Inokuchi S, Kosai-Fujimoto Y, Harada N, Itoh S, Toshima T, Takeishi K, Yoshiya S, Mori M. Predictor of outcome after living donor liver transplantation for patients with hepatocellular carcinoma beyond the Japan criteria. Ann Gastroenterol Surg 2020;4:413-21. [PMID: 32724885 DOI: 10.1002/ags3.12335] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
465 Navin PJ, Venkatesh SK. Hepatocellular Carcinoma: State of the Art Imaging and Recent Advances. J Clin Transl Hepatol 2019;7:72-85. [PMID: 30944823 DOI: 10.14218/JCTH.2018.00032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
466 Pal S, Ramachandran J, Kurien RT, Eapen A, Ramakrishna B, Keshava SN, Goel A, Sajith KG, Eapen CE. Hepatocellular carcinoma continues to be diagnosed in the advanced stage: profile of hepatocellular carcinoma in a tertiary care hospital in South India. Trop Doct 2013;43:25-6. [PMID: 23443626 DOI: 10.1177/0049475512473600] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
467 Vogl TJ, Gruber-Rouh T. HCC: Transarterial Therapies-What the Interventional Radiologist Can Offer. Dig Dis Sci 2019;64:959-67. [PMID: 30835030 DOI: 10.1007/s10620-019-05542-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
468 Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncologist. 2014;19:394-402. [PMID: 24652387 DOI: 10.1634/theoncologist.2013-0114] [Cited by in Crossref: 86] [Cited by in F6Publishing: 81] [Article Influence: 12.3] [Reference Citation Analysis]
469 Strasser SI. Managing hepatitis B to prevent liver cancer: recent advances. Expert Rev Gastroenterol Hepatol 2014;8:409-15. [PMID: 24580046 DOI: 10.1586/17474124.2014.893823] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
470 Hu H, Duan Z, Long X, Hertzanu Y, Shi H, Liu S, Yang Z. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. PLoS One. 2014;9:e96620. [PMID: 24817002 DOI: 10.1371/journal.pone.0096620] [Cited by in Crossref: 36] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
471 Suh SW, Choi YS. Predictors of Micrometastases in Patients with Barcelona Clinic Liver Cancer Classification B Hepatocellular Carcinoma. Yonsei Med J 2017;58:737-42. [PMID: 28540985 DOI: 10.3349/ymj.2017.58.4.737] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
472 Lin ZY, Wang JH, Yeh ML, Huang CI, Kee KM, Yen YH, Chen SC, Huang CF, Huang JF, Dai CY, Yu ML, Chuang WL. Primary cultures of aspiration residual specimens predict outcomes of hepatocellular carcinoma patients receiving curative treatment. Kaohsiung J Med Sci 2020;36:750-6. [PMID: 32349190 DOI: 10.1002/kjm2.12221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
473 Toyoda H, Kumada T, Tada T, Mizuno K, Hiraoka A, Tsuji K, Ishikawa T, Akita T, Tanaka J. Impact of hepatocellular carcinoma aetiology and liver function on the benefit of surveillance: A novel approach for the adjustment of lead-time bias. Liver Int 2018;38:2260-8. [PMID: 29981527 DOI: 10.1111/liv.13927] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
474 Zhang YF, Zhou J, Wei W, Zou RH, Chen MS, Lau WY, Shi M, Guo RP. Intermediate-stage hepatocellular carcinoma treated with hepatic resection: the NSP score as an aid to decision-making. Br J Cancer. 2016;115:1039-1047. [PMID: 27701389 DOI: 10.1038/bjc.2016.301] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
475 Ding HF, Zhang XF, Bagante F, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Lv Y, Pawlik TM. Prediction of tumor recurrence by α-fetoprotein model after curative resection for hepatocellular carcinoma. Eur J Surg Oncol 2021;47:660-6. [PMID: 33082065 DOI: 10.1016/j.ejso.2020.10.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
476 Acharya SK. Epidemiology of hepatocellular carcinoma in India. J Clin Exp Hepatol 2014;4:S27-33. [PMID: 25755607 DOI: 10.1016/j.jceh.2014.05.013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
477 Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Mol Cancer Ther 2016;15:2553-62. [PMID: 27496136 DOI: 10.1158/1535-7163.MCT-15-0976] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
478 Zhao Y, Duran R, Bai W, Sahu S, Wang W, Kabus S, Lin M, Han G, Geschwind JF. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL? Cardiovasc Intervent Radiol. 2018;41:433-442. [PMID: 29086058 DOI: 10.1007/s00270-017-1829-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
479 Yang Y, Ye F, Xin Y, Wang Y, Li X, Feng D, Chen Y, Zhou X. Prognostic significance of controlling nutritional status score-based nomogram for hepatocellular carcinoma within Milan criteria after radiofrequency ablation. J Gastrointest Oncol 2020;11:1024-39. [PMID: 33209495 DOI: 10.21037/jgo-20-225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
480 Aarås AM, Reitan-Gjersøe TA, Waage A, Mala T, Edwin B, Løberg EM, Abildgaard A, Røsok BI. Laparoscopic resection of recurrent ectopic hepatocellular carcinoma: A case report with review of the literature and guidelines for follow-up. Int J Surg Case Rep 2015;17:92-5. [PMID: 26590353 DOI: 10.1016/j.ijscr.2015.10.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
481 Guo J, Liu S, Gao S, Kou F, Zhang X, Liu P, Yang R, Zhu X. γ-Glutamyltranspeptidase as a Prognostic Biomarker in Advanced Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. J Vasc Interv Radiol 2021;32:419-428.e2. [PMID: 33067120 DOI: 10.1016/j.jvir.2020.07.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
482 Mohkam K, Dumont PN, Manichon AF, Jouvet JC, Boussel L, Merle P, Ducerf C, Lesurtel M, Rode A, Mabrut JY. No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm. J Hepatol 2018;68:1172-80. [PMID: 29410287 DOI: 10.1016/j.jhep.2018.01.014] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 10.7] [Reference Citation Analysis]
483 Kong LM, Yao L, Lu N, Dong YL, Zhang J, Wang YQ, Liu L, Zhang HL, Huang JG, Liao CG. Interaction of KLF6 and Sp1 regulates basigin-2 expression mediated proliferation, invasion and metastasis in hepatocellular carcinoma. Oncotarget 2016;7:27975-87. [PMID: 27057625 DOI: 10.18632/oncotarget.8564] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
484 Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, Guo W, Zhang H, Wang H, Cheng S, Cao G. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol. 2013;31:3647-3655. [PMID: 24002499 DOI: 10.1200/jco.2012.48.5896] [Cited by in Crossref: 158] [Cited by in F6Publishing: 81] [Article Influence: 19.8] [Reference Citation Analysis]
485 Ronot M, Clift AK, Vilgrain V, Frilling A. Functional imaging in liver tumours. J Hepatol 2016;65:1017-30. [PMID: 27395013 DOI: 10.1016/j.jhep.2016.06.024] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
486 Wang M, Wang Y, Feng X, Wang R, Zeng H, Qi J, Zhao H, Li N, Cai J, Qu C. Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience of the Chinese National Cancer Center. Int J Infect Dis. 2017;65:15-21. [PMID: 28935244 DOI: 10.1016/j.ijid.2017.09.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
487 Kudo M. Early hepatocellular carcinoma: definition and diagnosis. Liver Cancer. 2013;2:69-72. [PMID: 24159598 DOI: 10.1159/000343842] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
488 Chen X, Zhang Y, Zhang N, Ge Y, Jia W. Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report. Onco Targets Ther. 2019;12:7355-7359. [PMID: 31686845 DOI: 10.2147/ott.s217123] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
489 Dong L, Zhu K, Chen M, Li D, Jiang C, Chen L. Long non-coding RNA GACAT3 promotes liver cancer progression by regulating the proliferation, apoptosis and migration of tumor cells. Exp Ther Med 2020;19:3377-83. [PMID: 32266036 DOI: 10.3892/etm.2020.8604] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
490 Zuo C, Sheng X, Liu Z, Ma M, Xiong S, Deng H, Li S, Yang D, Wang X, Xiao H, Quan H, Xia M. MicroRNA-138 enhances TRAIL-induced apoptosis through interferon-stimulated gene 15 downregulation in hepatocellular carcinoma cells. Tumour Biol 2017;39:1010428317710410. [PMID: 28639887 DOI: 10.1177/1010428317710410] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
491 Bianco C, Jamialahmadi O, Pelusi S, Baselli G, Dongiovanni P, Zanoni I, Santoro L, Maier S, Liguori A, Meroni M, Borroni V, D'Ambrosio R, Spagnuolo R, Alisi A, Federico A, Bugianesi E, Petta S, Miele L, Vespasiani-Gentilucci U, Anstee QM, Stickel F, Hampe J, Fischer J, Berg T, Fracanzani AL, Soardo G, Reeves H, Prati D, Romeo S, Valenti L. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.J Hepatol. 2021;74:775-782. [PMID: 33248170 DOI: 10.1016/j.jhep.2020.11.024] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 30.0] [Reference Citation Analysis]
492 Hsu C, Chen BB, Chen CH, Ho MC, Cheng JC, Kokudo N, Murakami T, Yeo W, Seong J, Jia JD. Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer. 2015;4:96-105. [PMID: 26020032 DOI: 10.1159/000367732] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
493 Seto WK, Lau EH, Wu JT, Hung IF, Leung WK, Cheung KS, Fung J, Lai CL, Yuen MF. Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study. Aliment Pharmacol Ther. 2017;45:501-509. [PMID: 27976416 DOI: 10.1111/apt.13895] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
494 Murata S, Mine T, Sugihara F, Yasui D, Yamaguchi H, Ueda T, Onozawa S, Kumita SI. Interventional treatment for unresectable hepatocellular carcinoma. World J Gastroenterol 2014; 20(37): 13453-13465 [PMID: 25309076 DOI: 10.3748/wjg.v20.i37.13453] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
495 Ahn SH, Kim SH, Choi GH, Choi JS, Kim KS. The optimal follow-up period in patients with above 5-year disease-free survival after curative liver resection for hepatocellular carcinoma. J Korean Surg Soc 2013;85:269-74. [PMID: 24368984 DOI: 10.4174/jkss.2013.85.6.269] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
496 Méndez Romero A, de Man RA. Stereotactic body radiation therapy for primary and metastatic liver tumors: From technological evolution to improved patient care. Best Pract Res Clin Gastroenterol 2016;30:603-16. [PMID: 27644908 DOI: 10.1016/j.bpg.2016.06.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
497 Akamatsu N, Kokudo N. Liver transplantation for hepatocellular carcinoma from living-donor vs. deceased donor. Hepatobiliary Surg Nutr 2016;5:422-8. [PMID: 27826557 DOI: 10.21037/hbsn.2016.08.03] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
498 Gao SX, Liao R, Wang HQ, Liu D, Luo F. A Nomogram Predicting Microvascular Invasion Risk in BCLC 0/A Hepatocellular Carcinoma after Curative Resection. Biomed Res Int 2019;2019:9264137. [PMID: 31428651 DOI: 10.1155/2019/9264137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
499 Nguyen LH, Robinton DA, Seligson MT, Wu L, Li L, Rakheja D, Comerford SA, Ramezani S, Sun X, Parikh MS, Yang EH, Powers JT, Shinoda G, Shah SP, Hammer RE, Daley GQ, Zhu H. Lin28b is sufficient to drive liver cancer and necessary for its maintenance in murine models. Cancer Cell 2014;26:248-61. [PMID: 25117712 DOI: 10.1016/j.ccr.2014.06.018] [Cited by in Crossref: 119] [Cited by in F6Publishing: 114] [Article Influence: 17.0] [Reference Citation Analysis]
500 Guan YS, Ahmad Al-Shatouri M, He Q, Liu WM. Hepatocellular carcinoma: carcinogenesis, establishment, progression, and therapies. Biomed Res Int. 2014;2014:706142. [PMID: 25028663 DOI: 10.1155/2014/239706] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
501 Ladep NG, Lesi OA, Mark P, Lemoine M, Onyekwere C, Afihene M, Crossey MM, Taylor-Robinson SD. Problem of hepatocellular carcinoma in West Africa. World J Hepatol 2014; 6(11): 783-792 [PMID: 25429316 DOI: 10.4254/wjh.v6.i11.783] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 4.9] [Reference Citation Analysis]
502 Lim S, Lee MW, Rhim H, Cha DI, Kang TW, Min JH, Song KD, Choi S, Lim HK. Mistargeting after Fusion Imaging–Guided Percutaneous Radiofrequency Ablation of Hepatocellular Carcinomas. Journal of Vascular and Interventional Radiology 2014;25:307-14. [DOI: 10.1016/j.jvir.2013.10.025] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
503 Walter I, Schulz U, Vogelhuber M, Wiedmann K, Endlicher E, Klebl F, Andreesen R, Herr W, Ghibelli L, Hackl C, Wiest R, Reichle A. Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial. Med Oncol 2017;34:192. [PMID: 29098441 DOI: 10.1007/s12032-017-1040-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
504 Ding M, Zhao X, Zhao M, Shi Y, Wang T, Cui D, Shi D, Zhai B. Prognostic Nomogram for Patients with Hepatocellular Carcinoma After Thermal Ablation. Cardiovasc Intervent Radiol 2020;43:1621-30. [PMID: 32814990 DOI: 10.1007/s00270-020-02617-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
505 Farid K, Elalfy H, Abo El-Khair SM, Elgamal H, Besheer T, Elmokadem A, Shabana W, Abed S, Elegezy M, El-Khalek AA, El-Morsy A, Negm A, Elsamanoudy AZ, El Deek B, Amer T, El-Bendary M. Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients. Expert Rev Gastroenterol Hepatol 2020;14:1203-14. [PMID: 32933325 DOI: 10.1080/17474124.2020.1823215] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
506 Popovic P, Leban A, Kregar K, Garbajs M, Dezman R, Bunc M. Computed Tomographic Perfusion Imaging for the Prediction of Response and Survival to Transarterial Chemoembolization of Hepatocellular Carcinoma. Radiol Oncol 2018;52:14-22. [PMID: 29520201 DOI: 10.1515/raon-2017-0052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
507 Amisaki M, Saito H, Tokuyasu N, Sakamoto T, Honjo S, Fujiwara Y. Prognostic value of postoperative complication for early recurrence after curative resection of hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International 2018;17:323-9. [DOI: 10.1016/j.hbpd.2018.03.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
508 Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31:3517-3524. [PMID: 23980084 DOI: 10.1200/jco.2012.48.4410] [Cited by in Crossref: 458] [Cited by in F6Publishing: 257] [Article Influence: 57.3] [Reference Citation Analysis]
509 Wörns MA, Klöckner R, Weinmann A, Galle PR. [Therapy of hepatocellular carcinoma]. Internist (Berl). 2014;55:23-24, 26-30. [PMID: 24240604 DOI: 10.1007/s00108-013-3318-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
510 Lee YB, Lee DH, Cho Y, Yu SJ, Lee JH, Yoon JH, Lee HS, Kim HC, Yi NJ, Lee KW. Comparison of transarterial chemoembolization and hepatic resection for large solitary hepatocellular carcinoma: a propensity score analysis. J Vasc Interv Radiol. 2015;26:651-659. [PMID: 25824316 DOI: 10.1016/j.jvir.2015.02.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
511 Green TJ, Rochon PJ, Chang S, Ray CE, Winston H, Ruef R, Kreidler SM, Glueck DH, Shulman BC, Brown AC. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization. J Vasc Interv Radiol. 2013;24:1613-1622. [PMID: 24060436 DOI: 10.1016/j.jvir.2013.07.024] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
512 Melancon MP, Yevich S, Avritscher R, Swigost A, Lu L, Tian L, Damasco JA, Dixon K, Cortes AC, Munoz NM, Liang D, Liu D, Tam AL. A novel irinotecan-lipiodol nanoemulsion for intravascular administration: pharmacokinetics and biodistribution in the normal and tumor bearing rat liver. Drug Deliv 2021;28:240-51. [PMID: 33501859 DOI: 10.1080/10717544.2020.1869863] [Reference Citation Analysis]
513 Giannini EG, Bucci L, Garuti F, Brunacci M, Lenzi B, Valente M, Caturelli E, Cabibbo G, Piscaglia F, Virdone R, Felder M, Ciccarese F, Foschi FG, Sacco R, Svegliati Baroni G, Farinati F, Rapaccini GL, Olivani A, Gasbarrini A, Di Marco M, Morisco F, Zoli M, Masotto A, Borzio F, Benvegnù L, Marra F, Colecchia A, Nardone G, Bernardi M, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) group. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. Hepatology 2018;67:1784-96. [DOI: 10.1002/hep.29668] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 16.3] [Reference Citation Analysis]
514 Piscaglia F, Ogasawara S. Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. Liver Cancer. 2018;7:104-119. [PMID: 29662837 DOI: 10.1159/000485471] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
515 Mandorfer M, Schwabl P, Steiner S, Reiberger T, Peck-Radosavljevic M. Advances in the management of HIV/HCV coinfection. Hepatol Int. 2016;10:424-435. [PMID: 26758592 DOI: 10.1007/s12072-015-9691-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]
516 Schraml C, Kaufmann S, Rempp H, Syha R, Ketelsen D, Notohamiprodjo M, Nikolaou K. Imaging of HCC-Current State of the Art. Diagnostics (Basel). 2015;5:513-545. [PMID: 26854169 DOI: 10.3390/diagnostics5040513] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
517 Wörns MA, Galle PR. Patient prioritisation in HCC treatment: All (good) things come in threes. J Hepatol 2018;68:1311-2. [PMID: 29496352 DOI: 10.1016/j.jhep.2017.11.035] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
518 Casals G, Perramón M, Casals E, Portolés I, Fernández-Varo G, Morales-Ruiz M, Puntes V, Jiménez W. Cerium Oxide Nanoparticles: A New Therapeutic Tool in Liver Diseases. Antioxidants (Basel) 2021;10:660. [PMID: 33923136 DOI: 10.3390/antiox10050660] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
519 Wu S, Zhang Z, Cheng N, Xiong X, Yang L. Preoperative serum ferritin is an independent prognostic factor for liver cancer after hepatectomy. Surgical Oncology 2019;29:159-67. [DOI: 10.1016/j.suronc.2019.05.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
520 Yang SW, Kim GH, Chung JW, Sohn HR, Lee SS, Hong S, Chung SM, Jang ES, Jeong SH, Kim JW. Prediction of risk for hepatocellular carcinoma by response of serum α-fetoprotein to entecavir therapy. J Gastroenterol Hepatol 2015;30:1175-82. [PMID: 25707935 DOI: 10.1111/jgh.12921] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
521 Gallicchio R, Nardelli A, Mainenti P, Nappi A, Capacchione D, Simeon V, Sirignano C, Abbruzzi F, Barbato F, Landriscina M. Therapeutic Strategies in HCC: Radiation Modalities. Biomed Res Int. 2016;2016:1295329. [PMID: 27563661 DOI: 10.1155/2016/1295329] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
522 Timaran Montenegro DE, Torres Ramirez CA, Mateo C YS, Govea Palma J, Quiñones JC, Orozco Vazquez JS. CT-Based Hepatic Residual Volume and Predictors of Outcomes of Patients with Hepatocellular Carcinoma Unsuitable for Surgical Therapy Undergoing Transarterial Chemoembolization. Acad Radiol 2020;27:807-14. [PMID: 31575476 DOI: 10.1016/j.acra.2019.09.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
523 Ho SY, Liu PH, Hsu CY, Hsia CY, Lee YH, Lee RC, Huang YH, Lee FY, Hou MC, Tsai YJ, Huo TI. Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. PLoS One. 2017;12:e0180408. [PMID: 28672011 DOI: 10.1371/journal.pone.0180408] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
524 Lee PC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lee MH, Hou MC, Lee FY, Lin HC, Huang YH. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma. Liver Int. 2018;38:321-330. [PMID: 28736952 DOI: 10.1111/liv.13527] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
525 Yue W, Wang S, Xu H, Sun L, Guo L, Bo X, Li X, Zhao C, Wang D, Liu B. Parametric imaging with contrast-enhanced ultrasound for differentiating hepatocellular carcinoma from metastatic liver cancer. CH 2016;64:177-88. [DOI: 10.3233/ch-162060] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 4.4] [Reference Citation Analysis]
526 Lee DH, Lee JM. Recent Advances in the Image-Guided Tumor Ablation of Liver Malignancies: Radiofrequency Ablation with Multiple Electrodes, Real-Time Multimodality Fusion Imaging, and New Energy Sources. Korean J Radiol 2018;19:545-59. [PMID: 29962861 DOI: 10.3348/kjr.2018.19.4.545] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
527 Calvisi DF. Molecularly targeted therapies for human hepatocellular carcinoma: should we start from β-catenin inhibition? J Hepatol 2015;62:257-9. [PMID: 25463532 DOI: 10.1016/j.jhep.2014.11.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
528 Bae SH, Park HC, Yoon WS, Yoon SM, Jung IH, Lee IJ, Kim JW, Seong J, Kim TH, Nam TK, Choi Y, Lee SY, Jang HS, Lee DS, Kim JH. Treatment Outcome after Fractionated Conformal Radiotherapy for Hepatocellular Carcinoma in Patients with Child-Pugh Classification B in Korea (KROG 16-05). Cancer Res Treat 2019;51:1589-99. [PMID: 30971065 DOI: 10.4143/crt.2018.687] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
529 Bize P, Duran R, Fuchs K, Dormond O, Namur J, Decosterd LA, Jordan O, Doelker E, Denys A. Antitumoral Effect of Sunitinib-eluting Beads in the Rabbit VX2 Tumor Model. Radiology 2016;280:425-35. [PMID: 26919561 DOI: 10.1148/radiol.2016150361] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
530 Ungureanu BS, Dumitrascu SI, Margaritescu C, Pirici D, Gheonea IA, Sandulescu L, Tudorache S, Tudorache S, Tica OS, Sandru V, Saftoiu A. In Vivo Experimental Study of an Endoscopic Ultrasound Multifunctional Radiofrequency Ablation Probe. Curr Health Sci J 2016;42:359-64. [PMID: 30581590 DOI: 10.12865/CHSJ.42.04.05] [Reference Citation Analysis]
531 Sohn W, Choi MS, Cho JY, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Yoo BC. Role of radiofrequency ablation in patients with hepatocellular carcinoma who undergo prior transarterial chemoembolization: long-term outcomes and predictive factors. Gut Liver. 2014;8:543-551. [PMID: 25071073 DOI: 10.5009/gnl13356] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
532 Shin SW, Jeong WK, Lim S, Kim Y, Kim J. Alteration of laboratory findings after radiofrequency ablation of hepatocellular carcinoma: relationship to severity of the underlying liver disease and the ablation volume. Clin Mol Hepatol 2015;21:71-9. [PMID: 25834804 DOI: 10.3350/cmh.2015.21.1.71] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
533 Park J, Cho J, Lim JH, Lee MH, Kim J. Relative Efficacy of Systemic Treatments for Patients with Advanced Hepatocellular Carcinoma According to Viral Status: A Systematic Review and Network Meta-Analysis. Target Oncol. 2019;14:395-403. [PMID: 31290003 DOI: 10.1007/s11523-019-00651-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
534 Wu TH, Wang YC, Cheng CH, Lee CF, Wu TJ, Chou HS, Chan KM, Lee WC. Outcomes associated with the intention of loco-regional therapy prior to living donor liver transplantation for hepatocellular carcinoma. World J Gastrointest Surg 2020; 12(1): 17-27 [PMID: 31984121 DOI: 10.4240/wjgs.v12.i1.17] [Reference Citation Analysis]
535 Liang KH, Ahn SH, Lee HW, Huang YH, Chien RN, Hu TH, Lin KH, Yeh CS, Hsu CW, Lin CL, Pan TL, Ke PY, Chang ML, Yeh CT. A novel risk score for hepatocellular carcinoma in Asian cirrhotic patients: a multicentre prospective cohort study. Sci Rep 2018;8:8608. [PMID: 29872158 DOI: 10.1038/s41598-018-26992-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
536 Cho MK, Kwon JH, Gwak MS, Joh JW, Hwang J, Kim GS. Liver transplantation in an adult patient with hepatocellular carcinoma following liver cirrhosis as a complication of the Fontan procedure -A case report. Anesth Pain Med (Seoul) 2020;15:466-71. [PMID: 33329850 DOI: 10.17085/apm.20037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
537 Sapisochin G, Sevilla EF, Echeverri J, Charco R. Management of “very early” hepatocellular carcinoma on cirrhotic patients. World J Hepatol 2014; 6(11): 766-775 [PMID: 25429314 DOI: 10.4254/wjh.v6.i11.766] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
538 Kim BH, Lim YS, Kim EY, Kong HJ, Won YJ, Han S, Park S, Hwang JS. Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis B virus-endemic population. J Gastroenterol Hepatol 2018;33:475-83. [PMID: 28612951 DOI: 10.1111/jgh.13848] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
539 Petrizzo A, Buonaguro L. Application of the Immunoscore as prognostic tool for hepatocellular carcinoma. J Immunother Cancer. 2016;4:71. [PMID: 27879973 DOI: 10.1186/s40425-016-0182-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
540 Chapiro J, Geschwind J. Have we finally found the ultimate staging system for HCC? Nat Rev Gastroenterol Hepatol 2014;11:334-6. [DOI: 10.1038/nrgastro.2014.67] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
541 Liu YS, Lin CY, Chuang MT, Lin CY, Tsai YS, Wang CK, Ou MC. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. BMC Gastroenterol 2018;18:124. [PMID: 30075752 DOI: 10.1186/s12876-018-0848-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
542 Liu L, Zhang Q, Geng J, Li S, Zhao S, Zhang X, Hu J, Feng D. Comparison of radiofrequency ablation combined with sorafenib or sorafenib alone in patients with ECOG performance score 1: identifying optimal candidates. Ann Transl Med 2020;8:583. [PMID: 32566610 DOI: 10.21037/atm.2020.03.71] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
543 Jasirwan COM, Fahira A, Siregar L, Loho I. The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia. BMC Gastroenterol 2020;20:215. [PMID: 32646378 DOI: 10.1186/s12876-020-01365-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
544 Huang F, Gao J. Modified Child-Pugh grade vs albumin-bilirubin grade for predicting prognosis of hepatocellular carcinoma patients after hepatectomy. World J Gastroenterol 2020; 26(7): 749-758 [PMID: 32116422 DOI: 10.3748/wjg.v26.i7.749] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
545 Kim M, Kang TW, Cha DI, Jang KM, Kim YK, Kim SH, Sinn DH, Kim K. Identification of Arterial Hyperenhancement in CT and MRI in Patients with Hepatocellular Carcinoma: Value of Unenhanced Images. Korean J Radiol 2019;20:236-45. [PMID: 30672163 DOI: 10.3348/kjr.2018.0339] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
546 Torres HA, Vauthey JN, Economides MP, Mahale P, Kaseb A. Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment. J Hepatol. 2016;65:862-864. [PMID: 27255582 DOI: 10.1016/j.jhep.2016.05.034] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 12.6] [Reference Citation Analysis]
547 Schütte K, Schulz C, Link A, Malfertheiner P. Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J Hepatol 2015; 7(2): 139-149 [PMID: 25729470 DOI: 10.4254/wjh.v7.i2.139] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 7.2] [Reference Citation Analysis]
548 Suh SW, Choi YS. Influence of liver fibrosis on prognosis after surgical resection for resectable single hepatocellular carcinoma. ANZ J Surg 2019;89:211-5. [PMID: 30117629 DOI: 10.1111/ans.14732] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
549 Refolo MG, Messa C, Guerra V, Carr BI, D'Alessandro R. Inflammatory Mechanisms of HCC Development. Cancers (Basel) 2020;12:E641. [PMID: 32164265 DOI: 10.3390/cancers12030641] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 23.0] [Reference Citation Analysis]
550 Hsieh CE, Venkatesulu BP, Lee CH, Hung SP, Wong PF, Aithala SP, Kim BK, Rao A, Tung-Chieh Chang J, Tsang NM, Wang CC, Lee CC, Lin CC, Tseng JH, Chou WC, Wang YC, Krishnan S, Hong JH. Predictors of Radiation-Induced Liver Disease in Eastern and Western Patients With Hepatocellular Carcinoma Undergoing Proton Beam Therapy. Int J Radiat Oncol Biol Phys. 2019;105:73-86. [PMID: 30797890 DOI: 10.1016/j.ijrobp.2019.02.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
551 Yang M, Yuan JQ, Bai M, Han GH. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Mol Biol Rep. 2014;41:6575-6582. [PMID: 25091939 DOI: 10.1007/s11033-014-3541-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
552 Kato H, Yoshida H, Taniguch H, Nomura R, Sato K, Suzuki I, Nakata R. Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma. World J Gastroenterol 2015; 21(46): 13101-13112 [PMID: 26673627 DOI: 10.3748/wjg.v21.i46.13101] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
553 Lee DH, Lee JM, Kim PN, Jang YJ, Kang TW, Rhim H, Seo JW, Lee YJ. Whole tumor ablation of locally recurred hepatocellular carcinoma including retained iodized oil after transarterial chemoembolization improves progression-free survival. Eur Radiol 2019;29:5052-62. [PMID: 30770968 DOI: 10.1007/s00330-018-5993-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
554 Pinyol R, Llovet JM. Genome-scale metabolic models for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2014;11:336-7. [DOI: 10.1038/nrgastro.2014.70] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
555 Chung JW, Kim BH, Lee CS, Kim GH, Sohn HR, Min BY, Song JC, Park HK, Jang ES, Yoon H, Kim J, Shin CM, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Lee J, Ahn S, Kim JW. Optimizing Surveillance Performance of Alpha-Fetoprotein by Selection of Proper Target Population in Chronic Hepatitis B. PLoS One 2016;11:e0168189. [PMID: 27997559 DOI: 10.1371/journal.pone.0168189] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
556 Pérez P, Rodríguez-Perálvarez M, Guerrero L, González V, Sánchez R, Centeno M, Poyato A, Briceño J, Sánchez-Frías M, Montero JL, De la Mata M. Incidental hepatocellular carcinoma after liver transplantation: Prevalence, histopathological features and prognostic impact. PLoS One 2017;12:e0175010. [PMID: 28403219 DOI: 10.1371/journal.pone.0175010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
557 Lamarca A, Abdel-rahman O, Salu I, Mcnamara MG, Valle JW, Hubner RA. Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib. Clin Transl Oncol 2017;19:364-72. [DOI: 10.1007/s12094-016-1537-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
558 Yong CC, Elsarawy AM, Wang SH, Lin TS, Wang CC, Li WF, Lin TL, Kuo FY, Cheng YF, Chen CL, Lin CC. The surgical challenges of salvage living donor liver transplantation for Hepatocellular carcinoma; The cumulative experience of 100 cases - A retrospective cohort study and a propensity score analysis. Int J Surg 2018;54:187-92. [PMID: 29723674 DOI: 10.1016/j.ijsu.2018.04.041] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
559 Vandewynckel YP, Laukens D, Devisscher L, Bogaerts E, Paridaens A, Van den Bussche A, Raevens S, Verhelst X, Van Steenkiste C, Jonckx B, Libbrecht L, Geerts A, Carmeliet P, Van Vlierberghe H. Placental growth factor inhibition modulates the interplay between hypoxia and unfolded protein response in hepatocellular carcinoma. BMC Cancer 2016;16:9. [PMID: 26753564 DOI: 10.1186/s12885-015-1990-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
560 Lin CH, Ho CM, Wu CH, Liang PC, Wu YM, Hu RH, Lee PH, Ho MC. Minimally invasive surgery versus radiofrequency ablation for single subcapsular hepatocellular carcinoma ≤ 2 cm with compensated liver cirrhosis. Surg Endosc 2020;34:5566-73. [PMID: 31993821 DOI: 10.1007/s00464-019-07357-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
561 Lee HW, Kim EH, Lee J, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase. Clin Transl Gastroenterol 2020;11:e00140. [PMID: 32352711 DOI: 10.14309/ctg.0000000000000140] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
562 Venkatesh SK, Hennedige T, Johnson GB, Hough DM, Fletcher JG. Imaging patterns and focal lesions in fatty liver: a pictorial review. Abdom Radiol (NY) 2017;42:1374-92. [PMID: 27999887 DOI: 10.1007/s00261-016-1002-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
563 Park VY, Choi JY, Chung YE, Kim H, Park MS, Lim JS, Kim KW, Kim MJ. Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT. Liver Int 2014;34:1593-602. [PMID: 24673802 DOI: 10.1111/liv.12550] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
564 Wang J, Shan Q, Liu Y, Yang H, Kuang S, He B, Zhang Y, Chen J, Zhang T, Glaser KJ, Zhu C, Chen J, Yin M, Venkatesh SK, Ehman RL. 3D MR Elastography of Hepatocellular Carcinomas as a Potential Biomarker for Predicting Tumor Recurrence. J Magn Reson Imaging 2019;49:719-30. [PMID: 30260529 DOI: 10.1002/jmri.26250] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
565 Chen S, Zhu Y, Liu Z, Liang C. Texture analysis of baseline multiphasic hepatic computed tomography images for the prognosis of single hepatocellular carcinoma after hepatectomy: A retrospective pilot study. Eur J Radiol 2017;90:198-204. [PMID: 28583634 DOI: 10.1016/j.ejrad.2017.02.035] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
566 Monteserin L, Mesa A, Fernandez-Garcia MS, Gadanon-Garcia A, Rodriguez M, Varela M. Bone metastases as initial presentation of hepatocellular carcinoma. World J Hepatol 2017; 9(29): 1158-1165 [PMID: 29085559 DOI: 10.4254/wjh.v9.i29.1158] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
567 Pinato DJ, Sharma R, Allara E, Yen C, Arizumi T, Kubota K, Bettinger D, Jang JW, Smirne C, Kim YW, Kudo M, Howell J, Ramaswami R, Burlone ME, Guerra V, Thimme R, Ishizuka M, Stebbing J, Pirisi M, Carr BI. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. Journal of Hepatology 2017;66:338-46. [DOI: 10.1016/j.jhep.2016.09.008] [Cited by in Crossref: 144] [Cited by in F6Publishing: 140] [Article Influence: 36.0] [Reference Citation Analysis]
568 Lin S, Lin Y, Fang Y, Mo Z, Hong X, Ji C, Jian Z. Clinicopathological and prognostic value of preoperative lymphocyte to monocyte ratio for hepatocellular carcinoma following curative resection: A meta-analysis including 4,092 patients. Medicine (Baltimore) 2021;100:e24153. [PMID: 33546030 DOI: 10.1097/MD.0000000000024153] [Reference Citation Analysis]
569 Kim SW, Oh D, Park HC, Lim DH, Shin SW, Cho SK, Gwak GY, Choi MS, Paik YH, Paik SW. Transcatheter arterial chemoembolization and radiation therapy for treatment-naïve patients with locally advanced hepatocellular carcinoma. Radiat Oncol J 2014;32:14-22. [PMID: 24724047 DOI: 10.3857/roj.2014.32.1.14] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
570 Schelhorn J, Best J, Dechêne A, Göbel T, Bertram S, Lauenstein T, Kinner S. Evaluation of combined Gd-EOB-DTPA and gadobutrol magnetic resonance imaging for the prediction of hepatocellular carcinoma grading. Acta Radiol 2016;57:932-8. [PMID: 26586852 DOI: 10.1177/0284185115616293] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
571 Yu SJ, Yoon JH, Lee JM, Lee JY, Kim SH, Cho YY, Yoo JJ, Lee M, Lee DH, Cho Y, Cho EJ, Lee JH, Kim YJ, Kim CY. Percutaneous ethanol injection therapy is comparable to radiofrequency ablation in hepatocellular carcinoma smaller than 1.5 cm: A matched case-control comparative analysis. Medicine (Baltimore) 2016;95:e4551. [PMID: 27583865 DOI: 10.1097/MD.0000000000004551] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
572 Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol (NY). 2018;43:13-25. [PMID: 28647765 DOI: 10.1007/s00261-017-1209-1] [Cited by in Crossref: 159] [Cited by in F6Publishing: 153] [Article Influence: 79.5] [Reference Citation Analysis]
573 Sinn DH, Choi GS, Park HC, Kim JM, Kim H, Song KD, Kang TW, Lee MW, Rhim H, Hyun D, Cho SK, Shin SW, Jeong WK, Kim SH, Yu JI, Ha SY, Lee SJ, Lim HY, Kim K, Ahn JH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Joh JW, Lim HK, Paik SW. Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. PLoS One. 2019;14:e0210730. [PMID: 30640924 DOI: 10.1371/journal.pone.0210730] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 13.5] [Reference Citation Analysis]
574 Chopra S, George K, Engineer R, Rajamanickam K, Nojin S, Joshi K, Swamidas J, Shetty N, Patkar S, Patil P, Ostwal V, Mehta S, Goel M. Stereotactic body radio therapy for inoperable large hepatocellular cancers: results from a clinical audit. Br J Radiol 2019;92:20181053. [PMID: 31219706 DOI: 10.1259/bjr.20181053] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
575 Lee TH, Rangan V, Khallafi H. A Case of Sphenoid Sinus Metastasis in Hepatocellular Carcinoma. Hepatology 2016;63:2050-3. [PMID: 26928869 DOI: 10.1002/hep.28516] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
576 Choi JW, Kim H, Lee J, Yu SJ, Kim YJ, Yoon J, Jae HJ, Hur S, Lee M, Chung JW. Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus. Eur Radiol 2017;27:1448-58. [DOI: 10.1007/s00330-016-4511-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
577 Lin Y, Pan XB. Differences in Survival Between First-Line Radiofrequency Ablation versus Surgery for Early-Stage Hepatocellular Carcinoma: A Population Study Using the Surveillance, Epidemiology, and End Results Database. Med Sci Monit 2020;26:e921782. [PMID: 32461542 DOI: 10.12659/MSM.921782] [Reference Citation Analysis]
578 Liu Y, Xie K, Li J, Wang Z, Zeng Y, Wu H. Successful management of the hepatocellular carcinoma with inferior vena cava tumor thrombus: A case report. Medicine (Baltimore) 2021;100:e26081. [PMID: 34032742 DOI: 10.1097/MD.0000000000026081] [Reference Citation Analysis]
579 Cieslak KP, Bennink RJ, van Gulik TM. Prediction of postoperative liver failure in patients diagnosed with hepatocellular carcinoma using (99m)Tc-GSA SPECT/CT. Hepatobiliary Surg Nutr 2015;4:203-5. [PMID: 26151060 DOI: 10.3978/j.issn.2304-3881.2014.12.07] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
580 Nishigori S, Numata K, Irie K, Fukuda H, Chuma M, Maeda S. Fusion imaging with contrast-enhanced ultrasonography for evaluating the early therapeutic efficacy of radiofrequency ablation for small hypervascular hepatocellular carcinomas with iso-echoic or unclear margins on conventional ultrasonography. J Med Ultrason (2001) 2018;45:405-15. [PMID: 29362966 DOI: 10.1007/s10396-018-0861-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
581 Vivarelli M, Montalti R, Risaliti A. Multimodal treatment of hepatocellular carcinoma on cirrhosis: An update. World J Gastroenterol 2013; 19(42): 7316-7326 [PMID: 24259963 DOI: 10.3748/wjg.v19.i42.7316] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
582 Chai Y, Li K, Zhang C, Chen S, Ma K. The short-term efficacy of no-touch radiofrequency ablation in treating cirrhosis-based small hepatocellular carcinoma. BMC Cancer 2019;19:497. [PMID: 31133001 DOI: 10.1186/s12885-019-5707-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
583 Hu H, Chen GF, Yuan W, Wang JH, Zhai B. Microwave ablation with chemoembolization for large hepatocellular carcinoma in patients with cirrhosis. Int J Hyperthermia 2018;34:1351-8. [PMID: 29720001 DOI: 10.1080/02656736.2018.1462536] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
584 Chon YE, Jung KS, Kim MJ, Choi JY, An C, Park JY, Ahn SH, Kim BK, Kim SU, Park H, Hwang SK, Rim KS, Han KH, Kim DY. Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillance. Aliment Pharmacol Ther 2018;47:1201-12. [PMID: 29492988 DOI: 10.1111/apt.14578] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
585 Feng K, Yan J, Li X, Xia F, Ma K, Wang S, Bie P, Dong J. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012;57:794-802. [PMID: 22634125 DOI: 10.1016/j.jhep.2012.07.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
586 Ng KKC, Cheng NMY, Huang J, Liao M, Chong CCN, Lee KF, Wong J, Cheung SYS, Lok HT, Fung AKY, Wong GLH, Wong VWS, Lai PBS. Development and validation of a novel nomogram predicting 10-year actual survival after curative hepatectomy for hepatocellular carcinoma. Surgeon 2021:S1479-666X(20)30186-4. [PMID: 33423927 DOI: 10.1016/j.surge.2020.11.013] [Reference Citation Analysis]
587 Si WK, Chung JW, Cho J, Baeg JY, Jang ES, Yoon H, Kim J, Shin CM, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Lim S, Kim JW. Predictors of Increased Risk of Hepatocellular Carcinoma in Patients with Type 2 Diabetes. PLoS One 2016;11:e0158066. [PMID: 27359325 DOI: 10.1371/journal.pone.0158066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
588 Kreidieh M, Zeidan YH, Shamseddine A. The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors. J Oncol. 2019;2019:4304817. [PMID: 31182960 DOI: 10.1155/2019/4304817] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
589 Inchingolo R, Faletti R, Grazioli L, Tricarico E, Gatti M, Pecorelli A, Ippolito D. MR with Gd-EOB-DTPA in assessment of liver nodules in cirrhotic patients. World J Hepatol 2018; 10(7): 462-473 [PMID: 30079132 DOI: 10.4254/wjh.v10.i7.462] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
590 Gmür A, Kolly P, Knöpfli M, Dufour J. FACT-Hep increases the accuracy of survival prediction in HCC patients when added to ECOG Performance Status. Liver Int 2018;38:1468-74. [DOI: 10.1111/liv.13711] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
591 Li M, Li H, Zhou C, Li X, Gong J, Chen C, Zhang Y. Comprehensive analysis of prognostic immune-related genes in the tumor microenvironment of hepatocellular carcinoma (HCC). Medicine (Baltimore) 2021;100:e27332. [PMID: 34596136 DOI: 10.1097/MD.0000000000027332] [Reference Citation Analysis]
592 Hanouneh IA, Alkhouri N, Singal AG. Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm? Clin Mol Hepatol. 2019;25:264-269. [PMID: 30827081 DOI: 10.3350/cmh.2019.1001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
593 Flemming JA, Yang JD, Vittinghoff E, Kim WR, Terrault NA. Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer. 2014;120:3485-3493. [PMID: 25042049 DOI: 10.1002/cncr.28832] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 11.3] [Reference Citation Analysis]
594 Mouli SK, Goff LW. Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma. Curr Treat Options in Oncol 2017;18. [DOI: 10.1007/s11864-017-0509-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
595 El-Hamouly MS, Azzam AA, Ghanem SE, El-Bassal FI, Shebl N, Shehata AMF. Circulating microRNA-301 as a promising diagnostic biomarker of hepatitis C virus-related hepatocellular carcinoma. Mol Biol Rep 2019;46:5759-65. [PMID: 31471732 DOI: 10.1007/s11033-019-05009-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
596 Sukowati CHC, El-Khobar KE, Tiribelli C. Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. World J Stem Cells 2021; 13(7): 795-824 [PMID: 34367478 DOI: 10.4252/wjsc.v13.i7.795] [Reference Citation Analysis]
597 Cho YY, Yu SJ, Yoo JJ, Lee M, Lee DH, Cho Y, Yoon KW, Cho EJ, Lee JH, Kim YJ, Yoon JH. The Model to Estimate Survival in Ambulatory Hepatocellular Carcinoma Patients Aids in the Decision for TACE Retreatment. J Clin Gastroenterol 2020;54:370-7. [PMID: 30439763 DOI: 10.1097/MCG.0000000000001148] [Reference Citation Analysis]
598 Liu K, Min XL, Peng J, Yang K, Yang L, Zhang XM. The Changes of HIF-1α and VEGF Expression After TACE in Patients With Hepatocellular Carcinoma. J Clin Med Res 2016;8:297-302. [PMID: 26985249 DOI: 10.14740/jocmr2496w] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
599 Marquez HP, Puippe G, Mathew RP, Alkadhi H, Pfammatter T, Fischer MA. CT Perfusion for Early Response Evaluation of Radiofrequency Ablation of Focal Liver Lesions: First Experience. Cardiovasc Intervent Radiol 2017;40:90-8. [PMID: 27812781 DOI: 10.1007/s00270-016-1444-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
600 Zeng J, Qin Z, Zhou L, Fang G, Chen J, Li J, Niu L, Liang B, Xu K. Comparison between cryoablation and irreversible electroporation of rabbit livers at a location close to the gallbladder. Radiol Oncol. 2017;51:40-46. [PMID: 28265231 DOI: 10.1515/raon-2017-0003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
601 Nada Y, Rashad N, Eissa M, Ghonaim A, Farag K, Saadawi I, Sheha A, El Gewaity M, Abdel-Rahman O. Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study. Expert Rev Gastroenterol Hepatol 2018;12:99-107. [PMID: 29124987 DOI: 10.1080/17474124.2018.1403898] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
602 Somma F, D'Angelo R, Serra N, Gatta G, Grassi R, Fiore F. Use of Ethanol in the Trans-Arterial Lipiodol Embolization (TAELE) of Intermediated-Stage HCC: Is This Safer than Conventional Trans-Arterial Chemo-Embolization (c-TACE)? PLoS One 2015;10:e0129573. [PMID: 26110810 DOI: 10.1371/journal.pone.0129573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
603 Kang TW, Rhim H, Lee MW, Kim W, Park JG. Predicting Coverage of Transverse Subcostal Sonography With the Use of Previous Computed Tomography Before a Sonographic Liver Examination: A Prospective Study. Journal of Ultrasound in Medicine 2013;32:2053-61. [DOI: 10.7863/ultra.32.12.2053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
604 Arslan B, Padela MT, Madassery S, Masrani A, Tasse J, Supanich M, Ahmed O. Combination Ipsilateral Lobar and Segmental Radioembolization Using Glass Yttrium-90 Microspheres for Treatment of Multifocal Hepatic Malignancies. Journal of Vascular and Interventional Radiology 2018;29:1110-6. [DOI: 10.1016/j.jvir.2018.04.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
605 Kim BK, Kim SU. Reply to "Response assessment for HCC patients treated with repeated TACE: The optimal time-point is still an open issue". J Hepatol 2015;63:1532. [PMID: 26375243 DOI: 10.1016/j.jhep.2015.09.003] [Reference Citation Analysis]
606 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications. Clin Mol Hepatol 2020;26:83-127. [PMID: 31918536 DOI: 10.3350/cmh.2019.0010n] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
607 Toesca DAS, Barry A, Sapisochin G, Beecroft R, Dawson L, Owen D, Mouli S, Lewandowski R, Salem R, Chang DT. Clinical Case Panel: Treatment Alternatives for Inoperable Hepatocellular Carcinoma. Semin Radiat Oncol 2018;28:295-308. [PMID: 30309640 DOI: 10.1016/j.semradonc.2018.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
608 Gurian E, Di Silvestre A, Mitri E, Pascut D, Tiribelli C, Giuffrè M, Crocè LS, Sergo V, Bonifacio A. Repeated double cross-validation applied to the PCA-LDA classification of SERS spectra: a case study with serum samples from hepatocellular carcinoma patients. Anal Bioanal Chem 2021;413:1303-12. [PMID: 33294938 DOI: 10.1007/s00216-020-03093-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
609 Toyoda H, Tada T, Yasuda S, Mizuno K, Sone Y, Kaneoka Y, Maeda A, Akita T, Tanaka J, Kumada T. The emergence of non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C. Aliment Pharmacol Ther 2019;50:1232-8. [PMID: 31588590 DOI: 10.1111/apt.15490] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
610 Manas D, Bell JK, Mealing S, Davies H, Baker H, Holmes H, Hubner RA. The cost-effectiveness of TheraSphere in patients with hepatocellular carcinoma who are eligible for transarterial embolization. Eur J Surg Oncol 2021;47:401-8. [PMID: 32958370 DOI: 10.1016/j.ejso.2020.08.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
611 Su TS, Li LQ, Meng WW, Wang YD, Chen YT, Li JX, Du YQ, Qu S, Zhao C, Huang DJ, Liang SX, Li LQ. Long-Term Survival Analysis of Transarterial Chemoembolization Plus Radiotherapy vs. Radiotherapy for Hepatocellular Carcinoma With Macroscopic Vascular Invasion. Front Oncol 2020;10:1205. [PMID: 32850352 DOI: 10.3389/fonc.2020.01205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
612 Zhang W, Tan Y, Jiang L, Yan L, Yang J, Li B, Wen T, Wu H, Wang W, Xu M. Prognostic nomogram for patients with non-B non-C hepatocellular carcinoma after curative liver resection. Int J Surg 2017;44:160-5. [PMID: 28629767 DOI: 10.1016/j.ijsu.2017.06.041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
613 Baiz D, Dapas B, Farra R, Scaggiante B, Pozzato G, Zanconati F, Fiotti N, Consoloni L, Chiaretti S, Grassi G. Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines. World J Gastroenterol 2014; 20(3): 795-803 [PMID: 24574752 DOI: 10.3748/wjg.v20.i3.795] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
614 Hafeez Bhatti AB, Dar FS, Waheed A, Shafique K, Sultan F, Shah NH. Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective. Gastroenterol Res Pract 2016;2016:5942306. [PMID: 26955390 DOI: 10.1155/2016/5942306] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
615 Bargellini I, Battaglia V, Bozzi E, Lauretti DL, Lorenzoni G, Bartolozzi C. Radiological diagnosis of hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:137-48. [PMID: 27508183 DOI: 10.2147/JHC.S44379] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
616 Bardou-Jacquet E, Legros L, Soro D, Latournerie M, Guillygomarc’h A, Lan CL, Brissot P, Guyader D, Moirand R. Effect of alcohol consumption on liver stiffness measured by transient elastography. World J Gastroenterol 2013; 19(4): 516-522 [PMID: 23382630 DOI: 10.3748/wjg.v19.i4.516] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 40] [Article Influence: 5.8] [Reference Citation Analysis]
617 Demirtas CO, Ricco G, Ozdogan OC, Baltacioglu F, Ones T, Yumuk PF, Dulundu E, Uzun S, Colombatto P, Oliveri F, Brunetto MR, Gunduz F. Proposal and Validation of a Novel Scoring System for Hepatocellular Carcinomas Beyond Curability Borders. Hepatol Commun 2021. [PMID: 34751001 DOI: 10.1002/hep4.1836] [Reference Citation Analysis]
618 Jugé L, Petiet A, Lambert SA, Nicole P, Chatelin S, Vilgrain V, Van Beers BE, Bilston LE, Sinkus R. Microvasculature alters the dispersion properties of shear waves--a multi-frequency MR elastography study. NMR Biomed 2015;28:1763-71. [PMID: 26768491 DOI: 10.1002/nbm.3438] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
619 Feng LH, Wang H, Dong H, Zhu YY, Cong WM. The stromal morphological changes for differential diagnosis of uninodular high-grade dysplastic nodule and well-differentiated small hepatocellular carcinoma. Oncotarget 2017;8:87329-39. [PMID: 29152084 DOI: 10.18632/oncotarget.20607] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
620 Rodríguez de Lope C, Reig ME, Darnell A, Forner A. Approach of the patient with a liver mass. Frontline Gastroenterol 2012;3:252-62. [PMID: 28839677 DOI: 10.1136/flgastro-2012-100146] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
621 Schobert I, Chapiro J, Pucar D, Saperstein L, Savic LJ. Fluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Liver Tumors. PET Clinics 2019;14:437-45. [DOI: 10.1016/j.cpet.2019.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
622 Poté N, Cauchy F, Albuquerque M, Cros J, Soubrane O, Bedossa P, Paradis V. Contribution of virtual biopsy to the screening of microvascular invasion in hepatocellular carcinoma: A pilot study. Liver Int 2018;38:687-94. [PMID: 28872754 DOI: 10.1111/liv.13585] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
623 Nakano R, Ohira M, Kobayashi T, Ide K, Tahara H, Kuroda S, Shimizu S, Kimura T, Nagata Y, Aikata H, Chayama K, Ohdan H. Hepatectomy versus stereotactic body radiotherapy for primary early hepatocellular carcinoma: A propensity-matched analysis in a single institution. Surgery 2018;164:219-26. [PMID: 29801728 DOI: 10.1016/j.surg.2018.03.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
624 Revel-Mouroz P, Otal P, Jaffro M, Petermann A, Meyrignac O, Rabinel P, Mokrane FZ. Other non-surgical treatments for liver cancer. Rep Pract Oncol Radiother 2017;22:181-92. [PMID: 28490991 DOI: 10.1016/j.rpor.2017.02.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
625 Genco C, Cabibbo G, Maida M, Brancatelli G, Galia M, Alessi N, Butera G, Genova C, Romano P, Raineri M. Treatment of hepatocellular carcinoma: present and future. Expert Rev Anticancer Ther. 2013;13:469-479. [PMID: 23560841 DOI: 10.1586/era.13.21] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
626 Sadik NA, Ahmed NR, Mohamed MF, Ashoush OA. Serum Vascular Endothelial Growth Factor in Patients with Hepatocellular Carcinoma and its Validity as a Tumor Biomarker. TOBIOMJ 2019;9:84-94. [DOI: 10.2174/1875318301909010084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
627 Cohen D, Shimakawa Y, Ndow G, Sow A, Tamba S, Njie R, Lo G, Ghosh S, Toure-Kane C, Ka M, Mboup S, Okeke E, Toure S, Diop M, D'Alessandro U, Taylor-Robinson S, Mendy M, Zoulim F, Thursz MR, Lemoine M, Chemin I. [Prevention of liver fibrosis and liver cancer linked to hepatitis B virus in Africa: the Prolifica study]. Med Sci (Paris) 2019;35:431-9. [PMID: 31115326 DOI: 10.1051/medsci/2019076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
628 Takeishi K, Kawanaka H, Itoh S, Harimoto N, Ikegami T, Yoshizumi T, Shirabe K, Maehara Y. Impact of Splenic Volume and Splenectomy on Prognosis of Hepatocellular Carcinoma Within Milan Criteria After Curative Hepatectomy. World J Surg 2018;42:1120-8. [PMID: 28920178 DOI: 10.1007/s00268-017-4232-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
629 Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Saito T, Motoyama T, Suzuki E, Tawada A, Kanai F, Yokosuka O. Sorafenib treatment in Child–Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs 2015;33:729-39. [DOI: 10.1007/s10637-015-0237-3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 7.0] [Reference Citation Analysis]
630 Kudo M, Lencioni R, Marrero JA, Venook AP, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Ye SL. Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study. Liver Int 2016;36:1196-205. [PMID: 26901163 DOI: 10.1111/liv.13096] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
631 Leone V, Ali A, Weber A, Tschaharganeh DF, Heikenwalder M. Liver Inflammation and Hepatobiliary Cancers. Trends Cancer 2021;7:606-23. [PMID: 33674229 DOI: 10.1016/j.trecan.2021.01.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
632 Kim JH, Kang SH, Lee M, Youn GS, Kim TS, Jun BG, Kim MY, Kim YD, Cheon GJ, Kim DJ, Baik SK, Choi DH, Suk KT. Serum Myostatin Predicts the Risk of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Multicenter Study. Cancers (Basel) 2020;12:E3347. [PMID: 33198216 DOI: 10.3390/cancers12113347] [Reference Citation Analysis]
633 Zhao H, Tsauo JW, Zhang XW, Li X. Interventional Radiology in China: Current Status and Future Prospects. Chin Med J (Engl) 2017;130:1371-5. [PMID: 28524838 DOI: 10.4103/0366-6999.206355] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
634 Min JH, Kim JM, Kim YK, Kang TW, Lee SJ, Choi GS, Choi S, Ahn S. Prospective Intraindividual Comparison of Magnetic Resonance Imaging With Gadoxetic Acid and Extracellular Contrast for Diagnosis of Hepatocellular Carcinomas Using the Liver Imaging Reporting and Data System: XXXX. Hepatology 2018;68:2254-66. [DOI: 10.1002/hep.30122] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 17.3] [Reference Citation Analysis]
635 Yim SY, Park BJ, Um SH, Han NY, Sung DJ, Cho SB, Lee SH, Kim MJ, Jung JY, Kim JD, Seo YS, Kim DS, An H, Kim YH. Diagnostic performance of gadoxetic acid (Primovist)-enhanced MR imaging versus CT during hepatic arteriography and portography for small hypervascular hepatocellular carcinoma. Medicine (Baltimore) 2016;95:e4903. [PMID: 27684824 DOI: 10.1097/MD.0000000000004903] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
636 Ponziani FR, Bhoori S, Castelli C, Putignani L, Rivoltini L, Del Chierico F, Sanguinetti M, Morelli D, Paroni Sterbini F, Petito V, Reddel S, Calvani R, Camisaschi C, Picca A, Tuccitto A, Gasbarrini A, Pompili M, Mazzaferro V. Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease. Hepatology 2019;69:107-20. [DOI: 10.1002/hep.30036] [Cited by in Crossref: 155] [Cited by in F6Publishing: 165] [Article Influence: 51.7] [Reference Citation Analysis]
637 Mahnken AH. [Transarterial ablative therapy of hepatocellular carcinoma]. Radiologe 2014;54:685-93. [PMID: 25047524 DOI: 10.1007/s00117-014-2655-1] [Reference Citation Analysis]
638 Charette JH, Burak KW, Coffin CS, Congly SE, Lee SS, Israelson H, Williams S, Sadler M, Borman MA, Aspinall AI, Swain MG, Shaheen AA. Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma. J Hepatol 2020;73:1287-9. [PMID: 32883554 DOI: 10.1016/j.jhep.2020.07.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
639 Strazzulla A, Iemmolo RMR, Carbone E, Postorino MC, Mazzitelli M, De Santis M, Di Benedetto F, Cristiani CM, Costa C, Pisani V. The Risk of Hepatocellular Carcinoma After Directly Acting Antivirals for Hepatitis C Virus Treatment in Liver Transplanted Patients: Is It Real? Hepat Mon. 2016;16:e41933. [PMID: 28070200 DOI: 10.5812/hepatmon.41933] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
640 Zhang X, Li C, Wen T, Peng W, Yan L, Yang J. Postoperative Prognostic Nutritional Index Predicts Survival of Patients with Hepatocellular Carcinoma within Milan Criteria and Hypersplenism. J Gastrointest Surg 2017;21:1626-34. [DOI: 10.1007/s11605-017-3414-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
641 Burak KW, Sherman M. Hepatocellular carcinoma: Consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting. Can J Gastroenterol Hepatol. 2015;29:178-184. [PMID: 25965437 DOI: 10.1155/2015/824263] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
642 Lee JH, Kim YR, Lee GM, Ryu JH, Cho EY, Lee YH, Yoon KH. Coefficient of variation on Gd-EOB MR imaging: Correlation with the presence of early-stage hepatocellular carcinoma in patients with chronic hepatitis B. Eur J Radiol 2018;102:95-101. [PMID: 29685552 DOI: 10.1016/j.ejrad.2018.02.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
643 Ho E, Michielsen P, Van Damme P, Ieven M, Veldhuijzen I, Vanwolleghem T. Point-of-Care Tests for Hepatitis B Are Associated with A Higher Linkage to Care and Lower Cost Compared to Venepuncture Sampling During Outreach Screenings in an Asian Migrant Population. Ann Glob Health 2020;86:81. [PMID: 32742939 DOI: 10.5334/aogh.2848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
644 Elmahallawy EK, Mohamed Y, Abdo W, Yanai T. Melatonin and Mesenchymal Stem Cells as a Key for Functional Integrity for Liver Cancer Treatment. Int J Mol Sci 2020;21:E4521. [PMID: 32630505 DOI: 10.3390/ijms21124521] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
645 Gabr A, Abouchaleh N, Ali R, Vouche M, Atassi R, Memon K, Asadi AA, Baker T, Caicedo JC, Desai K, Fryer J, Hickey R, Abeccassis M, Habib A, Hohlastos E, Ganger D, Kulik L, Lewandowski RJ, Riaz A, Salem R. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. European Journal of Radiology 2017;93:100-6. [DOI: 10.1016/j.ejrad.2017.05.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
646 Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, Bellentani S; HCC-NAFLD Italian Study Group. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology. 2016;63:827-838. [PMID: 26599351 DOI: 10.1002/hep.28368] [Cited by in Crossref: 270] [Cited by in F6Publishing: 253] [Article Influence: 54.0] [Reference Citation Analysis]
647 Francica G, Meloni MF, Riccardi L, de Sio I, Terracciano F, Caturelli E, Iadevaia MD, Amoruso A, Roselli P, Chiang J, Scaglione M, Pompili M. Ablation treatment of primary and secondary liver tumors under contrast-enhanced ultrasound guidance in field practice of interventional ultrasound centers. A multicenter study. European Journal of Radiology 2018;105:96-101. [DOI: 10.1016/j.ejrad.2018.05.030] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
648 Cao J, Dong Y, Mao F, Wang W. Dynamic Three-Dimensional Contrast-Enhanced Ultrasound to Predict Therapeutic Response of Radiofrequency Ablation in Hepatocellular Carcinoma: Preliminary Findings. Biomed Res Int 2018;2018:6469703. [PMID: 30225261 DOI: 10.1155/2018/6469703] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
649 Lee YR, Kim G, Tak WY, Jang SY, Kweon YO, Park JG, Lee HW, Han YS, Chun JM, Park SY, Hur K. Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma: Circulating exosomal noncoding RNAs in HCC. Int J Cancer 2019;144:1444-52. [DOI: 10.1002/ijc.31931] [Cited by in Crossref: 75] [Cited by in F6Publishing: 86] [Article Influence: 25.0] [Reference Citation Analysis]
650 Robinson A, Tavakoli H, Cheung R, Liu B, Bhuket T, Wong RJ. Low Rates of Retention Into Hepatocellular Carcinoma (HCC) Surveillance Program After Initial HCC Screening. J Clin Gastroenterol 2019;53:65-70. [PMID: 29629906 DOI: 10.1097/MCG.0000000000001024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
651 Wang WD, Zhang LH, Ni JY, Jiang XY, Chen D, Chen YT, Sun HL, Luo JH, Xu LF. Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization Therapy Versus Surgical Resection for Hepatocellular Carcinoma within the Milan Criteria: A Meta-Analysis. Korean J Radiol 2018;19:613-22. [PMID: 29962868 DOI: 10.3348/kjr.2018.19.4.613] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
652 Zheng H, Yang Y, Ye C, Li PP, Wang ZG, Xing H, Ren H, Zhou WP. Lamp2 inhibits epithelial-mesenchymal transition by suppressing Snail expression in HCC. Oncotarget 2018;9:30240-52. [PMID: 30100986 DOI: 10.18632/oncotarget.25367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
653 Vennarecci G, Ferraro D, Tudisco A, Levi Sandri GB, Guglielmo N, Berardi G, Sperduti I, Ettorre GM. The ALPPS procedure: hepatocellular carcinoma as a main indication. An Italian single-center experience. Updates Surg 2019;71:67-75. [DOI: 10.1007/s13304-018-0596-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
654 Giani A, Cipriani F, Famularo S, Donadon M, Bernasconi DP, Ardito F, Fazio F, Nicolini D, Perri P, Giuffrida M, Pontarolo N, Zanello M, Lai Q, Conci S, Molfino S, Germani P, Pinotti E, Romano M, La Barba G, Ferrari C, Patauner S, Manzoni A, Sciannamea I, Fumagalli L, Troci A, Ferraro V, Floridi A, Memeo R, Crespi M, Chiarelli M, Antonucci A, Zimmitti G, Frena A, Percivale A, Ercolani G, Zanus G, Zago M, Tarchi P, Baiocchi GL, Ruzzenente A, Rossi M, Jovine E, Maestri M, Dalla Valle R, Grazi G, Vivarelli M, Ferrero A, Giuliante F, Torzilli G, Aldrighetti L, Gianotti L, Romano F, Ciulli C, Braga M, Ratti F, Costa G, Razionale F, Russolillo N, Marinelli L, De Peppo V, Cremaschi E, Calabrese F, Larghi Laureiro Z, Lazzari G, Cosola D, Montuori M, Salvador L, Cucchetti A, Franceschi A, Ciola M, Sega V, Calcagno P, Pennacchi L, Tedeschi M. Performance of Comprehensive Complication Index and Clavien-Dindo Complication Scoring System in Liver Surgery for Hepatocellular Carcinoma. Cancers (Basel). 2020;12. [PMID: 33371419 DOI: 10.3390/cancers12123868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
655 Bak-Fredslund KP, Munk OL, Keiding S, Sørensen M. 2-[(18)F]fluoro-2-deoxy-D-galactose PET/CT of hepatocellular carcinoma is not improved by co-administration of galactose. Nucl Med Biol 2016;43:577-80. [PMID: 27434609 DOI: 10.1016/j.nucmedbio.2016.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
656 Baid-Agrawal S, Pascual M, Moradpour D, Somasundaram R, Muche M. Hepatitis C virus infection and kidney transplantation in 2014: what's new? Am J Transplant 2014;14:2206-20. [PMID: 25091274 DOI: 10.1111/ajt.12835] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 7.1] [Reference Citation Analysis]
657 Johnson P, Berhane S, Kagebayashi C, Satomura S, Teng M, Fox R, Yeo W, Mo F, Lai P, Chan SL, Tada T, Toyoda H, Kumada T. Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. Br J Cancer. 2017;116:441-447. [PMID: 28081537 DOI: 10.1038/bjc.2016.422] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
658 Burt AD, Alves V, Bedossa P, Clouston A, Guido M, Hübscher S, Kakar S, Ng I, Park YN, Reeves H, Wyatt J, Yeh MM, Ellis DW. Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology 2018;73:369-85. [DOI: 10.1111/his.13520] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
659 Zhao J, Chen HQ, Yang HF, Li XY, Liu WB. Gene expression network related to DNA methylation and miRNA regulation during the process of aflatoxin B1-induced malignant transformation of L02 cells. J Appl Toxicol 2021. [PMID: 34561900 DOI: 10.1002/jat.4233] [Reference Citation Analysis]
660 Long X, Wang X, Chen Y, Guo X, Zhou F, Fan Y, Ge N, Guo M, Zhang Z, Dong G. Polymorphisms in POLG were associated with the prognosis and mtDNA content in hepatocellular carcinoma patients. Bull Cancer 2017;104:500-7. [PMID: 28457473 DOI: 10.1016/j.bulcan.2017.02.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
661 Mansy SS, El-Ahwany E, Mahmoud S, Hassan S, Seleem MI, Abdelaal A, Helmy AH, Zoheiry MK, AbdelFattah AS, Hassanein MH. Potential ultrastructure predicting factors for hepatocellular carcinoma in HCV infected patients. Ultrastruct Pathol 2017;41:209-26. [PMID: 28494215 DOI: 10.1080/01913123.2017.1316330] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
662 Galandi D, Antes G. Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma. Cochrane Database Syst Rev. 2004;CD003046. [PMID: 15106188 DOI: 10.1002/14651858.cd003046.pub3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 38] [Article Influence: 1.8] [Reference Citation Analysis]
663 Jung KH, Rumman M, Yan H, Cheon MJ, Choi JG, Jin X, Park S, Oh MS, Hong S. An ethyl acetate fraction of Artemisia capillaris (ACE-63) induced apoptosis and anti-angiogenesis via inhibition of PI3K/AKT signaling in hepatocellular carcinoma: ACE-63 induced apoptosis and anti-angiogenesis. Phytotherapy Research 2018;32:2034-46. [DOI: 10.1002/ptr.6135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
664 Brandi G, de Rosa F, Calzà L, Girolamo SD, Tufoni M, Ricci CS, Cirignotta F, Caraceni P, Biasco G. Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients? Liver Int. 2013;33:488-493. [PMID: 23402614 DOI: 10.1111/liv.12102] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
665 Pinter M, Haupt L, Hucke F, Bota S, Bucsics T, Trauner M, Peck-Radosavljevic M, Sieghart W. The impact of thyroid hormones on patients with hepatocellular carcinoma. PLoS One 2017;12:e0181878. [PMID: 28771610 DOI: 10.1371/journal.pone.0181878] [Cited by in Crossref: 12] [